connecting annual report mission global quest improve quality human life enabling people feel better live longer spirit undertake quest enthusiasm entrepreneurs excited constant search innovation value performance achieved integrity attain success world class global leader every one people contributing passion unmatched sense urgency strategic intent want become indisputable leader industry glaxosmithkline plc english public limited company shares listed london stock exchange new york stock exchange glaxosmithkline plc acquired glaxo wellcome plc smithkline beecham plc th december way scheme arrangement merger two companies became effective th december report annual report glaxosmithkline plc year ended st december comprises single document annual report company accordance united kingdom requirements annual report formf securities exchange commission united states america summary report year annual review intended investor needing full detail annual report produced separate document annual review includes joint statement chairman chief executive officer summary review operations summary financial statements summary remuneration report annual review issued shareholders annual report issued shareholders elected receive documents available glaxosmithklines web site visit corporate home wwwgskcomglaxosmithkline glaxosmithkline plc annual report year ended st december contents report directors financial summary joint statement chairman chief executive officer description business corporate governance remuneration report operating financial review prospects financial statements directors statements responsibility independent auditors report consolidated statement profit loss consolidated statement total recognised gains losses consolidated statement cash flow consolidated balance sheet reconciliation movements equity shareholders funds company balance sheet notes financial statements principal financial statements us financial record investor information shareholder return taxation information shareholders shareholder information share capital cross reference form f glossary terms annual report approved board index directors th march published th march contact details glaxosmithkline financial summary increase business performance cer sales trading profit profit taxation earningsnet income earnings per share p p total results profit taxation earningsnet income earnings per share p p business performance primary performance measure used management presented excluding merger items integration restructuring costs disposal subsidiaries management believes exclusion nonrecurring items provides better comparison business performance periods presented accordingly information provided supplement included consolidated statement profit loss pages prepared accordance ukgaap total results include nonrecurring items cer represents growth constant exchange rates represents growth actual exchange rates financial highlights pharmaceutical sales per cent excluding divested products strong growth regions usa per cent europe seven per cent rest world per cent strong growth key therapy areas central nervous system per cent respiratory per cent hivaids per cent new products per cent billion representing per cent total pharmaceutical sales seretideadvairachieved sales millionadvairlaunch one successful ever us pharmaceutical industry active inlicensing programme delivered new products clinical development merger manufacturing cost savings million achieved billion share buyback programme billion share purchases completed strong business performance eps growth per cent per cent cer shareholder return dividends per glaxosmithkline share p former glaxo wellcome shareholder p former smithkline beecham shareholder p dividends represent dividends paid glaxo wellcome smithkline beecham shareholders expressed dividends per glaxosmithkline share cautionary statement regarding forwardlooking statements group 's reports filed us securities exchange commission commission including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give group 's current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results group undertakes obligation update forwardlooking statements whether result new information future events otherwise forwardlooking statements involve inherent risks uncertainties group cautions investors number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual reportglaxosmithkline joint statement chairman chief executive officer time enhanced marketing power made possible combined salesforces given us size quality flexibility achieve rapid uptake acceptance glaxosmithklines products example seretideadvair newest asthma treatment enjoyed remarkable success around world fourth largest product globally number one europe achieving million worldwide sales usa advairlaunch one successful ever us pharmaceutical industry merger helped position glaxosmithkline marketing power development expertise partner choice companies seeking large pharmaceutical company maximise value new products active inlicensing programme delivered ten new products clinical development agreements include exciting compounds vardenafil erectile dysfunction expect launch partner bayer innovative agreements provide access pipelines two largest pharmaceutical successful first year glaxosmithkline companies japan shionogi tanabe first year merged company completed successfully reorganised rejuvenated entire rd organisation connecting employees together taking advantage size still maintaining flexibility worlds second largest pharmaceutical company largest efficiency smaller entrepreneurial centres excellence pharmaceutical company europe one fastest drug discovery cedds current rd expenditure billion growing pharmaceutical companies key us market one largest industry merger also enable line commitment shareholders pleased us save reinvest million rd report delivered business performance earnings per share disappointing lose tranilast prevention restenosis growth per cent per cent constant compound treatment diabetes exchange rates phaselll pipeline confidence continued performance company currently one strongest earlystage pipelines led us expect business performance earnings per share growth industry projects clinical development including midteens lowteens better new chemical entities new vaccines line extensions guidance assumes glaxosmithkline successfully defends intellectual property surrounding augmentinand paxilin usa discovery development programme together inlicensing activities hasgiven glaxosmithkline strong start delivering merger benefits achieving ambition build one best pipelines industry announced merger informed shareholders expected create company significant financial strength block drug successfully integrated consumer enhanced marketing power improved rd productivity healthcare business achieved sales billion last year made great progress turning expectations acquisition added sensodyne polidentand poligripto oral reality care business number significant brands overthe counter medicines result acquisition glaxosmithkline glaxosmithkline strong financial shape business become number two company globally oral care performance profit tax per cent constant critical mass added usa europe exchange rates billion net operating cashflow rest world billion nearly billion previous year also achieved merger manufacturing restructuring savings excess positioned success million year increased estimate annual savings merger million remain begin second year glaxosmithkline company track deliver total annual merger manufacturing excellent shape well positioned realise continued restructuring savings billion future success strong portfolio built six core products billion global sales seroxatpaxilfor depression financial strength enabled us announce augmentin antibiotic flixotidefloventfor asthma billion share buyback programme year end seretideadvairfor asthma imigranimitrexfor migraine half way towards completion group financial power avandiafor diabetes undertake programme whilst retaining flexibility consider investment opportunities may arise new products represent per cent total pharmaceutical sales grew per cent constant exchange rates billion glaxosmithkline global leader three key therapy areas antiinfectives respiratory central nervous system products glaxosmithklinejoint statement chairman chief executive officer expect several new product indications contribute company also recognises even usa future growth received us approval seroxatpaxil poorest citizens may able afford medicines need indications generalised anxiety disorder posttraumatic glaxosmithkline took leadership position launched stress disorder coregfor severe heart failure augmentin esfor orange cardprogramme january help people low ear infections children twinrix first combination incomes public private prescription drug hepatitis b vaccine january us fda advisory coverage committee recommended approval seretideadvairfor programmes reflect fundamental commitment treatment chronic obstructive pulmonary disease copd improving quality life patients across globe associated bronchitis connecting needs communities glaxosmithkline planning make several key regulatory filings employees live work compound hiv ariflofor copd ibandronate may publish review glaxosmithklines postmenopausal osteoporosis filed commitment society entitled performance integrity development partner roche lamictalfor bipolar disorder incorporate information pressing wellbutrin xlfor depression social environmental issues core business glaxosmithkline involved legal challenges usa europe regarding infringement patents relating acknowledgements major products continue defend intellectual property rights countries want thank board members employees support first year newly merged company commitment communities particular would like thank sir peter walters mr john young retire nonexecutive directors group delivering commitment support glaxosmithkline conclusion companys annual communities globally glaxosmithkline continued general meeting may invaluable service given play international leadership role increasing access boards smithkline beecham glaxosmithkline hivaids treatments developing countries maintained commitment reduce prices governments united behalf board corporate executive team nations aids accelerating access initiative announced also thank shareholders support company may outlined full range activities hope proud people achievements improve quality healthcare developing countries share enthusiasm tremendous publication called facing challenge included extending future prospects glaxosmithkline preferential pricing products countries customers including global funds antiretrovirals antimalarials offered fixed notforprofit prices public sector customers nonprofit organisations least developed countries subsaharan africa additionally gravity hivaids problem subsaharan africa offer preferential prices antiretrovirals employers provide hivaids treatment staff workplace clinics also reconfirmed commitment global programme sir richard sykes j p garnier eliminate lymphatic filariasis become industrys chairman chief executive officer largest donation programme addition drug donation glaxosmithkline provides extensive programme support partners working prevent disfiguring tropical disease message sir richard sykes message j p garnier seen recent announcement decided behalf board would like pay tribute sir richard retire board directors effect years annual made tremendous contribution glaxo general meeting th may time sir christopher hogg glaxo wellcome glaxosmithkline strong currently nonexecutive director glaxosmithkline become committed ambassador pharmaceutical industry chairman great champion uk science base wish well future time welcome sir christopher new feel right time depart overseen successful chairman look forward benefiting wideranging merger glaxosmithkline approach th birthday experience knowledge august wish devote time energy role rector imperial college leave glaxosmithkline great shape future would like record thanks companys employees dedication hard work also thank shareholders support many yearsglaxosmithkline description business description business discusses activities resourcesandthe operating environment business identifies developments achievements following headings business history development company products operating environment competition regulation operating activities marketing distribution manufacture supply research development operating resources intellectual property information technology glaxosmithkline people property plant equipment business community performance integrity environmental responsibility access medicines developing world global community partnerships corporate donations discussion groups management structures corporate governance procedures set corporate governance pagesto remuneration report gives details groups policies directors remuneration amounts earned directors senior management pages discussion groups operating financial performance financial resources given operating financial review andprospects pages report glaxosmithkline group means glaxosmithkline plc subsidiary undertakings thecompany means glaxosmithkline plcglaxosmithkline share means ordinary share ofglaxosmithkline plc p throughout report figures quoted market size market share market growth rates relate months ended th september orlater available glaxosmithkline estimates based onthe recent data independent external sources valued sterling relevant exchange rates figures quoted product market share reflect sales glaxosmithkline licensees brand names appearing italics throughout report trade marks glaxosmithkline plc subsidiaries associated companies theexception baycola trade mark bayer ag bexxar trade mark corixa corporation inc coreg trade mark roche laboratories inc factive trade mark oflgchemical ltd natrecora trade mark scios inc navelbine trade mark pierre fabre mdicament nicoderm trade mark aventis sa used licence group glaxosmithkline description business business history development company glaxosmithkline plc subsidiary associated undertakings constitute major global healthcare group engaged creation discovery development manufacture marketing pharmaceutical consumer healthrelated products glaxosmithkline corporate head office london area great west road brentford middlesex tw gs england tel glaxosmithkline also operational headquarters philadelphia pa research triangle park nc usa operating companies countries products sold countries principal research development rd facilities uk usa japan italy belgium products currently manufactured countries major markets groups products usa japan theuk france germany italy glaxosmithkline plc public limited company incorporated thdecember english law th december company acquired glaxo wellcome plc smithkline beecham plc english public limited companies way scheme arrangement merger two companies glaxo wellcome smithkline beecham major global healthcare businesses st october glaxo wellcome plc changed name glaxosmithkline services plc historical references glaxo wellcome plc document changed business segments glaxosmithkline operates principally two industry segments pharmaceuticals prescription pharmaceuticals vaccines consumer healthcare overthecounter medicines oral care nutritional healthcaredescription businessglaxosmithkline products pharmaceuticals therapeutic area trade mark compound mechanism indication may vary country cns disorders seroxatpaxil paroxetine selective serotonin reuptake depression panic anxiety inhibitor wellbutrin bupropion noradrenaline reuptake inhibitor depression imigranimitrex sumatriptan ht agonist migraine cluster headache naramigamerge naratriptan ht agonist migraine lamictal lamotrigine sodium channel modulator epilepsy requip ropinirole dopamine agonist parkinsons disease zyban bupropion sr noradrenaline reuptake inhibitor smoking addiction respiratory flixotideflovent fluticasone propionate inhaled antiinflammatory asthma bronchial conditions serevent salmeterol xinafoate bronchodilator bronchial asthma bronchitis seretideadvair salmeterol fluticasone bronchodilatorantiinflammatory asthma propionate flixonaseflonase fluticasone propionate intranasal antiinflammatory hayfever perennial rhinitis ventolin salbutamolalbuterol bronchodilator bronchial asthma bronchitis becotidebeclovent beclomethasone dipropionate inhaled antiinflammatory bronchial asthma bronchitis beconase beclomethasone dipropionate intranasal antiinflammatory hayfever perennial rhinitis antibacterials augmentin amoxicillin broad spectrum oralinjectable common infections anti malarials clavulanate potassium antibiotic zinnatceftin cefuroxime axetil oral antibiotic common infections fortumfortaz ceftazidime injectable antibiotic severe life threatening infections amoxil amoxicillin broad spectrum oralinjectable common infections antibiotic malarone atovaquoneproguanil electron transport system inhibitortreatment prophylaxis malaria zinacef cefuroxime injectable antibiotic surgical infections antivirals trizivir lamivudine zidovudine reverse transcriptase inhibitor hivaids abacavir combivirbiovir lamivudine zidovudine reverse transcriptase inhibitor hivaids epivirtc lamivudine reverse transcriptase inhibitor hivaids retrovirazt zidovudine reverse transcriptase inhibitor hivaids ziagen abacavir reverse transcriptase inhibitor hivaids agenerase amprenavir protease inhibitor hivaids valtrexzelitrex valaciclovir dna polymerase inhibitor shingles genital herpes zovirax aciclovir dna polymerase inhibitor herpes infections shingles chicken pox cold sores zeffixheptavir lamivudine reverse transcriptase inhibitor chronic hepatitis b infection heptodinepivir hbv relenza zanamivir neuraminidase inhibitor influenza treatment metabolic avandia rosiglitazone ppargamma agonist type diabetes gastrointestinal zantac ranitidine hydrochloride antisecretory duodenal ulcers stomach ulcers reflux dyspepsia vaccines havrix hepatitis engerixb hepatitis b twinrix hepatitis b infanrix diphtheria tetanus acellular pertussis oncology zofran ondansetron ht receptor antagonist nausea vomiting cancer emesis therapy hycamtin topotecan topoisomerase inhibitor ovarian cancer small cell lung cancer navelbine vinorelbine cytotoxic nonsmall cell lung cancer breast cancer cardiovascular coreg carvedilol alphabeta blocker congestive heart failure lanoxin digoxin cardiac antiarrhythmic congestive heart failure cardiac arrhythmia flolan epoprostenol inhibitor blood clotting primary pulmonary hypertension lacipil lacidipine calcium channel blocker hypertension pritor telmisartan angiotensin ii antagonist hypertension arthritis relafen nabumetone non steroidal antiinflammatory osteoarthritis rheumatoid arthritis glaxosmithkline description business products pharmaceuticals therapeutic area antibacterials antimalarials augmentinis broadspectrum antibiotic suitable treatment glaxosmithklines principal pharmaceutical products presently wide range common bacterial infections particularly directed major therapeutic areas analysis salesby effective respiratory tract infections new augmentin es therapeutic areas description principal products extra strength suspension specifically designed treat children setout recurrent persistent middle ear infections sales therapeutic area zinnatis oral antibiotic used primarily communityacquired central nervous system infections lower respiratory tract fortumand zinacefare respiratory used hospitalbased injectable antibiotics market antibacterials malaroneis oral antimalarial used treatment antivirals prophylaxis malaria caused plasmodium falciparum metabolic gastrointestinal vaccines antivirals oncology emesis combivir combination retrovirand epivir consolidated cardiovascular position two reverse transcriptase inhibitors arthritis cornerstone many multiple antihiv product regimens physician others acceptance clearly demonstrated value placed divested products minimising pill burden faced patients ziagenis groups new reverse transcriptase inhibitor products potency ease use resistance profile allow central nervous system cns disorders play significant role variety highly active well tolerated seroxatpaxilis selective serotonin reuptake inhibitor ssri andsimplified hiv treatment regimens approved depression panic obsessive compulsive disorder triziviris combination combivirand ziagen combining three social anxiety disorder approval received post antihiv therapies one tablet twice daily administration traumatic stress disorder generalised anxiety disorder usa uk european markets ageneraseis new protease inhibitor treatment hiv first medicine class brought market wellbutrinis also antidepressant available usa normal glaxosmithkline agenerasehas twice daily dosing regimen orsustained release tablet formulations significant food drink restrictions imigranimitrexis ht receptor agonist used treatment zeffixhas approved marketing usa europe china ofsevere frequent migraine cluster headache markets treatment chronic hepatitis b become reference product sector naramigamergeis groups newer migraine product zoviraxis used treatment herpes infections chicken pox genital herpes shingles cold sores newer lamictalis treatment epilepsy used alone combination antiherpes compound valtrex reinforces groups presence products achieved penetration mature inthis market treatment zoster episodic market successful treatment severe cases longterm suppression genital herpes requipis specific dopamine dlike receptor treatment ofparkinsons disease metabolic gastrointestinal avandiais potent insulin sensitising agent acts zybanis novel nicotinefree prescription medicine available underlying pathophysiology type diabetes asasustainedrelease tablet treating problem smokingaddiction zantac treatment peptic ulcer disease range ofgastric acid related disorders continues play major role respiratory treatment number markets even patent protection sereventis longacting bronchodilator ventolina selective lost pyloridtritecis used combination antibiotics shortacting bronchodilator treatment asthma eradication helicobacter pylori causative agent inulcers flixotidefloventand becotidebecloventare inhaled steroids treatment inflammation associated bronchial asthma chronic bronchitis seretideadvair combination sereventand flixotide offers alongacting bronchodilator antiinflammatory single inhaler flixonaseflonaseand beconaseare intranasal preparations treatment perennial seasonal rhinitis groups respiratory products available wide choice delivery systems including diskusaccuhaler dry powder multidose inhalerdescription businessglaxosmithkline vaccines sales include sales block drug products amounting glaxosmithkline markets range hepatitis vaccines havrix million divested products include divested protects hepatitis engerixbagainst hepatitis b due merger glaxo wellcome smithkline beecham twinrixis combined hepatitis b vaccine protecting major products diseases one vaccine available adult paediatric strengths category product infanrixis range paediatric vaccine combinations infanrix overthecounter medicines provides protection diphtheria tetanus pertussis analgesics panadol whooping cough infanrix penta provides additional protection dermatologicals oxy hepatitis b polio andinfanrix hexafurther adds zovirax protection haemophilus influenzae type b abreva causesmeningitis gastrointestinal tums citrucel additionally glaxosmithkline markets priorixa measles respiratory tract contac mumps rubella vaccine typherix vaccine protection beechams typhoid fever varilirix vaccine varicella smoking control nicorette chicken pox nicoderm cq niquitin cq oncology emesis nicabate zofranis used prevent nausea vomiting associated vitamins naturals abtei chemotherapy radiotherapy cancer available oral care aquafresh bothoral injectable forms also approved use corega prevention treatment postoperative nausea vomiting drbest hycamtinis second line treatment ovarian cancer macleans forsmall cell lung cancer odol polident cardiovascular poligrip coregis alphabeta blocker proven sensodyne effective intreating mild moderate severe heart failure nutritional healthcare horlicks lucozade arthritis ribena relafenis nonsteroidal antiinflammatory drug treatment arthritis overthecounter medicines leading products panadol widely available nonaspirin analgesic nicorettegum nicodermniquitincqand categories include groups principal dermatological nicabaterange smoking cessation patches tums calcium products betnovate thehigher potency dermovateand newer based antacid citrucellaxative contacfor treatment colds cutivateare antiinflammatory steroid products used treat skin influenza abtei natural medicines vitamin range diseases suchas eczema psoriasis oxyacne treatment zoviraxand abreva treatment cold sores divested products accordance agreements regulatory approvals oral care merger glaxo wellcome smithkline beecham leading oral care products aquafresh macleansand odol products kytril treatment chemotherapy toothpastes mouthwashes range toothbrushes sold radiotherapy induced nausea vomiting famvir aquafreshand dr bestnames acquisition block antiviral treatment shingles herpes divested drug january added sensodynetoothpaste range indecember denture care products available principally polident poligripand coregabrand names products consumer healthcare glaxosmithklines principal consumer products presently nutritional healthcare directedto three major areas analysis sales areas lucozadeglucose energy sports drinks ribenablackcurrant isset based juice drink rich vitamin c horlicks range milkbased malted food chocolate drinks leading products category overthecounter medicines oral care nutritional healthcare divested products glaxosmithkline description business operating environment competition pharmaceuticals antibacterials antimalarials major products competing glaxosmithklines semisynthetic pharmaceutical industry highly competitive glaxosmithklines penicillins antiinfectives including limited principal competitors large international pharmaceutical generic brands cephalosporins increasing degree companies substantial resources companies particularly japan quinolones augmentinhas experiencing major products mentioned increased competition usa particularly pfizers pharmaceuticals may subject competition different zithromax bayers cipro johnson johnsons levaquin therapies period patent protection lost patent protection various countries europe patent generic versions manufacturers generic success augmentinhas made target generic products typically donot bear research development costs manufacturers usa glaxosmithkline consequently areable offer products considerably lower continues respond appropriately see note financial prices thebranded competitors research development statements legal proceedings amoxilhas without patent based pharmaceutical company normally seek achieve protection number years subject competition sufficiently high profit margin sales volume period generic brands malarones safety profile convenient dosing patent protection repay original investment fund regimen helped put product strong position versus research forthe future competition generic products mefloquine following recent launch malaria prophylaxis generally occurs glaxosmithklines patents major markets expire antivirals glaxosmithkline pioneering role hiv market glaxosmithkline undertakes range activities including retrovirand epiviracting cornerstone combination introducing innovative products many markets possible therapy available combivirin single tablet launch accelerating process new products brought ziagen ageneraseand trizivirhave broadened thegroups portfolio tomarket hiv products valtrexhas helped strengthen companys increasing brand recognition among customers position antiherpes area although zoviraxfaces competition generic aciclovir ultimately glaxosmithkline believes competitive position dependent upon discovery development new products metabolic gastrointestinal together effective marketing existing products within major competitor avandiais takeda chemicals actos pharmaceutical industry introduction new products copromoted eli lilly usa gastrointestinal processes competitors may affect pricing levels result market zantacfaces significant competition omeprazole product replacement assurance proton pump inhibitor generic ranitidine hydrochloride glaxosmithklines products may become outmoded notwithstanding patent trademark protection addition vaccines increasing government pressure physicians glaxosmithklines major competitors vaccine market include patients use generic pharmaceuticals rather brandname aventis pasteur merck wyeth engerixband havrixcompete medicines may increase competition products gone vaccines produced merck comvax recombivax hb patent hepatitis b vaqta hepatitis infanrixsmajor competitors aventis pasteurs tripedia trihibit wyeths acelimune cns disorders tetramune major competitors paxilin us selective serotonin reuptake inhibitor ssri market prozac eli lilly generic fluoxetine competition consumer healthcare became available august zoloft pfizer forest laboratories celexa success seroxatpaxilhas made major competitors consumer healthcare markets target generic manufacturers glaxosmithkline major international companies procter gamble colgate continues respond appropriately see note financial palmolive american home products unilever johnson statements legal proceedings johnson addition many large small companies compete glaxosmithkline selected markets imigranhas grown one glaxosmithklines leading products addressing previously unmet needs migraine usa major competitor products overthecounter sufferers although companies launched competing otc medicines tylenol cold cold remedy clearasil acne products newer formulations imigransuch nasal spray treatment pepcid indigestion private label smoking cessation introduction naramighave helped glaxosmithkline products uk major competitor products lemsip cold retain lead competitors migraine market remedy nurofen anadin analgesics nicotinell smoking maintain growth cessation remedy oral care colgatepalmolive procter gamble unilever respiratory major international competitors combined performance glaxosmithklines flixotide serevent recently launched seretideadvair continued drive nutritional healthcare major competitors horlicksare growth market established products ventolin ovaltine milo malted food chocolate drinks competitors becotidehave faced generic competition years ribenaare primarily local fruit juice products lucozade maintained significant sales major competitor competes energy drinks glaxosmithklines respiratory products usa singulair glaxosmithkline holds leading global positions key merck consumer product areas second largest company worldwide otc medicines oral care fifth largest company worldwide nutritional healthcaredescription businessglaxosmithkline regulation pharmaceuticals usa debate reform healthcare system resulted increased focus pricing although international pharmaceutical industry highly regulated currently government price controls private sector purchases national regulatory authorities administer panoply laws usa federal legislation requires pharmaceutical manufacturers andregulations governing testing approval manufacturing pay prescribed rebates certain drugs enable labelling marketing drugs also review safety eligible reimbursement medicaid healthcare programmes andefficacy pharmaceutical products regulatory requirements major factor determining whether substance pharmaceutical market worldwide continued developed marketable product amount experience increasing pressure pricing reimbursement time expense associated development governments healthcare providers though nonprice factors new products higher volumes principally driving particular importance requirement many countries growth pharmaceutical expenditure products authorised registered prior marketing authorisation registration maintained subsequently europe historically affected government regulation pricing reimbursement pharmaceutical industry continued national regulatory authorities many jurisdictions including experience pressure prices range measures usa european union japan australia high including acrosstheboard price cuts linking prices lowcost standards technical appraisal consequently introduction countries price referencing delays agreeing reimbursement new pharmaceutical products generally entails lengthy increasing pressure generic substitution approvalprocess countries crossborder imports fromlowpriced markets exert european union two procedures obtaining commercial pressure incountrypricing marketing authorisations medicinal products japan discussions ongoing new price centralised procedure applications made direct reimbursement controls government introduce theeuropean medicines evaluation agency leading authorisation valid member states compulsory value money products derived biotechnology optional new becoming increasingly necessary demonstrate value activesubstances innovative medicinal products formoney new products particular impact upon drug mutual recognition procedure applicable budget expenditure burden disease majority conventional medicinal products operates mutual treated markets need satisfy healthcare purchasers recognition national marketing authorisations value money becoming additional hurdle product agreement reached resolved procedure acceptance regulatory tests ofsafety efficacy binding arbitration quality delay bringing effective improved medicines market reduce effective patent grant marketing authorisation affords company data protection time protection period competitor rely confidential data regulatory file basis many markets becoming increasingly difficult significant marketing authorisation data protection period begins improved therapy obtain premium price existing thedate authorisation first granted european union medication philosophies founded valuebased pricing andexpires ten years authorisations granted via difficult follow circumstances usa still centralised procedure ten six years authorisations possible price products reflect value grantedvia mutual recognition procedure depending onthecountry concerned future developments possible predict whether extent across international markets ie countries outside usa europe groupsbusiness may affected future legislative regulations regulatory environment continue regulatory developments relating specific pharmaceutical extremely varied challenging products pricing products glaxosmithkline anticipates introduction new products continue require substantial effort time expense regulation consumer healthcare comply regulatory requirements consumer healthcare industry subject national regulation regarding testing approval manufacturing labelling price controls marketing products many countries high standards addition forms regulation already referred technical appraisal entail lengthy approval process new manycountries prices pharmaceutical products controlled product launched law national regulatory authorisation also required approve governments may also influence prices pharmaceutical switch products prescription otc requirements products control national healthcare organisations include longterm experience quality safety efficacy may bear large part cost supplying products oftheproduct wide patient population data confirm consumers thatthe relevant condition selflimiting easily countries france japan prices individual diagnosed bythe consumer products regulated uk prices controlled reference limits upon overall profitability measured rate return capital employed sales products supplied national healthservice glaxosmithkline description business operating activities marketing distribution directtoconsumer dtc advertising major component product marketing usa dtc advertisements glaxosmithkline sells products worldwide primary source information patients requesting specific brand extensivenetwork subsidiaries licensees distributors name products physicians usa gross profit margins earned sales pharmaceutical outside usa dtc either prohibited limited products generally higher earned sales rolein informing patients european union canada consumer products reflecting many risks uncertainties dtc currently prohibited australia government allow dtc inherent developing marketing pharmaceuticals risks advertising pharmacyonly products subject certain safeguards include high level research development expenditure new zealand dtc allowed selfregulated industry required discover test obtain patent protection new collaboration advertising standards agency products competition new generic products markets allow dtc date impact limited glaxosmithklines worldwide business subject number addition direct marketing products subsidiaries risks inherent conducting business certain countries including glaxosmithkline entered agreements withother possible nationalisation expropriation restrictive pharmaceutical companies comarketing copromotion government actions capital regulation addition currency products many markets fluctuations changes economic conditions occur time time either favourable unfavourable marketing distribution consumer healthcare effect trading income glaxosmithkline regard factors deterrents expansion international principal markets consumer healthcares otc medicines operations however company closely reviews methods usa uk germany australia argentina italy mexico operation particularly developing countries develops japan canada france nutritional drinks business strategies respond changing economic political conditions particularly strong uk ireland india although range products available markets principal markets marketing distribution pharmaceuticals oral care products us germany uk analysis total pharmaceutical sales including otc oral care products primarily distributed divested products geographic region set pharmacy mass market outlets directly wholesalers nutritional healthcare products distributed similar sales geographic region extensive retail wholesale network usa europe manufacture supply rest world glaxosmithkline large portfolio products ranging asia pacific tablets toothpaste inhalers complex capsules japan different pack sizes presentations latin america middle east africa manufacture medicines begins development canada therapeutic active ingredient bulk active selected formulation global manufacture supply gms develops manufacturing processes full scale volume production active compounds glaxosmithkline sells prescription medicines primarily 'primary ' manufacturing sites converting active compounds wholesale drug distributors independent chain retail finished dosage formulation responsibility 'secondary ' pharmacies physicians hospitals clinics government entities manufacturing sites institutions products ordinarily dispensed following merger glaxo wellcome smithkline public pharmacies prescriptions written physicians beecham december gms operates single global usa worlds largest pharmaceutical market network sites countries employing pressureto contain healthcare costs encouraged growth people year gms produces around tonnes bulk managed care organisations pharmacy benefit managers actives billion packs packaged intermediaries use range methods lower costs including delivered sale countries throughout world substitution generic products cheaper therapies also supports approximately new product line extension branded products prescribed doctors glaxosmithkline contracts launches year managed care sector due increasing importance gms focused delivering supplier healthcare community secure source supply high quality products market glaxosmithkline deploys salesforces compliance regulatory requirements customer representatives supporting medical staff promote expectations prescription products medical prescribers healthcare best class cost purchasers personal visits leading edge practices performance sites promotion glaxosmithklines products supplemented procurement global functions scientific seminars advertising medical journals television advertising provision samples direct mailing ofprinted material information contained companys site world wide webdescription businessglaxosmithkline organisation part network rationalisation plan production ceased gms operations structured supply chains regions sites seven countries including hungary sri lanka taiwan disposal closure six sites antibiotics supply chain announced year global organisation sites spread across countries total around staff employed across external suppliers sites broad range antibiotic products procurement global function supporting functions areas manufactured packaged glaxosmithkline business manufacturing one largest areas billion spend external suppliers every actives supply chain year including purchase active ingredients chemical active ingredients nonantibiotic products produced intermediates part finished finished products gms taken ten sites across network located australia india ireland appropriate steps protect supply chains disruption singapore uk usa approximately staff resulting interrupted external supply appropriate stock employed manufacturing supplying active ingredients levels contracting alternative registered suppliers secondary pharmaceutical sites regions research development pharmaceuticals european region global biological pharmaceutical research sites european region spread across seven development rd function glaxosmithkline responsible countries employing around people total discovering developing registering commercialising supporting european sites manufacture nearly major effective marketing innovative prescription medicines vaccines pharmaceutical products marketed globally glaxosmithkline delivery systems treatment prevention human wide variety finished dosage forms disease north america region fundamental goal thorough understanding three pharmaceutical sites north america region diseases investigation increasingly involving pioneering work located puerto rico canada usa sites employ ingenetics predictive medicine well traditional around staff research disciplines pharmacology medicinal chemistry addition work create new medicines vaccines international region extensive efforts made gain clear understanding international region comprises manufacturing sites unmet needs patientsand healthcare providers payers countries spread across six distinct areas employs around contribution overall direction rd people five sites middle eastafrica sites glaxosmithkline invested billion spread across asia pacific area four sites china two japan pharmaceuticals rd approximately staff involved seven latin america biological pharmaceutical rd activities sites worldwide including vaccines supply chain vaccine production located principally rixensart belgium uk beckenham brentford cambridge dartford dresden germany sites employ around staff greenford harlow stevenage tonbridge ware vaccines production operates separate network welwyn garden city usa bristol tennessee philadelphia upper merion consumer healthcare supply chain upper providence pennsylvania research triangle consumer healthcare manufacturing sites spread park north carolina across countries employing around staff seven sites belgium rixensart added result january acquisition block drug canada mississauga incorporated supply organisation france les ulis evreux consumer healthcare supply chain diverse includes italy verona manufacturing supply otc medicines oral care nutritional japan tsukuba science city takasaki healthcare smoking cessation products spain tres cantos madrid first year merger integration rd undergone glaxosmithkline integration significant changes despite progress portfolio former glaxo wellcome strategic master plan smp maintained range products across many therapeutic smithkline beecham global supply initiative gsi programmes areas delivered market extensive focused improvements overall site network programme regulatory submissions markets worldwide consolidated one glaxosmithkline programme continued progression portfolio development cycle addition unprecedented inlicensing initiative long term integrated change programme called global strengthened pipeline particularly later stages practical supply network gsn structured deliver benefits management portfolio compounds development five major streams activity also focus ensuring glaxosmithkline rd invests resource projects achieve optimum value reduction site infrastructure costs procurement initiatives continued network rationalisation logistics improvements operational excellence lean sigma improvements glaxosmithkline description business product development pipeline product development pipeline set shows considerable breadth depth end glaxosmithkline pharmaceutical vaccine projects development clinic key date first submission date first regulatory approval maa first eu approval letter al approvable letter compound type indication phase maa nda antimicrobials host defence sb antifactor ix monoclonal antibody severe sepsis septic shock also stroke augmentingranules beta lactam antibiotic respiratory tract infections na incl penicillinresistant pneumoniae modified release granule formulation augmentin beta lactam antibiotic respiratory tract infections incl penicillinresistant pneumoniae daily formulation gr phospholipid antiendotoxin emulsion sepsis ii sitamaquine unknown treatment visceral leishmaniasis iii na tafenoquine sb aminoquinoline malaria prophylaxis adults iii lapdap antifolate treatment uncomplicated malaria iii na oxibendazole polymerase inhibitor treatment adult paediatric helminth iii na intestinal infections augmentin es beta lactam antibiotic acute otitis media incl penicillinresistant iii na pneumoniae highdose chewable tablet augmentin xr beta lactam antibiotic respiratory tract infections incl penicillinresistant submitted sdec sdec pneumoniae modified release formulation factive broad spectrum fluoroquinolone antibiotic respiratory urinary tract infections oral formulation submitted sfeb sdec antiviral gw hiv integrase inhibitor hiv infections ii ziagenepivir reverse transcriptase inhibitors hiv infection combination tablet iii gw protease inhibitor agenerase prodrug hiv infection iii valtrexzelitrex nucleoside analogue hsv suppression immunocompromised patients iii na valtrexzelitrex nucleoside analogue prevention hsv transmission iii valtrexzelitrex nucleoside analogue cold sores submitted na snov epivir reverse transcriptase inhibitor hiv infection daily dosing approved anov saug zeffix reverse transcriptase inhibitor paediatric hepatitis b approved sjun aaug cardiovascular urogenital gw peroxisome proliferatoractivator receptor dyslipidaemia ppar agonist gw ppar agonist dyslipidaemia sb antifactor ix monoclonal antibody stroke also severe sepsis septic shock sb lppla inhibitor atherosclerosis gw thrombin inhibitor prevention stroke secondary atrial fibrillation ii prevention treatment venous thrombosis gw angiotensin converting enzymeneutral hypertension ii endopeptidase inhibitor talnetant sb tachykinin nk antagonist urinary incontinence also irritable bowel syndrome ii copd cough schizophrenia sb indirect thrombin inhibitor prevention stroke secondary atrial fibrillation ii prevention treatment venous thrombosis sb ht antagonist atrial fibrillation ii sb potassiumcalcium channel blocker cardiac arrhythmia ii dutasteride gi alpha reductase inhibitor alopecia also bph ii natrecornesiritide recombinant betatype natriuretic peptide acute heart failure iii na pritortelmisartan angiotensin ii antagonist hypertension combination hydrochlorothiazide submitted sapr na vardenafil pdev inhibitor erectile dysfunction submitted sjan ssep dutasteride alpha reductase inhibitor benign prostatic hyperplasia also alopecia approved ssep anov coreg beta blocker severe heart failure approved na anov metabolic musculoskeletal gi ccka agonist obesity gw beta adrenergic agonist type diabetes sb beta adrenergic agonist type diabetes obesity gw u noradrenaline reuptake inhibitor obesity also attention deficit hyperactivity disorder ii tbd ibandronate bisphosphonate rd generation postmenopausal osteoporosis iii avandiametformin ppar gamma agonist plus metformin type diabetes combination tablet avandia ppar gamma agonist type diabetes combination insulin submitted alfebdescription businessglaxosmithkline compound type indication phase maa nda neurology gastrointestinal sb corticotropin releasing factor crfr irritable bowel syndrome also anxiety depression antagonist sb tr dual alpha integrin antagonist vla multiple sclerosis ms inflammatory bowel disease also asthma ra gw adenosine antagonist neuropathic pain migraine sb p kinase inhibitor inflammatory bowel disease also ra talnetant sb tachykinin nk antagonist irritable bowel syndrome also urinary incontinence copd cough gw cox inhibitor second generation pain including inflammatory pain sb ht antagonist alzheimers disease sb yh reversible proton pump antagonist gastroesophageal reflux disease sb endothelin antagonist haemorrhagic ischaemic stroke ii sb benzodiazepine inverse agonist alzheimers disease vascular dementia ii carabersat sb benzopyran epilepsy migraine ii imigranimitrex ht agonist migraine needlefree injection ii requip nonergot dopamine agonist parkinsons disease controlled release formulation ii requip nonergot dopamine agonist restless leg syndrome iii lotronex ht antagonist irritable bowel syndrome submitted na sdec snda imigranimitrex ht agonist adolescent migraine nasal formulation submitted sfeb sdec oncology sb recombinant human interleukin immunologicallysensitive cancers melanoma renal cell immunomodulator gw erbb egfr dual kinase inhibitor solid tumours sb grot cxc chemokine prevention chemotherapyinduced cytopaenias gw multidrug resistancebreast cancer solid tumours resistant protein inhibitor sb tumour activated prodrug colorectal cancer second line therapy pancreatic maytansineantibody conjugate cancer first line therapy repifermin keratinocyte growth factor mucositis also wound care inflammatory bowel disease ii ethynylcytidine sb selective rna polymerase inhibitor solid tumours ii hycamtin topoisomerase inhibitor small cell lung cancer first line therapy ii hycamtin topoisomerase inhibitor nonsmall cell lung cancer second line therapy iii hycamtin topoisomerase inhibitor small cell lung cancer second line therapy iii oral formulation hycamtin topoisomerase inhibitor ovarian cancer first line therapy iii navelbine vinca alkaloid nonsmall cell lung cancer oral therapy iii na bexxar iradiolabelled antib monoclonal nonhodgkins lymphoma submitted na ssep antibody psychiatry gw noradrenalinedopamine reuptake depression bipolar disorder inhibitor talnetant sb tachykinin nk antagonist schizophrenia also urinary incontinence irritable bowel syndrome copd cough sb corticotropin releasing factor crfr anxiety depression also irritable bowel syndrome antagonist gw glycine antagonist smoking cessation gw nk antagonist depression anxiety sb ht antagonist schizophrenia alzheimer disease ii vilazodone sba ssri ht partial agonist depression ii emd lamictal sodium channel inhibitor bipolar disorder acute treatment iii na lamictal sodium channel inhibitor bipolar disorder longterm prophylaxis iii wellbutrin xl bupropion aminoketone depression cr formulation daily dosing iii seroxatpaxil cr selective serotonin reuptake inhibitor premenstrual dysphoric disorder pmdd iii tbd controlled release formulation seroxatpaxil cr selective serotonin reuptake inhibitor panic disorder controlled release formulation submitted tbd afeb seroxatpaxil selective serotonin reuptake inhibitor posttraumatic stress disorder ptsd approved asep adec glaxosmithkline description business compound type indication phase maa nda respiratory inflammation sb p kinase inhibitor rheumatoid arthritis also ibd gw alpha integrin antagonist inhaled asthma upper respiratory inflammatory disease urid sb osteoclast vitronectin antagonist rheumatoid arthritis sb tr dual alpha integrin antagonist vla asthma rheumatoid arthritis also ms ibd gw adenosine agonist asthma chronic obstructive pulmonary disease ii copd urid talnetant sb tachykinin nk antagonist copd cough also urinary incontinence ii irritable bowel syndrome schizophrenia mepolizumab sb antiil monoclonal antibody asthma atopic dermatitis ii ariflo pde iv inhibitor copd iii flovent inhaled corticosteroid asthma daily dosing submitted na soct flixotideflovent inhaled corticosteroid copd approved asep smay noncfc metered dose inhaler propellants gr serevent beta agonist asthma copd iii flixotideflovent inhaled corticosteroid asthma copd approved aapr sfeb seretideadvair beta agonistinhaled corticosteroid asthma approved ajun aloct diskusaccuhalerdry powder inhaler seretideadvair beta agonistinhaled corticosteroid adult paediatric asthma daily dosing iii seretideadvair beta agonistinhaled corticosteroid copd submitted ssep smay seretideadvair beta agonistinhaled corticosteroid asthma first line therapy submitted sjun sapr serevent beta agonist copd submitted smay ventolin beta agonist asthma approved adec aljul hepatitis vaccines hepatitis e recombinant hepatitis e prophylaxis ii extra strength hepatitis b recombinant extra strength hepatitis b prophylaxis iii tbd poornonresponders twinrix doses recombinant combined hepatitis b prophylaxis childadolescent submitted sjun paediatric vaccines rotarix live attenuated oral rotavirus prophylaxis ii n meningitidis ac conjugated meningitis prophylaxis ii meningitis b cuba subunit meningitis b prophylaxis ii tbd pneumoniae paediatric conjugated pneumoniae disease prophylaxis children iii mmrvaricella live attenuated measles mumps rubella varicella prophylaxis iii tbd infanrix pentahepbipv recombinant diphtheria tetanus pertussis hepatitis b inactivated polio prophylaxis approved aoct sjul infanrix hexahep b conjugatedrecombinant diphtheria tetanus pertussis hepatitis b approved aoct tbd ipvhib inactivated polio prophylaxis haemophilus influenzae type b prophylaxis vaccines new influenza subunit influenza prophylaxis new delivery hiv recombinant hiv prophylaxis pneumoniae elderly conjugated pneumoniae disease prophylaxis epsteinbarr virus recombinant ebv prophylaxis ii malaria recombinant malaria prophylaxis ii human papilloma virus recombinant prophylaxis hpv infections ii simplirix recombinant genital herpes prophylaxis ii boostrix subunit adolescentadult booster diphtheria tetanus approved aoct pertussis pharmaccines gwpowderject recombinant hepatitis b treatment sb recombinant treatment chronic hepatitis b ii sb recombinant treatment lung cancermelanoma ii joint venture shionogi license agreement scios inc copromotion bayer ag codevelopment copromotion roche content drug development portfolio change time new compounds progress discovery development development market owing nature drug development process unusual compounds especially early stages investigation terminated progress development competitive reasons new projects preclinical development disclosed project types may identifieddescription businessglaxosmithkline compounds progressed phase clinical development several discovery projects listed table progressed nonclinical safety testing early phase clinical development compounds continuing rigorous nonclinical clinical commercial assessments leading proof concept decisions next months compound mechanism indication sb p kinase inhibitor rheumatoid arthritis asthma exacerbations inflammatory bowel disease gw adenosine aa agonist intranasal upper respiratory inflammatory disease gw noradrenalinedopamine reuptake inhibitor unipolar depression bipolar disorder sb lipoproteinassociated phospholipase inhibitor atherosclerosis sb interleukin melanoma carcinoma gw adenosine agonist migraine neuropathic pain gw alpha integrin antagonist asthma inhaled upper respiratory inflammatory disease gw peroxisome proliferator activator receptor agonist dyslipidaemia sb corticotropinreleasing factor antagonist unipolar depression anxiety irritable bowel syndrome augmentin betalactam antibiotic betalactamase inhibitor oncedaily treatment bacterial infections carabersat gap junction modulator epilepsy migraine prophylaxis product approvals submissions approvals received number new products including several significant new indications formulations existing products summarised table countryregion product approval date description alkeran usa may reformulated tablet cytotoxic melphalan cancer augmentin es usa june paediatric high dose mgml suspension formulation amoxicillin betalactam antibiotic clavulanate beta lactamase inhibitor acute otitis media becotide europe july noncfc metereddose device inhalation delivery corticosteroid treatment asthma boostrix european countries combined diphtheria tetanus acellular pertussis vaccine january november booster indication coreg usa november betablocker carvedilol treatment severe heart failure deroxat seroxat france may selective serotonin reuptake inhibitor treatment social anxiety disorder dutasteride usa november alpha reductase inhibitor benign prostatic hyperplasia epivir europe november daily presentation reverse transcriptase inhibitor lamivudine hiv flixonase europe may intranasal formulation corticosteroid fluticasone propionate treating sinus pain pressure influenza vaccine europe july august influenza vaccine strains prevalent malarone europe april combination atovaquone proguanil malaria prophylaxis paxilseroxat usa april selective serotonin reuptake inhibitor treatment generalised european countries anxiety disorder incl uk marchsept paxilseroxat european countries selective serotonin reuptake inhibitor treatment posttraumatic incl uk februaryjuly stress disorder usa december seretide europe januaryjune combination salmeterol fluticasone propionate noncfc metered dose inhaler treating asthma twinrixadult usa may combined hepatitis b vaccine adults ventolin usa april noncfc metereddose inhaler formulation bronchodilator salbutamol treating asthma zeffix usa august reverse transcriptase inhibitor lamivudine treatment hepatitis b paediatric use glaxosmithkline description business number significant regulatory submissions made set product region description ambirix europe combined hepatitis b vaccine twodose treatment regimen dutasteride europe alpha reductase inhibitor benign prostatic hyperplasia dutasteride usa alpha reductase inhibitor two years data benign prostatic hyperplasia epivir usa lamivudine reverse transcriptase inhibitor daily treatment hiv flovent usa fluticasonepropionate inhaled corticosteroid daily dosing asthma flovent usa treatment chronic obstructive pulmonary disease myleran usa new tablet formulation busulphan cancer seretideadvairdiskus europe usa combination salmeteroland fluticasonepropionate diskusas first line therapy asthma seretideadvair diskus europe usa treatment chronic obstructive pulmonary disease serevent diskus usa salmeterolfor treatment chronic obstructive pulmonary disease telmisartan hydrochlorthiazide europe fixeddose combination telmisartan angiotensin ii antagonist hydrochlorthiazide diuretic hypertension ultiva europe remifentanil shortacting opioid use anaesthetic intensivecare units valtrex usa valaciclovir nucleoside analogue treatment cold sores zeffix europe usa lamivudine reverse transcriptase inhibitor paediatric treatment hepatitis b inlicensing establishing joint venture shionogi completed one focus identify compounds would joint venture exclusive rights develop commercialise enhance existing future franchises create innovative selected compounds contributed companies initial collaborations ensure glaxosmithkline regarded compounds provided shionogi gw partner choice large small companies following hiv integrase inhibitor hiv infection phase ii compounds subject inlicensing copromotion deals sb benzodiazepine partial inverse agonist alzheimers disease vascular dementia phase ii sb endothelina receptor antagonist treating sba mixed selective serotonin reuptake inhibitor haemorrhagic ischaemic stroke phase ii hta receptor partial agonist phase ii depression sb ampanmda antagonist stroke head licensed merck kgaa injury preclinical development grx phospholipid antiendotoxin emulsion phase ii sepsis inlicensed sepsicure sb kinesin spindle protein inhibitor treatment controlledrelease formulation bupropion wellbutrin cancer inlicensed part alliance cytokinetics phase iii development oncedaily treatment depression centred therapeutics targeting mitotic kinesins inlicensed biovail agreement also signed tanabe seiyaku broad ibandronate bisphosphonate phase iii development ranging global collaboration research development osteoporosis codevelopment copromotion commercialisation series tanabe preclinical compounds hoffmanla roche covering range potential therapeutic areas including vardenafil selective phosphodiesterase inhibitor male psychiatry neurology urology diabetes erectile dysfunction copromoted bayer ag nesiritide natrecor btype natriuretic peptide phase iii research development collaboration drug treatment acute heart failure inlicensed europe delivery systems dds division initiated formulate novel scios inc drugs fight respiratory diseases asthma chronic obstructive pulmonary disease copd addition several broader collaborative initiatives completed providing inlicensed compounds agreement also reached inex pharmaceuticals corporation develop targeted cancer drugs encapsulate glaxosmithkline signed worldwide development glaxosmithkline 's proprietary camptothecin anticancer agents commercialisation agreement neurocrine biosciences inside inexs drug delivery technology called transmembrane corticotropin releasing factor receptor antagonists crfr carrier system first drug developed inex crfr entirely new class compounds treat psychiatric hycamtin neurological gastrointestinal diseases including anxiety depression mood disorders irritable bowel syndrome neurocrines lead crfr antagonist sb currently phase developmentdescription businessglaxosmithkline rd processes discovery commercialisation delivery regard integrated new product development function combines responsibility clinical regulatory commercial activities necessary bring new medicine marketplace similarly creation new product supply organisation bridges traditional divide development manufacturing taking responsibility scaleup production centres genetics preclinical subsequent manufacture physical product another research excellence development new important step glaxosmithklines rd japan future medicines proven fully integrated companys global development drug discovery discovery new product value commercialisation processes order eliminate work duplication research development cedds speed regulatory filings plans rationalising discovery work japan tsukuba site development takasaki facility agreed part continuing focus optimising operational effectiveness rd glaxosmithkline completed sale affymax drug discovery operation based santa clara california syndicate venture capital firms rd also closed sites rennes france acquired bioproject milan intellectual property validated targets drugs products italy became location nikem research new company leads created demerger former local glaxosmithkline medicinal chemistry group rd processes line glaxosmithkline 's strategic intent become early research role genetics indisputable leader industry rd set goal early stages finding new medicines requires essentially two becoming productive rd organisation industry components targets shown affect mechanisms important pathological processes human disease ie target glaxosmithkline rd measures productivity compounds typically small molecules also including number innovativeness products creates also macromolecules protein therapeutics vaccines able value commercial value measure product 's ability modulate behaviour target glaxosmithkline 's heritage address unmet needs healthcare customers including smithkline beecham glaxo wellcome genomics patients healthcare professionals budget holders regulators genetics research means company wellplaced select perspective constitutes valuable human genome subset therapeuticallyrelevant new product rd positioned ensure generates targets hence focus earlystage research efforts right information respond different perspectives ie safety efficacy quality information also data part target validation process glaxosmithkline aims demonstrating overall reductions healthcare utilisation identify genes relevant common diseases large result use new medicine increased length quality unmet medical needs asthma noninsulin dependent life increased workplace productivity diabetes migraine osteoarthritis metabolic syndrome depression chronic obstructive pulmonary disease early onset heart disease order implement operationally drive towards product value alzheimers disease many diseases arise complex primary objective rd glaxosmithkline interactions number gene variants environmental implemented many rd processes devised merger factors challenge involved unravelling picture planning period especially designed eliminate underestimated nevertheless identifying genes traditional barriers successful rd successful predispose patients particular disease understanding commercialisation allows value asset role disease progression leads identification new ways maximised consistent prioritisation strategic direction intervene diseases earliest stages rd product launch subsequent lifecycle management discovery research key glaxosmithklines rd organisation development purpose discovery research dr identify lead design philosophy enables leverage critical compounds form basis new drug discovery efforts mass areas research clinical development centres excellence drug discovery cedds investment creates strategic advantage focused agile structure dr focused improving quality number drug discovery commensurate entrepreneurial approach lead compounds produced end rd began building new ensure efficient rapid validation lead candidates automation facilities tres cantos harlow preclinical testing proof concept criteria completed plans facility upper providence conducting pharmacological exploration effects new compounds similar speed capacity degree automation challenging substantive progress made implementing high throughput biology plans new discipline also help determine relevant therapeutic applications new drugs modulating pathological mechanisms may underpin several different diseases glaxosmithkline description business crucial success rd capacity embrace preclinical development develop new technologies streamline drug discovery process scientific technical activities support work establishment new technology development discovery research cedds new product development organisation rd keep abreast emerging technologies collected within preclinical development grouping may advance creation new medicines evaluate encompasses disciplines developing understanding technologies provide investment knowledge compounds absorbed body pharmacokinetics required develop selected technologies best advantage pharmacology metabolised well rd generates modifies technologies focus establishing probability either shortterm longterm glaxosmithkline 's internal goals also maximise toxicological effects additionally chemical development return rd assets sales spinouts outlicensing division responsible definition efficient synthesis mechanism candidate molecules minute quantities centres excellence drug discovery required initial testing appropriate scale support two crucial steps converting lead compounds drug commercialisation pharmaceutical development final candidates optimising lead potency selectivity dosage form testing establish optimum quality standards efficacy safety intrinsic characteristics molecule storage conditions experienced around world ii demonstrating validity therapeutic hypothesis also performed organisation early clinical trials resulting candidate molecule efficient delivery rapid worldwide uptake new part merger glaxosmithkline established six innovative products closely linked ease manufacture issues cedds take responsibility lead optimisation scaleup manufacturing technology considered proof therapeutic concept focusing specific disease early stage product development process moving areas cedds designed nimble entrepreneurial smallscale production experimental materials early largely autonomous matrix teams range skills scale clinical studies largescale industrial manufacturing resources required drive midstage development projects product supply fast efficient responsibility key decisionpoint major investments new product supply partnership rd global made fund largescale phase iii clinical trials manufacturing supply partnership ensures disease responsibilities three usa based cedds development organisation delivers product already aligned order increase focus increase optimised terms largescale commercial manufacturing efficient use resources new product development cardiovascular urogenital diseases centred upper merion provide focus development commercialisation metabolic viral diseases centred research triangle park process must proceed unison major functional microbial musculoskeletal proliferative diseases including components medical regulatory product strategy cancer centred upper merion upper providence integrated single management organisation six cedds complemented three europe crossfunctional therapeutic area strategy teams covering one group diseases neurology centred harlow uk psychiatry centred verona italy cardiovascular urogenital metabolic respiratory inflammation respiratory pathogens centred infectious diseases including developing world diseases stevenage uk neurology gastrointestinal oncology musculoskeletal inflammation cedds ' autonomy includes freedom select new psychiatry compounds either internal external sources respiratory reinforces close integration glaxosmithkline 's inlicensing function business development part rd organisation matrix teams responsible maximising worldwide cedd responsible selecting optimal candidate development opportunities product within remit series similar chemical compounds ensuring work ensure alignment regional marketing candidate safe animal models developed needs clinical commercial information generated technical perspective achieved cedds new product developed teams also collaborate responsible proving compound safe efficacious early stage cedds define target product profiles patients proofofconcept provisionofconfidence decision new molecules integrated technical development point decision made basis information manufacturing functions ensure rapid effective launch generated date progress compound late stage drug delivery product development necessary largescale clinical trials genetic research becomes highly informative stages conducted successfully register commercialise product drug candidate enters clinical trials indeed launch point responsibility project passes crossfunctional extensive use brings research teams led members new product development elucidate genetic basis underpins variable responses part glaxosmithkline 's major response challenges regard therapeutic efficacy sideeffects seen diseases affecting developing world microbial musculoskeletal medicines knowing enable healthcare providers proliferative diseases cedd responsibility new drug prescribe medicines accurately safely discovery unit based tres cantos spain dedicated finding new medicines treat diseasesdescription businessglaxosmithkline discontinuations animals research research development carries risk failure commensurate ethical regulatory scientific reasons research using animals extension scientific knowledge compound remains small vital part research development effects lead compounds identified possess new medicines vaccines animals used positive activity validated target prove safe alternative available glaxosmithkline constantly aims enough introduce humans feasible manufacture reduce numbers used glaxosmithkline strives exceed commercial scale glaxosmithkline rd endeavours ensure industry standards care welfare animals uses far possible risks ameliorated extensive predictive laboratory animals usually bred specifically research testing early possible development process well cared throughout lives qualified trained staff number new activities genetics research discovery animals used research unnecessary pain suffering research preclinical development initiated establish isscrupulously avoided validate leadingedge predictive toxicology enable glaxosmithkline actively engaged research develop optimisation early portfolio informed decision validate experimental methods provide better making prior largescale investment effort resources alternatives use animals research despite efforts ultimate test product remains point administered large numbers patients glaxosmithkline acknowledges use animals research disease purposes subject enormous sensitivity rightly commands high level public interest full glaxosmithkline public review data phase iiia trial tranilastshowed policyposition 'the care ethical use animals research ' benefit placebo development compound isavailable public company internet site therefore take place wwwgskcomtomorrowanimalshtm request review data gi peroxisome proliferator activated company secretary receptor ppar agonist phase iii clinical trials treatment type diabetes indicated meet target profile research development consumer healthcare established development product principal centres consumer healthcare research diabetes terminated work ongoing development uk usa focus rd indications identification rapid development novel products latestage projects terminated bring significant health benefits consumers otc oral care development micronised preparation nonsteroidal nutritional healthcare markets consumer healthcare liaises antiinflammatory drug nabumetone treating osteoarthritis closely pharmaceuticals maximise groups assets pain therapeutic antigen disabled infections single cycle prescription products also find application otc vaccine treatment herpes nebuliser formulation marketplace flixotide inhaled corticosteroid fluticasone propionate acute paediatric asthma research collaborations glaxosmithkline entered number agreements third parties codevelop comarket certain compounds arrangements range milestone payments third parties acquire rights intellectual property joint ventures develop commercialise specified compounds many agreements group obligations make payments future specified milestones achieved financial commitments summarised note financial statements commitments vaccines rd worldwide vaccines rd conducted biologicals team located principally rixensart belgium part pharmaceuticals sector team follows essentially similar approach development vaccines glaxosmithkline description business operating resources intellectual property lamictal patents active ingredient lamotrigine due expire usa virtue paediatric glaxosmithkline regards intellectual property key business exclusivity bin europe asset effective legal protection intellectual property key element ensuring effective return investment retrovirbasic patents active ingredient zidovudine rd intellectual property protected patents trade marks expired patents covering pharmaceutical formulations containing registered designs copyrights domain name registrations zidovudine medical use due expire glaxosmithkline regards patent trade mark rights usa europe particularly valuable epivirthe patents active ingredient lamivudine due expire usa bin europe patents glaxosmithklines policy obtain patent protection combivirthe patents specific combination lamivudine significant products discovered developed rd zidovudine due expire usa activities patent protection new active ingredients available bin europe significant markets addition protection also obtained valtrex patents active ingredient valaciclovir due new pharmaceutical formulations manufacturing processes expire usa bin europe well new medical uses special devices administering products ziagen patents active ingredient abacavir due expire usa bin europe glaxosmithkline continues patent protection one forms key pharmaceutical products major markets zofran patents active ingredient ondansetron addition obtained patents anticipates patent due expire usa bin europe protection granted new products patents use emesis expire glaxosmithkline development initiated legal action patents generic manufacturers us patent position respect significant products follows seretideadvairthe patents specific combination active paxilseroxatthe patent protecting commercial form ingredients salmeterol fluticasone propionate due paxilseroxatis due expire major markets expire usa bin europe however glaxosmithkline initiated patent infringement litigation usa europe number generic avandiathe patents active ingredient rosiglitazone maleate manufacturers attempting launch versions due expire usa bin europe product prior patent expiry serevent patents active ingredient salmeterol xinafoate augmentinthe basic patent key active ingredient potassium due expire bin europe b france clavulanate expired markets except usa bin italy usa italy us patents providing protection common many companies glaxosmithkline currently legal challenge us courts routinely engaged legal disputes defence patent rights flixotidefloventand flixonaseflonasein usa patent products see note financial statements legal active ingredient fluticasone propionate expires proceedings protection expected extended virtue paediatric exclusivity may european countries patents trade marks due expire b glaxosmithklines pharmaceutical products protected registered trade marks major markets general mark wellbutrin sr andzybanpatents basic active ingredient used product market around world expired various formulation patents protect currently may local variations example united states trade marketed sr formulations latest due expire mark paxilis used instead seroxatand advairis used instead usa patents legal challenge seretide uscourts europe regulatory data exclusivity additionally provides protection least trade mark protection may generally extended long countries trade mark used renewing necessary glaxosmithklines trade marks pharmaceutical products generally zinnatceftin patents active ingredient cefuroxime assume increasing importance patent product axetil generally expired expire expired particular country generic versions european countries patent extended product become available patents specific amorphous form used glaxosmithklineproduct due expire consumer healthcare business trade marks particularly glaxosmithkline initiated legal action important business brand orientated many patents two generic manufacturers usa products patent protection imigranimitrex patents active ingredient sumatriptan glaxosmithkline routinely engaged legal disputes defence due expire usa bin europe trade mark rights takes action companies found infringing versions products including extension term b including extension term supplementary protection certificatedescription businessglaxosmithkline information technology enhancing business performance virtually glaxosmithklines major business processes rely heavily information technology plays three strategic roles use information technology major programmes glaxosmithkline capture key information source electronic form make facilitates communication access information available wherever required global basis improving quality potential value molecules supports key business processes local regional move discovery development key aim rd functional global levels developed webbased tools provide chemists biologists enables transformation extension key business information need candidate medicines activities information targets molecule well computer infrastructure hardware software tested results obtained unique organisation responsible voice video technologies molecule molecules might similar monitoring business technology trends could characteristics way earlyphase rd teams draw impact glaxosmithkline preparing company short lists molecules consideration possible treatments risks associated modern information technology specific diseases faster confidence qualities shortlist areas rd playing throughout year focused helping business units important role highthroughput biology laboratory automation achieve merger synergies establishing networks imaging electronic data capture document knowledge systems new company whenever possible one clinical data management legacy companies systems selected glaxosmithkline combination completing critical systems integration work began extend manufacturing enterprise resources meeting synergy targets remain highest priority planning solution next four five years ability theshortterm consolidate mission critical operations way reflects growing availability reliability global data networks within consumer healthcare integration block drug ensures glaxosmithkline compliant systems place business glaxosmithkline systems achieved within common processes sixmonths acquisition led per cent reduction combined costs usa ways identified improve speed data delivery vendors streamline data processing financial data systems european countries adopting reduce per cent time taken provide retail euro base currency converted readiness prescription data reports business result sales january introduction representatives managers able make faster better informed decisions communication access information importance glaxosmithkline internet internal transforming extending business activities intranet continues grow internal websites allow information insights gained genomics proteomics transforming shared across company global basis supported way disease targets identified validated information search engines analogous used externally obtained variety external sources needs integrated internet ability provide shared access information internally generated information rapid flexible manner enabled growing use virtual teams work relies heavily information technology support analysis collaboratively spanning multiple geographies time zones databases also requires significant amounts processing often subject stringent time constraints glaxosmithklines power taking full advantage advances computer technology intranet adopted portal strategy order assist employees choose receive information need access information regulatory agencies clinical opinion leaders healthcare professionals patients public information exchanged electronically broad array enhanced number markets steps taken reduce suppliers customers partners hence protection reliance paper based processes clinical trials registration unauthorised access information assets growing risks new medicines use wireless handheld technologies posed computer viruses major issue well internet telephone video conferences familiar aspect business life complemented computerbased glaxosmithkline people collaborative working screensharing tools help teams glaxosmithkline people fundamental current future respond practical challenges posed operating global success business skills intellect key organisation enabling glaxosmithkline knowledge workers components successful implementation sound business productive key goal standard desktop strategy glaxosmithklines human capital maximises adopted globally assist support employees use potential groups scientific commercial financial assets software efficiently outcome effective human resources policy glaxosmithklines solid reputation international employer choice employer choice group initiated candidate care commitment seeking acquiring best employment candidates reflect diversity background experience perspective contribute success glaxosmithkline glaxosmithkline description business performance reward executive development programmes designed identify importance people must translate employment practices prepare talent required grow business worldwide demonstrate value individual compensation programmes develop skills areas key future business benefit packages glaxosmithklines totalreward competitive success entrepreneurialism strategic insight global mindset innovative either global local orientation depending crossfunctionalcultural collaboration competitive intelligence best drives business performance rewards individual innovative based peer interaction idea exchange contribution contribute strategy deployment compensation philosophy programme development underscore human resources services information systems glaxosmithklines commitment performance culture human resources services information delivered performancebased pay base variable share awards share low cost highly effective channels make easy job options performance development planning evaluation candidates employees retirees access information contribute retention key talent superior performance employment compensation benefits policies programmes accomplishment business targets glaxosmithklines human resource delivery strategy designed commitment flexible working flextime teleconferencing make technology available today deliver valuable remote working flexible work schedules recognises information employees convenience allow employees work best environment helps integrate return work quickly comprehensive content core work personal lives transactions delivered intuitive personalised webbased tools available employees many locations example communication involvement usa employees may supported employee response extensive range communications programmes stimulates center stateoftheart call centre provides information involvement glaxosmithkline goals progress including services presentations business results groupwide magazines site newspapers videos recorded voice mail messages senior property plant equipment executive officers access glaxosmithkline intranet glaxosmithkline operating establishments countries tools facilitated successful integration geographical spread groups activities indicated two companies one company note financial statements principal group companies share ownership schemes encourage participation owners glaxosmithkline conducts research development business increasing awareness short longterm business sites manufactures product sites objectives global local employee opinion surveys allow countries refer research development pharmaceuticals employees opportunity express views perspectives manufacture supply important company issues glaxosmithkline invested billion property acarrying value financial statements billion diversity billion carrying value invested plant equipment company wide diversity strategy focuses creating glaxosmithkline invested billion new andrenewal inclusive work environment benefits employees customers property plant equipment property mainly heldfreehold stakeholders approach aims enhance employee new investment financed existing group liquid resources innovation productivity valuing drawing st december group contractual commitments differing knowledge perspectives experiences styles resident future expenditure million operating global community diversity initiative lead lease commitments million corporate executive team jack ziegler president consumer healthcare sponsor key objective create glaxosmithklines business sciencebased technologyintensive communicate diversity strategies measurably improve employee highly regulated governmental authorities glaxosmithkline attraction development retention allocates significant financial resources renewal maintenance property plant minimise risks glaxosmithkline remains committed employment policies interruption production achieve compliance discriminate potential existing staff regulatory standards research development grounds colour race ethnic national origin gender marital manufacture active pharmaceutical ingredient require use status religious beliefs disability ofchemicals hazardous materials glaxosmithkline observes stringent procedures uses specialist skills manage leadership development talent management environmental risks activities environmental issues comprehensive leadership development opportunities available sometimes dating operations modified discontinued employees levels opportunities targeted help referenced environmental responsibility leaders meet challenges face global economy note financial statements legal proceedings matrixed organisation ensure glaxosmithklines leadership motivates enables teams individuals best work glaxosmithkline believes facilities adequate development planning key element overall performance current needs integration glaxo wellcome smithkline planning year beecham operations involved series announcements rationalisation potential disposal number sites properties considered changesdescription businessglaxosmithkline business community performance integrity integrating environment health safety planning decision making manufacturing processes packaging design product first time glaxosmithkline producing social labelling helps differentiate products protect extend environmental review entitled performance integrity lives incorporate information pressing issues core business generated significant interest global corporate citizen glaxosmithkline demonstrates external shareholders include medicines developing responsibility implementing global standards guidelines targets world community investment environment health management systems auditing reporting publicly safety performance integrity available openly performance seeks dialogue external secretariat companys head office company web stakeholders considers views developing approaches site wwwgskcom may information made available ehs management web site constitute part document glaxosmithklines operations must achieve legal compliance ehs regulations continuously improve performance particularly environmental responsibility areas accident prevention waste minimisation environment health safety ehs section performance emissions reductions seeks align business processes ensuring integrity incorporate information groups ehs incorporated planning decisionmaking environmental responsibility well covering issues programmes budgeting training communications performance although group makes ongoing capital expenditures environmental protection equipment well cash expenditures environment health safety management site remediation operation maintenance successful management environment health safety high environmental facilities anticipate expenditures priority glaxosmithkline companys first year material impact upon groups capital expenditures primary focus create management organisation cash flows management system integrated concepts features high standards practice heritage companies objectives metrics targets represents systematic approach alignment established broad goal environment health safety international standards starts comprehensive ehs policy establishment organisation framework management among first policies approved glaxosmithkline system new company established year policy supported standards foundation also baseline year establishing performance levels ehs management system establish basic requirements intensive consultation process followed establish targets operations must comply ensure compliance local accomplished end based laws regulations guidelines giving detailed information feasible improvement projects specific sites ' opportunities recommended ways meet standards development improvement targets set individual sites rolled followed additional technical information training form overall company targets resulting complete framework ehs programmes associated documentation environment health safety audits glaxosmithkline performed audits selected sites assess stakeholder dialogue status environment health safety programs group extensive internal stakeholder dialogue ehs development glaxosmithkline ehs standards audits programmes initiatives including target setting process conducted standards established engages major contributors develop concrete plans heritage companies audit protocol follows new improvements groups environmental profile standards developed implemented glaxosmithkline also worked key external stakeholders form basis exploring iso certification ensure approach ehs meets expectations injury illness environment health safety strategy glaxosmithkline aspires work environment environment health safety considerations integral result injury illness employee target set injury way glaxosmithkline business ehs strategy aligned illness improvement reduce rate per cent per business drivers embraces principles continuous year baseline end result improvement also supports corporate social responsibilities rate one lowest pharmaceutical industry vital protect health safety employees contractors visitors others affected companys important issues operations group designs facilities processes conducts several issues important glaxosmithkline risk assessments provides training order eliminate work either global significance issue related safety health hazards specific group impact issues include climate change air emissions use material resources efficiency processes glaxosmithklines products carefully designed create company generates handles disposes waste biological change patients result potential ehs risks profile contract manufacturers key suppliers public impacts throughout lifecycle applying principles issues pharmaceuticals environment glaxosmithklines product stewardship throughout organisation delivers positive commitment issues covered webbased social ehs benefits minimises risk principles also apply environmental review performance integrity contract manufacturers key suppliers glaxosmithkline description business access medicines developing world preferential pricing arrangements glaxosmithkline understands need prices reflect far healthcare developing countries pressing problem possible ability purchase offered sustainable widely acknowledged poverty root cause large preferential pricing arrangements least developed countries parts populations developing countries subsaharan africa vaccines years secure regular access food clean water let alone hivaids medicines since groups longterm healthcare services glaxosmithkline vital role play commitment make contributions world health developing suitable products making available sustainable preferential prices therefore set preferential prices encouraging supporting others commercially viable levels sustained long play full part company however patients need treatment mandate expertise resources address underlying problems exist sectors global society governments working partnership international agencies well private sector must work significant barriers stand way access together improve healthcare developing world medicines developing world must tackled shared efforts must backed funding massive scale responsibility sectors global society glaxosmithkline welcomes therefore creation global glaxosmithkline continued engage stakeholders working fund fight aids tb malaria gfatm looks forward access medicines developing world including many time provide appropriate funding maximise nongovernmental organisations ngos company also benefit patients companys preferential pricing offers consulted worked governments developed much focus debate access medicines developing world un patents glaxosmithkline believe patents restrict investment community continue constructive dialogue access medicines contrary true patents stimulate organisations share aim trying improve access fundamentally underpin framework medical medicines developing world advances depend led sustained investment glaxosmithkline making vital contribution improving health research development rd effective intellectual property care developing world group continue legislation mechanisms enforce essential efforts focusing areas make difference maintaining rd new better medicines including helping find innovative ways making medicines diseases prevalent developing world available accessible developing countries part glaxosmithkline takes innovative responsible holistic approach care may company publish sustainable approach addressing healthcare challenges social environmental review expand groups developing world june company published facing approach progress made addressing issue access challenge report sets principles commitment medicines developing world contribution improving healthcare developing world three key areas company contribute global community partnerships corporate donations continuing investment rd diseases particularly glaxosmithkline 's community investment charitable donations affect developing world offering sustainable preferential pricing totalled million equivalent per cent arrangements taking leading role partnership group profit tax community activities promote effective healthcare many programmes longterm commitments help rd diseases developing world bring sustain change donations made continued investment research diseases affect number years group 's community investment activities developing world essential improvement focused following areas disease programmes regional health people live regions least community initiatives education product donations employee challenges drug resistance poor patient compliance involvement lack funding healthcare means often commercial market products therefore glaxosmithkline disease programmes frequently works partnership share expertise costs risks global alliance eliminate lymphatic filariasis make rd developing world diseases viable glaxosmithkline key member global alliance scale glaxosmithklines commitment substantial eliminate lymphatic filariasis lf unique partnership glaxosmithkline company currently involved research includes world health organization ministries health development prevention treatment three endemic countries ngos communitybased organisations top priority diseases world health organization academic institutions international organisations private malaria tuberculosis hivaids company numerous sector glaxosmithkline supports alliance donating anti rd projects medicines largest programme research parasitic drug albendazole help coalitionbuilding vaccines diseases prevalent developing world planning training communications initiatives glaxosmithkline glaxosmithkline recognises importance work committed donate much albendazole required investing effort basic research centre achieve goal eliminating lf anticipated year life tres cantos spain established site research drugs programme third year programme diseases developing world approximately million tablets shipped countries numbers expand programme extends billion people risk countriesdescription businessglaxosmithkline positive action hivaids donated total british retinitis positive action glaxosmithklines longterm international pigmentosa society marie curie institute mental health programme hivaids education care community support foundation parkinsons disease society research ageing programme glaxosmithkline works partnership support medical research donation made networks people living hivaids community groups equip laboratory bristol interactive exhibition international agencies nongovernment organisations combines science nature arts governments intensify community responses hivaids glaxosmithkline international impact awards recognise diverse array partners reflective community identified needs work voluntary community healthcare organisations ten winners requirements respond effectively hiv epidemic received award unrestricted requirements include implementation initiatives deliver group donated noahs ark appeal hiv education prevention psychosocial care support helped kickstart fund build first childrens hospital alleviate stigma discrimination positive action supports capacity wales group supporting red cross gateway project building programmes provide organisations advocacy scotland donating help young people disabilities fund raising strategic management leadership communication live independent lives skills thus promoting rights improving quality lives people living hivaids example company sponsored american sublime exhibition tate britain february may works exhibition positive action partnered international council never seen uk aids service organisations implement programme dialogue care treatment infrastructure issues royal botanic gardens kew redeveloped extensive community mobilisation project twoyear programme collection grasses around world display advance community discussion infrastructure issues gardens donation company hivaids care treatment strengthen community europe based response hivaids programmes europe focused children 's health total centre african family studies initiative supports funding million supporting range longterm programmes organisational development people living hivaids including africa glaxosmithkline funded pilot programme reaching young europe programme run increase participation communitybased groups befrienders international umbrella organisation networks people living hivaids local national samaritan movement worldwide help children denmark international hivaids policy discussions programme lithuania develop stress coping skills enabled participating organisations deliver effective services including home based care extended project hope run programme russia ukraine combat substance abuse paediatric positive action supports community attendance regional rehabilitation programme bosnia international hivaids conferences support includes barretstown gang camp ireland l'envol france community scholarship programmes support meeting areas provide therapeutic recreation seriously ill children exclusive people living hivaids implementation europe received respectively community orientation sessions support enables individuals underresourced communities attend conferences share north america experiences particular address discrimination stigma programmes north america focused improving access violation human rights home countries better healthcare partnership funding million allocated positive action main supporter community north america community partnerships team attendance conferences trinidad thailand million invested regional community activities addition million donation made new york city community malaria programme disaster fund july announced malaronedonation programme established would end september threeyear grant million made support upon completion pilot phase donation programme childrens health funds referral management initiative rmi proved efficient effective use resources grant ensures continuity care medically underserved achieve objective reducing suffering death malaria highrisk children often homeless company committed focus resources allocated third annual share awards recognise communitybased malaronedonation programme new community partnership programmes meet needs racially ethnically malaria initiative announced culturally diverse elders total million awards distributed threeyear period awards administered regional community initiatives university pennsylvania institute aging united kingdom threeyear partnership exists ovarian cancer glaxosmithkline made charitable donations million uk national alliance heighten awareness ovarian cancer charities uk corporate donations committee among women physicians managed care organisations projects science education medical research carter centers rosalynn carter fellowships mental health healthcare arts environment funded journalism three year programme promote long addition glaxosmithkline companies uk provided term systemic change american publics belief million community investment purposes giving combined perception mental illness total million support projects uk glaxosmithkline description business glaxosmithklines three year grant united way concern children trust charity established promote southeastern pennsylvania create effective healthcare health wellbeing children pakistan specific delivery united ways member agencies glaxosmithklines focus preventive primary healthcare education international impact awards acknowledge reward excellence glaxosmithkline provided funding healthcare nonprofit healthcare community greater philadelphia screening education immigrant children lowincome area ten winners received areas karachi around glaxosmithklines facilities north carolina community health education mothers major childhood killers relations staff work address issues affect employees programme completed third final year families communities glaxosmithkline supports glaxosmithkline provided three years nine programmes health education arts civic affairs country initiative aimed providing mothers developing countries basic information needed recognise major promising practices supports prevention treatment childhood killers chronic diseases affect lowwealth communities received three years education schools links glaxosmithkline supported education contributions education programme glaxosmithkline works inkind donations volunteerism supporting nc range partners develop young peoples knowledge business committee education various education foundations understanding technical personal skills number areas governors entrepreneurial schools award particular focus science programmes include playmakers repertory companys educational matinee series brings science across world international educational arts classroom glaxosmithkline provided programme encouraging communication shared learning across different cultures habitat humanity received toward construction annual health matters european schools awards three homes lowwealth families glaxosmithkline employees introduce students importance health issues today 's volunteered build habitat homes society develop teamworking investigation research glaxosmithklines investment volunteer excellence give communication skills provided grants qualifying nonprofit organisations based support royal institution christmas lectures employeepartner volunteer time give grants totalled provide opportunity young people learn science glaxosmithkline employees volunteered hours eminent scientists active science new web resource pupils aged five plus finally north carolina glaxosmithkline foundation people medicine new webbased resource supporting advancement education science health endowed science students aged selffunding organisation operates separate entity foundation publishes annual report available glaxosmithkline 's local sites also participated actively promoting request uses asset base support maths science learning education local communities health education north carolina product donations international glaxosmithkline donates essential products humanitarian relief glaxosmithkline 's international community partnerships projects efforts donations made request governments addressed health education mobilisation providing partnership major charitable organisations made product funding million programmes included inventory nongovernmental organisations complete needs assessment order product needed international support phase initiative personal hygiene communities ensures right product reaches right sanitation education kenya uganda nicaragua peru person right time total value groups phase provides hygiene sanitation education school children international product donations excluding lfprogramme aim reducing diarrhoearelated disease deaths million wholesale acquisition cost allocated two health improvement programmes indigenous population communities australia employee involvement glaxosmithkline employees encouraged contribute provided fund new hivaids clinic masoyi local communities employee volunteering schemes tribal area mpumalanga south africa clinic part support varies around world includes paid time threeyear glaxosmithkline programme provide donations charities employees completed voluntary quality continuum care region work matched giving glaxosmithkline matches infected affected hivaids personal cash contributions employees qualifying institutions glaxosmithkline 's rural nursing excellence programme matching gifts programme usa thailand sponsors female high school graduates rural glaxosmithkline matched employee gifts areas complete four year nursing degrees glaxosmithkline value million donated five years train nurses march addition special disaster relief fund established help saw first graduates programme victims tragedy took place usa th september total gifts made totalling glaxosmithkline also matched giftsglaxosmithkline corporate governance section discusses glaxosmithklines management structures governance procedures board corporate executive team governance policy dialogue shareholders annual general meeting accountability audit combined code glaxosmithkline corporate governance b board sir peter job aged cg nonexecutive director sir peter formerly nonexecutive sir richard sykes aged director glaxo wellcome plc former chief executive nonexecutive chairman sir richard chairman glaxo reuters group plc nonexecutive director schroders wellcome plc completion merger plc shell transport trading company plc tibco software inc formglaxosmithkline plc rector imperial college instinet group llc science technology medicine doctorate microbial f biochemistry bristol university doctor science degree john mcarthur aged university london fellow royal society sits nonexecutive director mr mcarthur formerly nonexecutive number government scientific committees received director glaxo wellcome plc former dean harvard knighthood services pharmaceutical industry business school nonexecutive director bce inc cabot also nonexecutive director rio tinto plc corporation rohm haas company springs industries inc df aes corporation sir roger hurn aged fh nonexecutive deputy chairman sir roger appointed donald mchenry aged nonexecutive director glaxo wellcome plc deputy nonexecutive director mr mchenry formerly non chairman nonexecutive chairman prudential plc executive director smithkline beecham plc nonexecutive director cazenove group plc also distinguished professor practice diplomacy school chairman court governors henley management foreign service georgetown university president centre irc group llc nonexecutive directorships include bd cocacola company fleetboston financial corporation att sir peter walters aged corporation previously served ambassador us nonexecutive deputy chairman sir peter non permanent representative united nations executive director smithkline beecham plc since b chairman completion merger also sir ian prosser aged chairman institute economic affairs nonexecutive director sir ian formerly nonexecutive director smithkline beecham plc chairman six dr jeanpierre garnier aged continents plc nonexecutive deputy chairman bp plc chief executive officer dr garnier appointed executive also chairman executive committee world travel director smithkline beecham plc served tourism council member cbi presidents committee chairman pharmaceuticals appointment chief operating officer became chief executive officer dr ronaldo schmitz aged april nonexecutive director united technologies nonexecutive director chairman audit committee corporation member board trustees dr schmitz formerly nonexecutive director glaxo eisenhower exchange fellowships holds phd pharmacology wellcome plc nonexecutive director legal general university louis pasteur france mba group plc member board directors rohm stanford university usa haas company cabot corporation formerly member board executive directors deutsche bank ag john coombe aged h chief financial officer mr coombe formerly executive dr lucy shapiro aged director glaxo wellcome plc responsible nonexecutive director dr shapiro formerly nonexecutive finance investor relations member uk director smithkline beecham plc professor accounting standards board code committee uk department developmental biology director takeover panel beckman centre stanford university school medicine f holds phd molecular biology albert einstein college paul allaire aged medicine nonexecutive director mr allaire formerly nonexecutive e director smithkline beecham plc nonexecutive director john young aged lucent technologies inc sara lee corporation pricelinecom nonexecutive director chairman remuneration inc chairman ford foundation chairman nominations committee mr young formerlynonexecutive xerox corporation mr allaire succeed mr young chairman vice chairman smithkline beecham plc non remuneration nominations committee executive appointments include directorships chevrontexaco fh corp lucent technologies inc affymetrix inc perlegen sciences dr michle barzach aged inc ciphergen biosystems fluidigm grassroots enterprise nonexecutive director dr barzach formerly nonexecutive agere systems director glaxo wellcome plc chairman external advisory panel health nutrition population world sir richard sykes sir peter walters mr young retiring bank director board international aids vaccine board annual general meeting may initiative consultant health strategy formerly french minister health family membership board committees indicated following bd symbols sir christopher hogg aged nonexecutive director sir christopher formerly chairman member nonexecutive director smithkline beecham plc non audit b executive chairman reuters group plc st march finance c allied domecq plc anonexecutive director air remuneration nominations e f liquide sa chairman royal national theatre board corporate social responsibility g hcorporate governanceglaxosmithkline corporate executive team howard pien president jp garnier pharmaceuticals international chief executive officer worked abbott laboratories merck mr pien joined formerly chief executive officer smithkline beecham dr garnier smithkline beecham held commercial positions us joined smithkline beecham president uk asia became president pharmaceuticals pharmaceutical business north america chairman responsibility commercial operations worldwide pharmaceuticals appointment chief pharmaceuticals vaccines business operating officer elected smithkline beecham 's board directors david stout president rupert bondy us pharmaceuticals senior vice president general counsel mr stout became president pharmaceuticals north america mr bondy joined smithkline beecham senior counsel smithkline beecham joined senior vice corporate appointed head corporate legal president director sales marketing us secretarial group joining smithkline beecham president schering laboratories responsibilities included lawyer private practice mr bondy responsible legal matters us pharmaceutical operations worldwide manufacturing across glaxosmithkline tim tyson ford calhoun president senior vice president global manufacturing supply information technology mr tyson joined glaxo appointed senior vice dr calhoun joined smithkline french faculty president director worldwide manufacturing supply glaxo mount sinai school medicine doctoral training wellcome previously vice president general microbial genetics postdoctoral training biomathematics manager business operations marketing glaxo wellcome computer science notable accomplishments smithkline inc member glaxo wellcome executive committee beecham bioinformatics drug development processes collaborative computing healthcare information products chris viehbacher internet products services president pharmaceuticals europe john coombe regional director europe mr viehbacher member chief financial officer glaxo wellcome executive committee addition role joining glaxo group financial controller mr coombe chairman chief executive president directeur general glaxo appointed board executive director wellcome france became director continental europe responsible finance investor relations later added joined wellcome responsibilities group finance director glaxo wellcome plc tachi yamada chairman bob ingram research development chief operating officer president smithkline beecham dr yamada appointed chairman pharmaceutical operations research development pharmaceuticals previously mr ingram chief executive glaxo wellcome plc president smithkline beecham healthcare services chairman glaxo wellcome inc us subsidiary joined joined smithkline beecham nonexecutive member board glaxo inc merck appointed board directors glaxo wellcome became chief executive glaxo wellcome jennie younger senior vice president james palmer corporate communications community partnerships senior vice president mrs younger appointed current post december new product development pharmaceuticals rd joined glaxo wellcome director investor relations dr palmer responsible glaxosmithklines new product three years british gas head investor relations development including worldwide responsibility medical mrs younger financial analyst kleinwort benson regulatory product strategy held similar position glaxo barclays de zoete wedd wellcome member glaxo wellcome executive committee physician training joined glaxo jack ziegler president dan phelan consumer healthcare senior vice president mr ziegler appointed president consumer healthcare human resources smithkline beecham joined smithkline beecham mr phelan joined smithkline beecham manager head north american consumer healthcare division labour relations became vice president director became president north america division personnel us pharmaceuticals appointed senior appointed executive vice president vice president director human resources glaxosmithkline corporate governance governance policy corporate social responsibility committee consists entirely nonexecutive directors provides board level forum board executive regular review external issues potential serious directors listed board appointed impact upon groups business reputation rd may served since date board glaxosmithkline plc responsible group 's corporate executive team system corporate governance ultimately accountable executive management group responsibility group 's activities strategy financial performance chief executive officer senior managers form corporate executive team meets times per year board comprises executive nonexecutive directors members corporate executive team responsibilities role nonexecutive directors bring independent judgement listed 'corporate executive team ' board deliberations decisions sir richard sykes nonexecutive chairman dr jeanpierre remuneration directors garnier chief executive officer information remuneration directors given remuneration report sir roger hurn sir peter walters nonexecutive deputy chairmen dialogue shareholders sir richard sykes employed glaxosmithkline services plc company announces financial results quarterly formerly glaxo wellcome plc executive chairman completion merger nonexecutive directors company reports formally shareholders twice year considered board independent given two halfyear fullyear results announced full report nonexecutive deputy chairmen appointed andor summary review issued shareholders chief independent company consider necessary executive officer chief financial officer give presentations appoint either one senior independent director final year end results institutional investors analysts media london new york addition company holds board process teleconferences release first second third board meets regularly throughout year formal quarter results institutional investors analysts media schedule matters reserved decision otherwise may also accessed via companys web site delegates specific responsibilities board committees described annual general meeting company takes place london board works agreed agenda reviewing key formal notification sent shareholders least one month activities business receives papers presentations advance meeting business presentation made enable effectively minutes board committees except shareholders directors able attend available formally remuneration nominations committee placed meeting informally afterwards questions agenda board details annual general meeting set company secretary responsible board available section 'annual general meeting ' individual directors respect board procedures company chief executive officer chief financial officer maintain secretary simon bicknell dialogue institutional shareholders company plans objectives programme regular meetings board committees speak regularly external conferences presentations audit committee reviews financial internal reporting process system internal control management risks company 's investor relations department offices external internal audit process committee consists london philadelphia acts focal point contact entirely nonexecutive directors meets four times year investors throughout year chief executive officer chief financial officer general company 's internet site wwwgskcom gives access counsel heads internal audit corporate compliance current financial business information group external auditors attendance information made available web site constitute finance committee reviews approves major financial part document securities transactions company well dividends results announcements business annual general share buyback programme meeting committee consists chief executive officer october company announced plans invest chief financial officer four nonexecutive directors meets billion buying shares market programme covers four times year additional meetings may held time purchases companys employee trusts relating share option grants share based incentives also covers remuneration nominations committee determines terms purchases company shares cancellation accordance service remuneration executive directors authority given shareholders companys annual corporate officers considers appointments directors general meeting total billion spent corporate officers committee consists entirely non executive directors meets four times year otherwise company authorised purchase maximum necessary chief executive officer attends meetings except million shares million shares purchased remuneration considered cancellation details given note financial statements share capital share premium account exact amount timing offuture purchases determined company dependent market conditions factorscorporate governanceglaxosmithkline annual general meeting company identified number areas significant risk subject regular reporting company 's annual general meeting held pm th may queen elizabeth ii conference centre broad intellectual property sanctuary westminster london swp ee specific risks include maintaining enforcing intellectual property rights compliance relevant legislation infringement third directors party intellectual property rights protection inlicensed mr allaire dr barzach retire offer products technologies election board article company 's articles association biographical details given litigation legal 'the board ' normal course business glaxosmithkline subject proceedings legal actions claims matters auditors subject risks uncertainties outcomes resolutions proposed reappoint pricewaterhousecoopers predicted level certainty nature risks auditors authorise directors determine discussed note financial statements legal remuneration proceedings special business information technology company seek renew authority protecting glaxosmithkline electronic assets increasingly complex make donations eu political organisations incur eu business partnerships extend networks systems electronic political expenditure data third parties dependency internet give directors authority disapply preemption rights communications increases ensuring proper systems validation allotting new shares certain circumstances electronic records signatures key regulatory issues maximum five per cent current issued share capital matters potential risk company similarly web systems obtain authority purchase ordinary shares accessible public must comply legal regulatory maximum ten per cent current issued requirements share capital areas potential risk include use personally identifiable data electronic record retention outsourced business applications accountability audit potential susceptibility viruses outside incursions board recognises responsibility present balanced understandable assessment groups position prospects human resources discussion follows sets procedures legal requirements regarding discrimination harassment accountability control operated glaxosmithkline integrity workforce control use contractors temporary staff risks inherent company internal control framework employees company operates attaches importance clear principles procedures designed achieve accountability control corporate ethics compliance programme appropriate sciencebased business operating multinationally group operates complex legal regulatory environment highly regulated business sector central direction spans globe often inconsistencies one jurisdiction resource allocation risk management key functional next cornerstone groups compliance effort activities commercial strategy research development due diligence preventing detecting misconduct legal manufacture information systems human resources financial noncompliance promoting ethical behaviour compliance practice commercial financial responsibility clearly delegated laws regulations corporate responsibility levels local operating units supported regional management effective compliance systems structure product safety principles designed provide environment central pharmaceutical products bring benefits risks leadership local operating autonomy framework latter side effects intent pre exercise accountability control within group key clinical clinical trials conducted development functional activities management sectors represented potential products determine safety efficacy corporate executive team products use humans following approvals regulatory ongoing process identifying evaluating bodies spite efforts drugs introduced managing significant risks affecting business marketplace unanticipated adverse side effects may occur policies procedures risks managed process operation whole year manufacturing review continues operate date approval loss manufacturing site key production products report process accords guidance internal control important glaxosmithkline significant risk groups policy issued turnbull committee assessment manufacturing conducted accordance applicable group risks reviewed updated least annually similarly laws regulations well corporate standards may operating level business units required processes exceed requirements failure meet legal regulatory identifying evaluating managing risks significant requirements one number risks may result closing business specialist teams review report compliance asite critical supply important products glaxosmithkline corporate governance environment safety audit committee board employee injury changes health due occupational conditions audit committee board responsibility reviewing plant management potential impact plants behalf board effectiveness system internal environment risks company addresses control management risks process monitoring comprehensive architecture sets targets provides guidance compliance laws regulations ethical codes practice results achieved audit committee receives regular reports areas significant risk company related internal controls following financial risk appraisal consideration reports committee reports annually risks surrounding groups ability forecast board overall framework effectiveness controls future thus uncertainty ability meet financial targets set budgeting process group invests new products addition audit committee keeps review scope ventures based assumptions success results audit independence objectivity efforts may prove inaccurate addition risks external auditors committee also reviews nature extent around groups treasury operations including tax liabilities nonaudit services external auditors provide order transfer pricing possibility trading losses ensure fees services become significant counterparty fraud extensive financial controls procedures call question independence group selfassessment exercises auditing measures reviewed board considered audit committee report groups internal auditors place minimise effect effectiveness controls believes systems internal risks control provide reasonable absolute assurance part financial risk management process material misstatement loss comprehensive planning system annual budget approved controls may mitigate eliminate risks addition directors results operating units reported areas companys business necessary monthly compared budget forecasts prepared take risk order achieve satisfactory return shareholders regularly throughout year company announces results cases companys objective apply expertise quarterly basis prudent management rather elimination risk risk oversight compliance council rocc directors review relates company subsidiaries rocc responsible coordinating internal control extend material associated undertakings joint risk management activities company ensuring ventures investments company per cent assignment designated managers manage significant risks interest quest diagnostics inc quest accounted membership comprises several members cet heads associated company activities quest part department internal control risk management audit andor company 's core business competencies interest compliance responsibilities terms reference also include quest held investment company ensuring regular 'gap analysis ' carried identify gaps therefore reviewed quest 's system internal control internal controls providing reports audit committee addition reports provided separate internal control combined code audit compliance departments within company rocc company seeks uphold report compliance supported corporate compliance department best practice corporate governance 'the combined code principles good governance code best practice ' corporate social responsibility committee csrc combined code issued uk listing authority csrc committee board chaired sir richard combined code comprises recommendations best practice sykes comprising three nonexecutive directors terms control reporting functions board committee advises board social ethical environmental company combined code sets principles issues potential seriously impact glaxosmithklines headings business reputation directors committee meets formally twice year additional ad directors ' remuneration hoc meetings consultations required glaxosmithkline relations shareholders executives functional responsibility business areas accountability audit relating issues involved risk control interface external stakeholders attend meetings provide input prescribes detailed provisions respect principle committee committees activities feed internal specifically provisions require directors report annual control framework help board ensure group accounts complies combined code corporate governance directors ' remuneration directors ' responsibility accounts going concern internal control compliance directors ' report compliance combined code reports accordance provisions combined code set directors ' statements responsibility pageglaxosmithkline remuneration report remuneration report sets remuneration policies operated glaxosmithkline remuneration policy describes processes policies programmes took effect completion merger th december directors remuneration sets remuneration earned directors glaxosmithkline together interests share options share incentive plans directors senior management sets interests directors glaxosmithkline shares glaxosmithkline plc contracts information also provided aggregate remuneration interests directors senior management glaxosmithkline references glaxosmithkline shares adss mean respectively ordinary shares glaxosmithkline plc p american depositary shares glaxosmithkline plc ads represents two glaxosmithkline shares glaxosmithkline remuneration report remuneration policy glaxosmithkline remuneration policy special deferred bonus recognition extraordinary effort made corporate leading global healthcare company glaxosmithkline aims executive team cet integrate successfully two remuneration policies programmes enable legacy companies time delivering improved recruit retain motivate top calibre executive talent business performance rn committee decided award needs competes international market place special deferred bonus member cet including glaxosmithkline believes remuneration policies executive directors provide bonus amount equivalent programmes represent competitive advantage best practice salary st december cet member heavy emphasis pay performance risk treated notionally invested glaxosmithkline compensation top executives longterm incentive plans shares th february receive bonus cet designed align executive reward shareholders members required leave company voluntarily interests particular creation enhanced shareholder value th february payment made amount equivalent value shares notionally acquired remuneration nominations committee february plus dividends reinvested period amount may converted shares company committee board remuneration nominations rn deferring payment way fully aligns executive interest committee develops companys policy executive directors shareholders acts strong retention tool remuneration approval board determines deferred bonus pensionable change control remuneration package executive director rn company automatically trigger payment deferred committee consists exclusively independent nonexecutive bonus addition annual bonus however directors current members committee mr john agreeing deferred bonus committee held individual young chairman mr paul allaire dr michle barzach sir roger performance multiplier ipm normal annual bonus plan hurn mr john mcarthur mr donald mchenry mr allaire per cent cet member succeed mr young chairman committee exception dr garnier whose ipm held per cent remuneration companys nonexecutive directors given individual achievements considerably less determined glaxosmithkline board upon receipt would paid absence special deferred bonus advice external consultants longterm incentives policy remuneration executive directors comprise share options participation performance share plan link reward shareholder value long rn committee advice leading firm medium term respectively described compensation benefit consultants aims provide package incentives rewards competitive reference share options global healthcare companies well multinational share options allow holder buy shares future date companies considered similar glaxosmithkline terms size price determined reference open market price shares geographical spread complexity business time grant share options granted managers glaxosmithkline including executive directors constructing reviewing remuneration packages emphasisis linking pay performance rewarding effective vesting options granted executive directors subject management well individual achievement mix within tothe performance condition earnings per share growth apackage designed align personal reward enhanced excluding currency exceptional items least shareholder value short long term ninepercent increase uk retail price index executive directors remuneration consists four components threeyear measurement period respect future grants rn committee review performance conditions salary market conditions performance bonus longterm incentives performance share plan benefits participations performance share plan granted approximately top executives company including salary executive directors designating target number shares reflects executive directors experience responsibility eachparticipant vesting awards plan subject market value toa performance condition applies three year measurement period performance condition consists performance bonus twoparts applies per cent award based annual performance business teams demanding financial targets individual accomplishments objectives bonuses subject upper limits target business performance brings total compensation line competitor panel compensation rises target performance exceeded executives total compensation falls well level compensation competitors targets achieved option invest bonus glaxosmithkline shares inwhich case bonus enhanced ten per cent shares must held minimum three yearsremuneration reportglaxosmithkline first part condition compares glaxosmithklines directors service contracts totalshareholder returns tsr period tsr executive directors employed service contracts ofcompanies uk ftse index period glaxosmithkline required give two years notice termination ifglaxosmithkline ranked top ftse executive directors required give months notice inrelation tsr performance per cent sharessubject part performance condition vest dr garniers contract specifies compensation paid iftheranking th position ftse per company termination employment including centofthe shares vest glaxosmithkline ranked immediate payment two years salary bonus dr garnier thposition none shares subject part also entitled continue participate companys longterm performance condition vest th th incentive plans first months following notice positions vesting occur slidingscale termination company dr garniers notice period reduced two years three years dr garnier also receive second part performance condition requires three years pension accrual termination certain glaxosmithkline earnings per share growth excluding currency circumstances three years accrual andexceptional items least nine per cent theincrease uk retail price index threeyear mr coombes contract specifies compensation paid performance period condition met shares event redundancy event notice termination subject part performance condition vest given case redundancy mr coombe condition met none shares subject part required mitigate loss earnings resulting thereafter ofthe performance condition vest executive directors service contracts contain garden leave benefits noncompetition nonsolicitation confidentiality clauses executive directors participate glaxosmithklines senior executive rn committee believes one year contracts would pension plans defined benefit plans uk cash bein best interest glaxosmithkline regard offering balance plans usa benefits payable age us aglobally competitive overall remuneration package securing cash balance plans provide pension payable fund maximum protection intellectual property rights contributions tenpercent earnings paid interest accrues based treasury bill rates bonuses pensionable nonexecutive directors glaxosmithkline service participating employees us plans including executive contracts directors payment nonexecutive directors glaxosmithkline executive directors participate legacy glaxo wellcome shares smithkline beecham employee share plans either uk usa glaxosmithkline plans replaced enhance link directors shareholders us arrangements dr garnier received four per cent basic pay glaxosmithkline requires nonexecutive directors receive form glaxosmithkline shares ukarrangements significant part fees form shares allocated mr coombe member sharesave plan november share account offers opportunity invest part joined employee sharereward plan contributing balance fees share account shares paid per month buy shares number shares bought month directors retirement board later date matched company onthe basis dividends reinvested interim benefits healthcare provided line practice market executive employed share ownership guidelines align executive interest shareholders executive directors required hold shares company chief executive officer required hold shares value four times base pay executive directors glaxosmithkline required hold shares value three times base pay purposes requirements shares adss held smithkline beechams bonus deferral plans vested deferred awards longterm incentive plans included yearend dr garniers total shareholding basis adss mr coombes shares result directors exceeded share ownership guidelines glaxosmithkline remuneration report directors remuneration table sets remuneration earned directors glaxosmithkline plc comparative amounts represent remuneration earned directors glaxo wellcome plc smithkline beecham plc statutory disclosures respect directors remuneration attributable directors glaxosmithkline plc relation services company subsidiaries th st december set note financial statements annual compensation annual total total fees emoluments deferred annual fees emoluments annual salary benefits bonus compensation salary benefits bonus compensation notes executive directors dr j p garnier ae mr j coombe total nonexecutive directors sir richard sykes cf sir roger hurn dfg sir peter walters fgh mr p allaire fh dr barzach df mr c bonham df sir christopher hogg fh sir peter job dfg mr j h mcarthur dfg mr f mchenry fh sir ian prosser fgh dr r schmitz dfg dr l shapiro fghi mr j young fgh total total compensation dr garnier executive director smithkline beecham salary fees also include company match compensation deferred b mr coombe executive director glaxo wellcome included within bonus company match deferred bonus addition bonus shown mr coombe received awarded respect second half paid c sir richard sykes executive chairman glaxo wellcome remunerated executive director andreceived annual performance bonus st january remunerated nonexecutive chairman glaxosmithkline addition sir richard received bonus awarded respect second half paid nonexecutive director glaxo wellcome mr bonham resigned nonexecutive director glaxosmithkline stmay e bonuses include special deferred bonus payable described f shares adss automatically allocated following nonexecutive directors part fees sir richard sykes shares sir roger hurn shares sir peter walters shares mr p allaire adss dr barzach shares mr c bonham shares sir christopher hogg shares sir peter job shares mr j h mcarthur adss mr f mchenry adss sir ian prosser shares dr r schmitz shares dr l shapiro adss mr j young adss shares allocated accounts also included directors interests g following nonexecutive directors elected receive part balance fees form shares adss sir roger hurn sir peter walters sir peter job mr j h mcarthur sir ian prosser dr r schmitz dr l shapiro nil mr j young shares allocated accounts also included directors interests h nonexecutive director smithkline beecham additional remuneration awarded nonexecutive directors paid form smithkline beecham shares adss sir peter walters shares mr p allaire adss sir christopher hogg shares mr f mchenry adss sir ian prosser shares dr l shapiro adss mr j young adss shares allocated accounts also included directors interests glaxosmithkline shares dr shapiro member glaxosmithklines scientific advisory board received addition fees shown fees form adssremuneration reportglaxosmithkline share options lapsed granted average average options adss grant price exercised number grant price number grant price dr j p garnier lapsed granted average average options shares grant price exercised number grant price number grant price mr j coombe sir richard sykes none directors interest option companys shares glaxosmithkline intends grant share options directors senior managers annual basis november initial grant made following completion merger march measurement period options granted march commenced st january measurement period options granted november commenced st january march november grants dr garnier received ads options mr coombe received share options consequence merger options granted prior merger became exercisable exception options granted mrcoombe options together options granted mr coombe dr garnier become exercisable varying times february november options lapse exercised varying times may november directors hold options various share option plans referred note financial statements employee share schemes share price thmarch per glaxosmithkline share per glaxosmithkline ads connection merger circular listing particulars sent shareholders july time holders options glaxo wellcome smithkline beecham shares adss offered opportunity exchange options options glaxosmithkline shares directors elected exchange outstanding glaxo wellcome smithkline beecham options applicable new options glaxosmithkline shares along glaxo wellcome smithkline beecham share option plan participants elected exchange options receive additional benefit cash sum equal ten per cent exercise price original option additional benefit given new option exercised provided exercise second anniversary effective date merger case sir richard sykes cessation executive employment earlier highest lowest prices year ended st december glaxosmithkline shares respectively highest lowest prices glaxosmithkline adss year st december respectively market prices glaxosmithkline share st december st december glaxosmithkline ads st december grant market options exercised adss date number price price dr j p garnier grant market options exercised shares date number price price sir richard sykes gain options exercised directors year st december comprising relating drgarnier relating sir richard sykes compares gain exercise options year st december comprising relating dr garnier relating sir richard sykes glaxosmithkline remuneration report incentive plans adss adss performance share plan adss lapsed awarded granted dr j p garnier plan plan shares shares performance share plan shares lapsed awarded granted mr j coombe plan plan performance share plan psp mediumterm incentive scheme introduced psp replaces longterm incentive plan midterm incentive plan operated respectively glaxo wellcome smithkline beecham terms psp number shares actually vesting determined following end relevant measurement period three years dependent glaxosmithklines performance period usually award shares made november year preceding start three year measurement period initial grant made following completion merger march measurement period relating shares awarded march commenced st january end st december shares awarded november measurement period commenced st january end st december shares exercised average money market price value shares exercise exercise shares shares longterm incentive plan shares number vesting mr j coombe sir richard sykes longterm incentive plan ltip share award scheme operated glaxo wellcome plan closed new entrants upon completion merger grants made awards made mr coombe march february vest march february respectively awards made march february sir richard sykes vested sir richard left executive office completion merger awards made ltip lapse exercised within months vesting performance conditions lapsed upon completion merger shares ltip awarded atnominal cost recipient vested vested deferred deferred unvested participations participations unvested participations participations participations lapsed awarded participations midterm incentive plan adss dr j p garnier midterm incentive plan mtip share award scheme operated smithkline beecham plan closed new entrants upon completion merger participations granted connection merger performance conditions respect grants made lapsed although final award made employees resign end relevant measurement period final award shares made receipt award may deferred director dr garnier deferred receipt full amount awarded deferred awards together additional adss subsequently received dividend reinvestment arenot included directors interests table since technically retained mtip paid average stock appreciation rights sars adss grant price exercised granted dr l shapiro dr shapiro member glaxosmithklines scientific advisory board sab dr shapiro member smithkline beechams sab completion merger glaxo wellcome along members sab received annual grants smithkline beecham sars general vested three years date grant grants sars sab members ceased sars entitle holder cash sum future date based share price growth date grant date exercise full provision made accounts accrued gains sars date grant connection merger previously granted sars became immediately exercisableremuneration reportglaxosmithkline pensions pension benefits accruing following directors defined benefit schemes accrued annual benefits individual directors retirement set change year net inflation age dr j p garnier mr j coombe sir richard sykes dr garnier member smithkline beecham allemployee us pension plans entitlement spouses childrens pension surrendering part pension early retirement pension reduced factors relating age service apply employees however dr garniers case receives additional three years service retires glaxosmithkline certain circumstances three years accrual pension increases may granted discretionary basis transfer values payable leaving theplans dr garnier also member money purchase scheme contributions paid scheme mr coombe sir richard sykes members glaxo wellcome uk pension plan spouses would provided pension twothirds executives pension event death event either decided take early retirement pension would reduced three per cent year age retire company agreed procure sir richard sykes pension age calculated basis salary st december remained fulltime employment th birthday pensions guaranteed increase payment rate increase uk retail price index rpi maximum per cent year discretionary increases may paid addition allowance would made discretionary increases transfer values leaving glaxosmithkline remuneration report directors senior management directors interests following beneficial interests directors company shown register maintained company accordance companies act shares adss th march december december th march december december note dr j p garnier mr j coombe ab sir richard sykes ce sir roger hurn e sir peter walters e mr p allaire e dr barzach e sir christopher hogg e sir peter job e mr j h mcarthur e mr f mchenry de sir ian prosser e dr r schmitz e dr l shapiro e mr j young e one glaxosmithkline ads represents two glaxosmithkline shares includes shares purchased glaxosmithkline sharereward plan totalling shares st december nil shares th march b includes nonbeneficial interest trusts hold shares st december shares th march c includes nonbeneficial interest trusts hold shares st december shares th march addition interests shown mr mchenry interests deferred fees plan relating period mrmchenry director smithkline beckman priorto merger beecham group deferred fees indexed total return glaxosmithkline shares payable seven years following mr mchenrys retirement total accumulated value deferred fees st december restated reflect merger equivalent glaxosmithkline adss fully provided e includes shares adss received part fees described footnotes f g h annual compensation table directors remuneration dividends received shares adss converted shares adss st december also included directors interests interests abovementioned directors thmarch reflect changes end financial year thmarch directors beneficially owns less one per cent issued share capital company directors interests contracts except described end financial year director connected person material interest contract significance relation groups business group company directors senior management us reporting purposes necessary provide information compensation interests directors senior management asagroup group purposes disclosure group defined directors members corporate executive team company secretary th march numbering persons glaxosmithkline aims provide package incentives rewards competitive reference global healthcare companies well multinational companies considered similar glaxosmithkline terms size geographical spread complexity business remuneration group consists salary performance bonus longterm incentives form share options participation performance share plan benefits respect financial year total compensation paid group aggregate increase accrued pension benefits aggregate payment defined contribution schemes thmarch group owned shares adss constituting less one per cent issued share capital company group also held date options purchase shares adss issued pursuant various executive share option plans described note financial statements group also awarded shares adss glaxosmithklines performance share plan th march held shares adssglaxosmithkline operating financial review prospects operating financial review prospects discusses operating financial performance group financial outlook financial resources group following headings financial trends ratios year results year st december compared year st december financial position resources st december outlook risk factors additionally accordance us requirements year results year st december compared year st december selected financial data ukus gaap results us accounting principles results year compared primarily results preceding year reference made also quarterly halfyearly trends within results exchange group multinational business operates many countriesand earns revenues incurs costs many currencies results group reported sterling therefore affected bymovements exchange rates sterling overseascurrencies company uses average exchange rates prevailing period translate results cash flows overseas group subsidiary associated undertakings joint ventures sterling period end rates translate net assets undertakings currencies influence translations usdollar euro japanese yen order illustrate underlying business performance excluding theeffect exchange rate movements translation groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used totranslate results overseas companies sterling remained unchanged used previous period discussion review therefore terms cer unless otherwise stated glaxosmithkline operating financial review prospects financial trends ratios business performance total cer total cer total cer sales pharmaceuticals consumer healthcare total cost sales selling general administration research development trading profit retained businesses trading profit divested businesses trading profit total profit taxation earnings earnings per share pence p p p research development business performance pharmaceuticals consumer healthcare total business performance primary performance measure used management presented excluding merger items integration restructuring costs disposal subsidiaries management believes exclusion nonrecurring items provides better comparison business performance periods presented accordingly information provided supplement included consolidated statement profit loss pages prepared accordance ukgaap total results include nonrecurring items total results profit taxation earnings earnings per share pence p p p interest net interest payable interest cover times times times interest cover calculated total profit interest divided net interest payable tax rate business performance total results borrowings net debt gearing ratio gearing ratio calculated net debt percentage shareholders funds net debt minority interestsoperating financial review prospects glaxosmithkline year world economy world market pharmaceuticals characterised sharp deterioration global global pharmaceutical sales increased per cent economic outlook sort downturn softlanding billion rate growth unequivocally emerging second part real magnitude slowdown became apparent moving world market value growth geographic region bn total many factors contributed significant investment especially technology significant usa impact energy costs due higher oil prices tempered europe consumer demand weakness japans economy last germany least tragic events usa september left france economy world uncertainty italy uk usa asia regions affected downturn japan us gdp growth decelerating swiftly per cent latin america per cent due strong exposure technology asia pacific excess capacity euroarea beginning year middle east africa seemed able weather slowdown much better canada economies also started decelerate significantly particularly total germany japan continued laggard trapped deflation bad credit problems soaring public debt us market remained buoyant represents per cent year emerging markets hit turmoil turkey global prescription pharmaceutical market compared argentina contagion effects relatively limited far per cent decade ago compared previous crises glaxosmithkline holds second position world pharmaceutical background economic policy response market market share per cent excluding products remarkable usfederal reserve acted swiftly beginning divested result merger behind pfizer market year half per cent interest rate cut followed share per cent aggressive stance thereafter overall easing per cent european central bank reduced rates per glaxosmithkline eight products worlds top products cent japan although bank japan moved avandia augmentin flixotide imigran serevent quantitative easing monetary policy continued generally seroxatpaxil wellbutrin zofran ineffective due problem nonperforming loans affecting banking system differences monetary policy reflected world market value growth top five therapeutic classes bn total different degree slowdown deepest usa shallower cardiovascular europe also developments currency markets central nervous system us dollar reached highest level past years alimentary tract metabolic events september hit global economy hard antiinfectives bacterial already heading towards recession creating disruption viral fungal excluding vaccines specific sectors particularly transport insurance severely respiratory hit confidence collapsed around world global trade continued decline however last months year note data based months th september business consumer confidence stabilising towards preseptember levels boding well recovery exchange significant injection liquidity global level fiscal policy remaining stimulatory inventory cycle turning strongly euro us jpy jun favourable global economy seems set rebound doubts pace recovery due rising unemployment still high degree leverage corporate consumer levels overhang global spare capacity real gdp growth still likely moderate pharmaceutical markets generally showed consistent growth throughout year prices remained pressure legislators regulators several worlds largest wealthiest economies introducing proposing legislative jun dec jun dec jun dec jun dec jun dec jun dec measures cut prices andor slow rate growth spending medicines average sterling exchange rates weaker us dollar euro stronger yen compared aggregate currency movements compared net favourable effect sterling results two per cent respect sales five per cent respect business performance earnings per share glaxosmithkline operating financial review prospects pharmaceutical sales application eu registration seretidefor treatment chronic obstructive pulmonary disease copd submitted total pharmaceutical sales million compared september january fda advisory committee million increase nine per cent like recommended approval advairand floventfor treatment like basis sales products divested part copd associated bronchitis flixotideand sereventas regulatory approval merger glaxo wellcome individual agents already approved several countries smithkline beecham excluded sales grew per cent treatment copd million approximately one per cent overall growth came price increases expected sales flixotidefloventand sereventdeclined various markets due increased momentum seretideadvair within glaxosmithklines existing portfolio sales new products sales flixonaseflonase used treatment perennial launched major market within last five years rhinitis grew strongly accounted per cent total sales grew per cent million sales established franchise products older respiratory products ventolinand becotidecontinued amounted million representing per cent total sales decline patients converted newer products growth per cent compared last year although older products less actively promoted million account antibacterials per cent total sales sales products declined seven although overall sales antibacterials showed little growth per cent broadspectrum antibiotic augmentinis still one highest selling products groups portfolio achieved per cent pharmaceutical sales growth fourth quarter growth worldwide augmentin esextra strength per cent million sales usa contributing launched usa october treatment children million growth per cent although us wholesaler recurrent persistent middle ear infections submission buying patterns distorted product sales total reported fda approval augmentin xrextended release sales growth line underlying demand indicated submitted extra data information requested prescription data europe sales improved five per cent fda million rest world sales improved per cent million overall sales older products zinnatceftin fortumand amoxilcontinued decline although sales zinnatceftingrew pharmaceutical sales therapeutic area central eastern europe per cent central nervous system antivirals major therapeutic area glaxosmithklines portfolio recorded glaxosmithkline continues expand leadership hivaids sales growth per cent seroxatpaxiland wellbutrindrove current global market share per cent sales growth antidepressant sector per cent april paxilwas approved us food drug administration trizivir glaxosmithklines new triple combination medicine fda treatment generalised anxiety disorder gad hivaids available one tablet key driver growth december treatment posttraumatic stress disorder hivaids franchise launched number key markets ptsd seroxatpaxilis approved countries year including much europe usa canada treatment gad countries treatment ptsd sales combivir combination epivirand retrovir wellbutrinsales driven us sales growth per cent grew five per cent major growth markets japan asia result increased awareness amongst physicians efficacy pacific middle east latin america africa favourable side effect profile nonanxious depressed patients sales ziagenincreased five per cent approval received migraine sector successful launch japan imigran paediatric indication october use eu ziagenis tablets treatment previously available approved already countries worldwide injection helped imigranimitrexsales grow four per cent treatment hivaids adults lamictalfor treatment epilepsy grew strongly sales requipfor parkinsons disease zybanthe smoking cessation sales zeffix hepatitis b grew market regions product launched france usa zeffix marketed name epivirhbv approved treatment children two years old august respiratory performance herpes treatments valtrexand zovirax successful launch asthma treatment seretideadvair produced combined sales growth five per cent usa usa number countries europe valtrex sales helped dtc advertising campaign rest world helped boost sales growth product approval usa shorter threeday course therapy combination flixotidefloventand serevent available recurrent genital herpes decline zoviraxin regions countries worldwide sales seretideadvairexceeded world results transfer newer valtrexproduct billion usa three million prescriptions generic competition written nine months following launch april speed patients adopted seretideadvairin usa makes one successful pharmaceutical product launches ever seretideadvair glaxosmithkline 's largest product europe sales million operating financial review prospectsglaxosmithkline pharmaceutical sales therapeutic area total usa europe row therapeutic area cer cer cer cer major products total growth growth growth growth cns depression seroxatpaxil c wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair flixotideflovent serevent seretideadvair flixonaseflonase ventolin becotide antibacterials augmentin zinnatceftin fortum amoxil antivirals hiv trizivir combivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix metabolic gastrointestinal avandia zantac vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total sales continuing business divested products total pharmaceutical sales cer represents sales growth constant exchange rates sterling growth calculated figures given analysis sales quarter given financial record pages glaxosmithkline operating financial review prospects metabolic gastrointestinal usa avandia glitazone treatment type diabetes group earned per cent total pharmaceutical revenue key driver growth metabolic gastrointestinal therapy usa year recording growth per cent area usa avandiasales benefited increased acceptance advairseretide launched midapril achieved sales revolutionary class drugs record growth per cent million although launch slowed sales growth avandia launched china italy currently approved constituent products flixotidefloventand serevent combined countries filed marketing approval japan sales three products amounted million december growth per cent sales zantachave continued decline face generic cns therapeutic area seroxatpaxil launched generalised competition anxiety disorder april grew strongly wellbutrincontinued good growth record products benefited vaccines growing antidepressant market usa lamictalindicated infanrix glaxosmithklines combination vaccine diphtheria epilepsy grew per cent tetanus pertussis whooping cough drove total vaccines sales antibacterials sector augmentinreflected gains share growth per cent together strong growth priorix adult paediatric markets growth bolstered tritanrixand typherixmore offset decline hepatitis launch es extra strength formulation indicated portfolio twinrix havrixand engerixb subsequent year treatment children acute otitis media middle ear end glaxosmithkline announced discontinuation lymerixin infections usa result poor demand product combination treatment trizivirwas launched us market oncology emesis late sales first full financial year amounted continued sales growth zofran used management million helping produce per cent sales growth nausea vomiting associated chemotherapy hivaids sector antivirals also antivirals market valtrex radiotherapy cancer treatment benefited oncology emesis herpes showed strong performance therapy area grew per cent overall sales hycamtin approved treatment recurrent ovarian cancer declined europe per cent principally result adverse wholesaler buying europe region contributed per cent pharmaceutical sales patterns usa largest market france showing strong growth good growth recorded major markets including italy spain cardiovascular central eastern europe seretidewas major sales driver sales coreggrew per cent november fda gave region although usa affected sales constituent approval treatment severe heart failure coregis products seretideadvairis largest product europe betablocking agent indicated increase survival mild moderate sales million severe heart failure patients glaxosmithkline exclusive cns area seroxat coupled launch zybanin rights market coregin usa markets contributed growth launches trizivir helped produce per cent growth hivaids sector therapeutic areas sales relafenfor arthritis fell reflecting generic competition metabolic gastrointestinal zantacsales continued decline usa face increased generic competition partially offset performance avandiawith launchesin number regional analysis markets including uk germany pharmaceutical sales geographic area antibacterials declined one per cent reflecting generic competition augmentinand amoxil vaccines showed growth due region cer major markets total growth decline hepatitis market germany although sales improved european countries principally uk spain italy usa europe oncology area growth attributable strong france sales zofranin france germany offset decline uk hycamtinsales european countries italy germany spain rest world central per cent sales growth rest world region reflected eastern europe strong growth major markets region europe market growth japan driven number therapeutic rest world areas launch tablet form imigranin august asia pacific seroxatin late key drivers switch becotideto japan latin america newer product flixotideand zoviraxto newer valtrex middle east africa contributed sales growth newer products led also canada decline older products canada significant growth achieved seretideand cer represents sales growth constant exchange rates sterling growth calculated avandia launched march therapeutic figures given analysis sales quarter given financial record areas trizivirfor hiv treatment launched november pages sales presented retained product basis exclude divested products sales market within europe adjusted effects parallel tradeoperating financial review prospectsglaxosmithkline seven per cent total sales derived asia pacific area oral care principally australia sales growth per cent acquisition block drug added number significant brands metered dose inhaler seretidewas launched market oral care business namely sensodyne polidentand poligrip may sales zybangrew successful launch late excluding block drug oral care sales grew three per cent reflecting strong growth europe partly offset strong competitive latin america reported eight per cent sales growth reflecting strong pressures aquafreshin us market growth mexico per cent area predominately benefited seretidesereventflixotide market grew nutritional healthcare per cent hivaids vaccines markets showed good nutritional healthcare business grew seven per cent reflecting return antibacterials declined due generic competition strong performances lucozadeand horlicks middle east africa area followed trends markets growth seretide avandiaand hivaids trading profit business performance markets vaccines area recorded growth per cent illustrate glaxosmithkline business performance zofranin oncology area drove growth per cent analysis trading profit subsequent discussion subsaharan south africa key drivers growth excludes merger items integration restructuring costs antivirals vaccines disposals subsidiaries management believes exclusion nonrecurring items provides better comparison business consumer healthcare sales performance periods presented accordingly information cer provided supplement contained consolidated statement profit loss pages prepared otc medicines accordance ukgaap analgesics dermatological gastro intestinal growth cer respiratory tract sales smoking control vitamins naturals cost sales oral care selling general nutritional healthcare administration research total sales continuing business development divested products trading profit total consumer healthcare sales cost sales acquisition block drug company inc completed cost sales increased percentage sales loss january adding million sales purchase added highmargin products divested december inclusion sensodynetoothpaste brand range denture care brands lower margin block drug products higher stock provisions worldwide significant additions otc medicines largely partly offset benefits merger manufacturing usa former block drug business integrated restructuring savings glaxosmithkline result acquisition glaxosmithkline become selling general administration number two company globally oral care added selling general administration sga costs benefited significant extra scale business particularly north america merger savings principally general administration expenditure japan europe inclusion block drug costs distorts year year comparison excluding estimated block drug expenses growth otc medicines sga expenses would four per cent sga expressed reported sales otc medicines grew eight per cent percentage sales would per cent lower million primarily result acquisition block drug excluding block drug otc medicines declined two per cent research development reflecting private label competition smoking control research development expenditure broadly level last us market sluggish growth global otc market year savings merger made expenditure research development planned increase future june glaxosmithkline reached agreement taisho merger savings begin reinvested area establish partnership introduce nicotine replacement products japan trading profit significant new product introduction otc medicines included business performance trading profit growth per cent niquitin lozenge effective otc product yet launched reflecting improved trading margins trading margin improved tohelp smokers quit eumovate topical steroid first per cent per cent result cost savings glaxosmithkline switch prescription otc two major merger integration partly offset divestment certain high new extensions panadolanalgesic fast acting formula margin products required regulatory authorities condition marketed actifast slow release product targeted merger persistent pain introduced scandinavia extend glaxosmithkline operating financial review prospects profit taxation business performance merger items restructuring costs disposal businesses analysis discussion profit taxation relates key items discussed business performance merger costs arising integration glaxo wellcome operating incomeexpense smithkline beecham businesses unified glaxosmithkline royalties income business referred merger integration costs amounted operating expense million costs primarily include consultancy fees severance asset writeoffs share option retention incentives income equity investments manufacturing restructuring costs million incurred implementing previously operating income significantly lower announced glaxo wellcome smithkline beecham plans due lower sales equity investments lower product restructuring manufacturing activities disposals higher costs related product withdrawals million charged respect postmerger restructuring activities costs include consultancy fees severance profit disposal interest associate asset writeoffs group sold million shares quest diagnostics inc year realising gain million st december block drug company inc share split quest share sale glaxosmithkline acquired block drug january costs glaxosmithkline held million shares incurred acquiring integrating business million comprising professional fees severance share profitslosses joint ventures associated asset write offs undertakings share profits associates arises principally groups disposal businesses holding inquest diagnostics inc loss disposal businesses primarily arose sale affymax charge includes million writeoff goodwill previously eliminated reserves net interest payable interest payable taxation investment income business performance share interest payable associate merger restructuring disposal subsidiaries total taxation net interest payable lower due lower average level net debt lower interest rates business performance taxation charge taxation business performance profit amounting profit taxation million represents effective tax rate per cent operating incomeexpense together disposal tax rate benefits lower rates tax applicable part interest inanassociate added million profit manufacturing operations singapore puerto rico ireland taxation compared million reduction onetime profits planned improve overall transfer pricing issues inevitable global business quality groups earnings taking account contribution glaxosmithkline integrated nature groups worldwide associates comprising share profit less share ofinterest operations involving significant investment research strategic less thegroups net interest payable business performance manufacture limited number locations consequential profit tax million compared million crossborder supply routes numerous endmarkets gives rise increase per cent complexity delay negotiations revenue authorities profits individual group companies liable tax disagreements revenue authorities price goods transferred group companies different tax jurisdictions produce conflicting claims revenue authorities profits fall taxed individual territories resolution issues continuing factoflife glaxosmithklineoperating financial review prospectsglaxosmithkline usa number years glaxosmithkline significant critical accounting policies open issues relating transfer pricing issues affect years consolidated financial statements prepared accordance present concern number products ukgenerally accepted accounting principles following accounting although significant relates success zantacin policies approved board described note respect claims us internal revenue service irs financial statements management required make estimates substantially exceed groups estimation taxation liabilities assumptions affect amounts assets liabilities revenue irs claims continue subject discussions expenses reported financial statements actual amounts us uk tax authorities competent authority provisions results could differ estimates following double tax convention two countries within considered critical accounting policies adopted discussions wide variation views us uk tax authorities exceptionally may unable legal disputes settle dispute event uk us tax authorities glaxosmithkline provides anticipated settlement costs reaching agreement matter may resolved litigation associated expenses arising legal disputes glaxosmithkline uses best advice determining transfer group reasonable estimate made likely pricing methodology seeking manage transfer pricing issues outcome dispute possible make reasonable satisfactory conclusion basis external professional estimate provision made advice continues believe made adequate provision although outcome claims legal proceedings matters liabilities likely arise open assessments glaxosmithkline involved predicted certainty directors taken appropriate legal advice merger restructuring expect groups ultimate liability matters taking credit taxation merger restructuring items account provisions tax benefits insurance material amounting million reflects estimated actual tax adverse effect financial condition results operations rateapplicable transactions territories cash flows theyarise earnings intangible assets intangible assets acquired glaxosmithkline third earnings parties costs acquisition capitalised licences compounds earnings per share p p development amortised estimated useful lives earnings per ads exceeding years estimated useful lives reviewed annually adjusted earnings impairment reviews undertaken events occur call adjusted earnings per share p p question carrying values assets adjusted earnings per ads brands acquired businesses capitalised independently weighted average number shares millions separable long term value group brands amortised estimated useful lives exceeding adjusted earnings adjusted earnings per share years except end useful economic life glaxosmithkline arepresented order illustrate business foreseen brands amortised subject annual performance primary measure used management impairment reviews discussed earlier future events could cause values intangible assets adjusted earnings increased per cent cer adjusted earnings significantly impaired would adverse effect per share also increased per cent cer weighted average future results group number shares purposes earnings per share decreased slightly due topurchases shares employee impairment fixed assets share ownership trust satisfy future exercises share options carrying values fixed assets subject amortisation shares purchased cancellation offset exercise share reviewed impairment indication values options year assets might impaired impairment determined reference higher net realisable value value use measured reference discounted cash flows future events could cause assumptions used impairment reviews change consequent adverse effect future results group glaxosmithkline operating financial review prospects financial position resources cash flow group purchases shares market cancellation amounted million summary group cash flow set preference shares classified nonequity minority interest amounting million redeemed using existing group resources first quarter total operating cash flow dividends joint ventures major products divested obtain regulatory approval net interest minority merger generated proceeds million december preference share dividends total net debt increased nearly billion billion tax payments free cash flow future cash flow net capital expenditure group expects future operating cash flow sufficient net cash operations fund operating debt service costs satisfy normal levels dividends shares capital expenditure meet obligations existing licensing business acquisitions agreements meet routine commitments including business disposals tax dividends subject risk factors discussed pages sale less purchase equity investments sale less purchase interest associates subsequent years group expects cash purchase shares share options outflows integrating operations glaxo wellcome use shares exercise share options smithkline beecham unified glaxosmithkline business shares issued exercise share options well cash outflows continued implementation purchase shares cancellation manufacturing restructuring plans redemption preference shares issued subsidiary group plans complete billion share buyback product divestments programme announced october exact amount movements including exchange timing purchases depend market conditions increasereduction net debt funded groups existing resources th march shares purchased cancelled net cash inflow total operating activities cost million million increase million group may time time additional demands merger restructuring items million net interest finance acquisitions group access payments minority preference share dividends tax sources liquidity banks financial institutions payments free cash flow representing cash flow addition cash flow operations forsuch needs discretionary spending amounted million increase million financial position capital expenditure tangible intangible fixed assets summarised reclassified presentation group balance sheet amounted million million set disposals realised million million group acquired block drug cash consideration million included within business acquisitions disposed goodwill part interest quest diagnostics inc sum intangible fixed assets million tangible fixed assets investments total million million realised working capital sales less purchases investments equity shares debtors creditors rd october glaxosmithkline announced plans invest provisions billion buying shares market programme taxation covers purchases companys employee share ownership deferred taxation trusts esots relating share option grants share net operating assets based incentives also covers purchases company shares shares cancellation programme billion dividends proposed spent net debt group funded purchase esots shares net assets glaxosmithkline plc satisfy future exercises options shareholders funds awards employee share incentive schemes total cost minority interests million million atotal million million received employees exercise financing net assets share options exercises satisfied shares previously purchased esots yielded million million exercises satisfied issue new shares yielded million millionoperating financial review prospectsglaxosmithkline book value net assets decreased million net debt increased million primarily due stdecember million st december purchase block drug cash consideration million decrease million reflects redemption restructuring merger costs million purchase million nonequity minority interest purchase shares company cancellation esots share cancellation shares share buyback programme option commitments totalling million effect net assets exchange rate movements partly offset retained profits million providing shareholders funds dividends summary movements equity shareholders funds set intangible fixed assets intangible fixed assets st december million st december million included fair value beginning year brands acquired million acquisition block drug profit year remaining increase intangible assets reflects acquisition dividends licences patents knowhow marketing rights partially offset shares issued exercise share options amortisation expense impairment losses shares issued cancelled exchange movements overseas net assets investments goodwill written back glaxosmithkline investments st december end year carrying value million st december million investments mainly equity shares holding equity shareholders funds decreased million derives directly groups business either arising st december million st december business divestment connection research collaboration primarily due retained profits shares purchased access biotechnology developments potential interest cancellation write back reserves goodwill glaxosmithkline equity investments included current assets regarded available sale otherwise included commitments contingent liabilities fixed assets market value investments st financial commitments summarised note financial december approximately billion st december statements commitments contingent liabilities billion market values volatile obligations respect short long term debt set note contingent liabilities note net debt shares st december esots held million shares payment policies company option commitments employee share incentive plans date million shares group companies responsible monitoring managing million exercisable working capital terms sales collections supplier payments reflect local commercial practice debtors creditors increase net creditors year reflects increased uk company uk subsidiaries operate accruals legal disputes inlicensing technologies procedures ensure suppliers paid time particular staff compensation uk companies seek settle terms payment suppliers agreeing provisions terms transaction group carried provisions million st december ensure suppliers made aware agreed terms respect estimated future liabilities ofpayment million related pensions postretirement abide terms payment benefits employees provision made legal disputes indemnified disposal liabilities costs procedures include arrangements accelerated payment manufacturing restructuring merger integration extent small suppliers balance sheet date actual constructive obligation existed case merger integration manufacturing payment performance restructuring majority remaining costs expected st december average number days purchases recognised end represented trade fixed asset creditors company nil days nil days respect company uk net debt subsidiaries aggregate days days group net debt st december comprised company seen deterioration payment performance result integration systems expects improve cash liquid investments borrowings repayable within one year borrowings repayable one year net debt glaxosmithkline operating financial review prospects treasury policies liquid assets surplus immediate operating requirements group companies invested managed centrally corporate glaxosmithkline plc ukbased business reporting sterling treasury requirements group companies operating finance paying dividends sterling profits met whenever possible central resources role corporate treasury glaxosmithkline manageand external borrowings mainly managed centrally corporate monitor groups external internal funding requirementsand treasury comprise portfolio long mediumterm instruments financial risks support group corporate objectives treasury shortterm finance activities governed policies procedures approved board monitored treasury management group glaxosmithkline hold issue derivative financial glaxosmithkline maintains treasury control systems procedures instruments trading purposes groups treasury policies monitor foreign exchange interest rate liquidity credit specifically prohibit activity transactions financial financial risks instruments undertaken manage risks arising underlying business activities speculation liquidity group operates globally primarily subsidiary companies funding maturity counterparty risk established markets group trades due group invests centrally managed liquid assets primarily nature groups business patent protection many government bonds shortterm corporate debt instruments ofthe products groups portfolio groups products minimum shortterm credit rating ap standard compete largely product efficacy rather price selling poors moodys respectively margins sufficient cover normal operating costs group manages net borrowing requirement groups operating subsidiaries substantially cash generative portfolio long mediumterm borrowings including bonds operating cash flow used fund investment research together shortterm finance us commercial paper development new products well routine outflows capital programme groups mediumterm borrowings mature dates expenditure tax dividends repayment maturing debt longdated sterling bond matures group time time additional demands finance share purchases acquisitions glaxosmithklines longterm debt rating aa standard december billion fixed rate year bond poors aa moodys agencies shortterm rating issued new billion european medium term paper issued groups commercial paper programme programme addition usbillion commercial paper p respectively programme signed december programmes replace premerger funding programmes give flexibility interest rate risk management groups funding options glaxosmithklines policy interest rate risk management requires amount net borrowings fixed rates increases glaxosmithkline operates low levels net debt addition ratio forecast net interest payable trading profit tothe strong positive cash flow normal trading activities additional liquidity readily available via us commercial sensitivity analysis considers sensitivity groups net debt paperprogramme backed committed lines credit hypothetical changes market rates assumes variables remain constant based composition net debt treasury operations st december one per cent increase decrease average objective treasury activity manage posttax net interest rates would result negligible change groups costincome financial operations benefit group annual interest expense earnings corporate treasury operate profit centre foreign exchange risk management glaxosmithkline uses variety financial instruments including glaxosmithkline foreign currency transaction exposure arising derivatives finance operations manage market risks normal trade flows respect external intragroup operations trade hedged glaxosmithklines policy minimise financial instruments comprise cash liquid resources exposure overseas operating subsidiaries transaction risk borrowings spot foreign exchange contracts bymatching local currency income local currency costs forthispurpose intragroup trading transactions matched glaxosmithkline uses number derivative financial instruments centrally intragroup payment terms managed reduce manage market risks treasury operations derivative risk exceptional foreign currency cash flows hedged selectively instruments principally comprising forward foreign currency management corporate treasury contracts interest rate currency swaps used corporate treasury swap borrowings liquid assets currencies based composition net debt st december required group purposes manage exposure market per cent appreciation sterling major currencies would risks changes foreign exchange rates interest rates result reduction groups net debt approximately million per cent weakening sterling major glaxosmithkline balances use borrowings liquid assets currencies would result increase groups net debt regard cash flow operating activities approximately million thecurrencies earned tax cost intragroup distributions currencies business assets denominated posttax cost borrowings compared totheposttax return liquid assetsoperating financial review prospects glaxosmithkline high proportion group borrowings including commercial company obtained shareholder approval annual paper programme us dollars benefit liquidity general meeting make market purchases shares us denominated capital markets certain rd october glaxosmithkline announced share borrowings swapped currencies required group repurchase programme esot share purchase programme purposes group seeks denominate borrowings billion announcement date st december currencies principal overseas assets borrowings denominated glaxosmithkline purchased million shares cancellation swapped foreign currencies match investments total cost million overseas group assets treated hedge relevant net assets european monetary union glaxosmithklines european companies made preparations derivative financial instruments hedging policy full introduction single currency st january within group uses limited number currency swaps interest countries europe directly affected preparations rate swaps redenominate external borrowings intothe currencies included conversion information systems data financial interest rate coupon required group purposes duration processes well training staff local implementation swaps matches duration theprincipal instruments teams supported central coordination team experience group manages centrally shortterm cash surpluses since introduction euro beginning borrowing requirements subsidiary companies uses forward shown conversions information systems data contracts hedge future repayments back originating financial processes successful currency contracts less years duration shortterm company expect costs derivative instruments accounted hedges relevant benefits introduction euro material effect assets liabilities groups trading performance equity risk management group use derivative financial instruments manage equity risk equity investments classified current assets available sale group manages disposals meet overall business requirements arise financial assets liabilities analysis net debt given note financial statements analysis financial assets liabilities carrying value fair value reconciliation net debt given innote together discussion derivative financial instruments quantitative disclosures market riskin accordance requirements financial reporting standard group net debt increased nearly billion st december st december primarily due impact acquisition block drug merger restructuring costs groups purchase shares market redemption preference shares classified nonequity minority interest group continues benefit strong positive cash flow groups financial assets liabilities st december representative treasury policies strategies glaxosmithkline applied consistently year significant changes policies throughout year esot share purchases shares purchased cancellation group funded market purchases employee share ownership trusts shares glaxosmithkline plc amounting million million shares held employee share ownership trusts satisfy future exercises options awards group share option award schemes proportion purchases respect options rules scheme require company satisfy exercises market purchases rather issue new shares purchases represent opportunity acquire shares satisfy future exercises prices exercise price purchases matched options granted diminish dilutive effect new share issues shareholders ' capital earnings glaxosmithkline operating financial review prospects outlook risk factors outlook generic drug manufacturers seeking market generic versions number groups important products including improving pharmaceutical sales growth existing products augmentin paxiland wellbutrin prior expiration seven per cent cer per cent per groups patents may products future cent key driver glaxosmithklines current efforts may involve challenges validity patent business performance company expects launch assertion alternative compounds infringe advair forcopd infanrix pentadutasteride vardenafil groups patents group successful maintaining merger savings million achieved exclusive rights market one major products together manufacturing restructuring savings excess particularly usa group highest margins million group expects deliver total annual merger sales country patent protection period manufacturing restructuring savings rd groups revenues margins would adversely affected reinvestment billion savings see note financial statements legal proceedings measured projected levels expenditure discussion patentrelated proceedings group forecast glaxo wellcome smithkline beecham involved immediately prior merger countries group operates patent glaxosmithkline expects deliver business performance earnings protection may significantly weaker usa per share growth midteens lowteens european union addition effort control public health better guidance assumes glaxosmithkline crises developing countries south africa brazil successfully defends intellectual property surrounding recently announced plans substantial reductions augmentinand paxilin usa scope patent protection pharmaceutical products particular countries could facilitate competition within glaxosmithkline engaged legal proceedings regarding validity markets generic manufacturers would otherwise infringement groups patents relating augmentinand unable introduce competing products number years paxilseroxat discussed risk factors loss patent protection likely affect adversely groups note financial statements legal proceedings operating results group net debt billion low relative pharmaceutical product prices subject controls pressures market capitalisation positions take advantage many markets governments intervene directly setting opportunities might arise build business prices addition markets major purchasers risks uncertainties inherent business pharmaceutical products whether governmental agencies discussed risk factors private health care providers economic power exert substantial pressure prices group predict whether risk factors existing controls increase new controls introduced reduce groups margins affect adversely ability risks uncertainties relevant groups business introduce new products profitably factors listed group thinks could cause groups actual results differ materially expected example usa group highest margins historical results factors besides listed could sales country pricing pressures could significantly also adversely affect group increase various proposals consideration reform medicare federal state programmes control group operates highly competitive businesses cost pharmaceuticals adopted medicare programme pharmaceuticals business faces competition provide outpatient pharmaceutical coverage proprietary products large international manufacturers beneficiaries us government enormous purchasing producers generic pharmaceuticals significant product power programme could demand discounts may innovations technical advances intensification price implicitly create price controls prescription drugs additionally competition competitors could adversely affect groups number states proposed implemented various schemes operating results continued consolidation pharmaceutical control prices senior citizens drug programmes industry could adversely affect groups competitive position including importation countries bulk purchasing continued consolidation among groups customers may drugs growth number patients covered increase pricing pressures large managed care institutions usa would likely particular group faces intense competition increase medicare reform also increases pricing pressures manufacturers generic pharmaceutical products groups products trends may adversely affect major markets generic products often enter market upon groups revenues margins sales usa expiration patents data exclusivity periods groups group must comply broad range regulatory controls products introduction generic products typically leads testing approval manufacturing marketing many dramatic loss sales reduces groups revenues pharmaceutical consumer healthcare products margins proprietary products expiration dates countries including usa european union patents groups major products set regulatory controls become increasingly demanding increasing description business patents cost product development also time required reach market uncertainty successfully group expects trend continue expand countriesoperating financial review prospectsglaxosmithkline stricter regulatory controls also heighten risk withdrawal group control changes inflation interest regulators approval previously granted would reduce rates foreign currency exchange rates controls revenues result product recalls product liability economic factors affecting businesses possibility lawsuits addition cases group may voluntarily political unrest legal regulatory changes nationalisation cease marketing product face declining sales based jurisdictions group operates factors could concerns efficacy safety whether scientifically materially affect groups future results operations justified even absence regulatory action effective tax rate groups earnings benefits continued development commercially viable new products fact portion earnings taxed favourable rates critical groups ability replace sales older products jurisdictions outside united kingdom changes tax decline upon expiration exclusive rights increase overall laws application respect matters transfer sales developing new products costly lengthy uncertain pricing see note financial statements taxation process new product candidate fail stage relate portion groups earnings taxed process one latestage product candidates could fail favourable rates could increase groups effective tax rate receive regulatory approval new product candidates may appear adversely affect net earnings promising development significant investment fail new revised accounting standards rules promulgated reach market limited commercial success time time uk us international accounting standardsetting result efficacy safety concerns inability obtain necessary boards could material adverse impact groups regulatory approvals difficulty excessive costs manufacture reported financial results infringement patents intellectual property rights others group currently defendant number lawsuits including class actions involve substantial claims damages governmental investigations lawsuits include product liability claims related groups pharmaceutical products antitrust actions number lawsuits class actions include claims punitive damages unfavourable resolution similar future proceedings may material groups results operations cash flows group may also make material provisions related legal proceedings would reduce earnings recent insurance loss experience including pharmaceutical product liability exposures increased cost insurance coverage group order contain insurance costs group adjusted coverage profile accepting greater degree selfinsurance see note financial statements legal proceedings discussion proceedings group currently involved environmental laws various jurisdictions impose actual potential obligations group remediate contaminated sites group also identified potentially responsible party us comprehensive environmental response compensation liability act number sites remediation costs relating groups use ownership sites see note financial statements legal proceedings discussion environmentalrelated proceedings group involved group currently six products million billion annual global sales among products augmentin paxilseroxatand wellbutrin group currently defending intellectual property rights usa groups major products become subject problem loss patent protection unexpected side effects regulatory proceedings publicity affecting doctor patient confidence pressure competitive products new effective treatment introduced impact groups revenues operating results could significant group conducts substantial portion operations outside united kingdom fluctuations exchange rates sterling currencies especially us dollar euro materially affect groups revenues operating results glaxosmithkline operating financial review prospects year accordance ussec disclosure requirements following rhinitis sector growth flixonaseflonasewas similarly offset discussion compares results year st december decline older product beconase overall groups results year st december products sector grew per cent supported dtc advertising usa exchange antibacterials average sterling exchange rates weaker sales antibacterial products increased two per cent us dollar yen stronger european growth augmentinoffset flat sales zinnatceftinand currencies aggregate currency movements amoxiland decrease fortum net favourable effect sterling results compared three per cent respect sales two per cent respect sales reaching billion augmentincontinued perform business performance earnings per share strongly usa sales grew per cent market share nearly quarter solid growth achieved latin america pharmaceutical sales south east asia europe sales affected generic competition glaxosmithkline pharmaceutical sales amounted million compared million increase zinnatceftindeclined seven per cent largest market ten per cent excluding sales divested products products usa offset growth emerging markets divested fulfil regulatory conditions approval middle east africa latin america asia pacific glaxo wellcomesmithkline beecham merger sales growth continuing business per cent growth substantially antivirals volume increase minor net increase price growth antiviral sales per cent reflected strong growth hiv franchise group markets range reverse pharmaceutical sales therapeutic area transcriptase inhibitors rtis recently launched protease inhibitor agenerase steady growth sales herpes products central nervous system continued uptake new products viral diseases antidepressant sector sales billion achieved strong growth seroxatpaxiland wellbutrincontributing sales rtis increased per cent combiviragain grew growth per cent important us market paxilwas strongly reflecting conversion patients constituent single supported successful directtoconsumer dtc campaign products epivirand retrovir aggregate three products promotional efforts also enabled wellbutrinto increase achieved real growth five per cent market share products benefited overall growth groups two herpes treatments newer valtrexand us antidepressant market older zovirax grew combined rate five per cent valtrex migraine portfolio imigranimitrexand naramigamerge continued protect groups franchise area strong grew five per cent reflected return growth usa increases regions successful launch japan august accounted three quarters sales dtc marketing zeffix chronic hepatitis b achieved sales million first campaigns migraine awareness programmes instrumental launched asia pacific area performed strongly increasing sales europe sales stable strong growth chinese south korean markets france offsetting declines markets relenza new influenza treatment doubled sales sales lamictal epilepsy treatment grew strongly worldwide million following launch japan december particularly usa greater market penetration available major markets achieved expanding market requip treatment parkinsons disease increased sales per cent smoking metabolic gastrointestinal cessation market zybans growth per cent reflected rollout avandia glaxosmithklines new treatment type diabetes european markets following european union approval april achieved sales approaching half billion pounds majority initial sales particularly strong uk germany usa first launched april us fda approved avandiain combination sulphonylurea respiratory previously approved monotherapy combination flixotidefloventsales increased per cent notably usa metformin august avandiareceived positive dtc promotion expanding market led per recommendation uk national institute clinical cent increase sales europe groups new excellence nice combination product seretide launched markets sales flixotidewere maintained despite seretides success zantaccontinued decline face competition generic sereventgrew eight per cent growth particularly products alternative antiulcerant treatments rate strong us market decline slowed per cent zantacs largest market japan sales remained stable seretide new combination flixotideand sereventgenerated sales million significant new markets lotronex treatment irritable bowel syndrome launched included spain italy australia uk germany usa march generated sales million seretidehad available year continued make withdrawn november following discussions strong gains market share us fda interpretation data relating gastrointestinal side effects company disagreed total antiasthmacopd sales grew per cent reflected fdas assessment safety profile lotronex agreed strong performance flixotide sereventand seretide offset withdraw us market also withdrawn declining sales older asthma products ventolinand regulatory submissions worldwide becotide patients converted newer productsoperating financial review prospectsglaxosmithkline pharmaceutical sales therapeutic area total usa europe row therapeutic area cer cer cer cer major products total growth growth growth growth cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretide flixonaseflonase ventolin becotide antibacterials augmentin zinnatceftin fortum amoxil antivirals hiv trizivir combivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix relenza metabolic gastrointestinal avandia zantac lotronex vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg dermatologicals arthritis relafen total sales continuing business divested products famvir kytril total pharmaceutical sales cer represents sales growth constant exchange rates sterling growth calculated figures given glaxosmithkline operating financial review prospects vaccines strong growth sales augmentinand amoxiloffset declines vaccines sales reached million increase per cent ceftinand fortum enabling sales antibacterial area hepatitis franchise engerixbdeclined eight per cent due outperform market growth augmentinbenefited increased lower sales usa havrix hepatitis grew slightly prescriber awareness effectiveness bacteria resistant twinrix combined hepatitis b vaccine adult antibiotics paediatric strengths grew five per cent million minor impact sales growth product disposals infanrix glaxosmithklines range combination vaccines anaesthesia portfolio dermatological range diphtheria tetanus pertussis whooping cough grew per october cent october european commission approved infanrix penta provides additional protection hepatitis b europe polio infanrix hexawhich adds protection sales europe representing per cent groups haemophilus influenzae typeb disease pharmaceutical sales grew six per cent france glaxosmithkline 's largest market within region sales oncology emesis grew strongly reflecting growth hiv portfolio zofran emesis wellestablished product leader asthma franchise major markets italy germany spain sector benefited market growth usa two seretidewas key contributor growth uk market benefited thirds sales generated increased sales seretideand successful launch zyban overall sales declined slightly due generic competition therapeutic areas parallel trade cardiovascular sales stable per cent growth coreg recent launches pritorfor hypertension european markets success seretidecontributed per cent growth offsetting declines older products future sales benefit asthmacopd range growth lamictaland launches new data showing coregs effectiveness treating severe zybancontributed per cent increase total cns sales sales heart failure hiv products increased per cent combination solid growth established product range uptake recently disposal anaesthesia franchise usa end launched ziagen sales infanrix combination vaccine contributed fall therapeutic area per cent children grew third recent approvals infanrix october glaxo wellcomes us company also disposed pentaand infanrixhexaoffering potential growth portfolio dermatological products contributing cardiovascular area launch pritorled per cent four per cent decline sector increase sales pharmaceutical sales geographic area offsetting strong performances decline sales augmentin due mild 'flu season impact generic usa competition uk germany continuing decline sales us market representing half total group zantac avandiawas launched uk germany late pharmaceutical sales grew per cent avandia launched june achieved sales million rest world market leader class benefited overall growth eight per cent reflected mix double digit withdrawal competitor product market first growth asia pacific middle east africa canada quarter year slower growth japan latin america respiratory sales increased per cent reflecting particular asia pacific markets principally contributing sales growth increased acceptance inhaled steroids treatment australia areas largest market launches seretide asthma august zybanin november china zeffix launched key factor sales growth per cent cns sales increased per cent growing anti depressant market dtc campaigns focussing social anxiety japan groups second largest market sales grew five per disorder helped paxilto grow per cent migraine cent sales asthma products grew quarter launch portfolio growth five per cent reversed decline seen paxilin november relenzain december together added previous year reflecting promotional efforts million sales offset decline sales overall expansion market lamictal although antibiotics smaller product contributed significantly growth sales latin america sales growth two per cent affected increased per cent difficult conditions brazil excluding brazil sales region antiviral sector hiv sales grew per cent reflecting grew per cent mexico groups largest market continuing growth established products uptake region sales grew per cent good performances newer products ziagen ageneraseand initial sales trizivir therapeutic areas particularly vaccines brazil sales affected together generated million sales approval government drive promote generic products market trizivirwas received november herpes impact hiv contracts repeated sector strong sales valtrexbenefited convenience middle east africa region grew per cent oncedaily dosage form wider usage long notable increases hiv products antibiotics term herpes suppression therapy canada sales grew per cent reflecting strong growth paxiland recent launches seretideand avandia rest asthmacopd range wellbutrinalso contributed growth zybandeclined per centoperating financial review prospectsglaxosmithkline consumer healthcare sales cost sales cost sales increased less increase sales smithkline cer beecham reflects benefits manufacturing rationalisation otc medicines changes product mix benefit newly launched products oral care reduced external royalties glaxo wellcome cost sales nutritional healthcare increased percentage sales reflecting lower production total sales continuing business volumes following stockbuild reduced rate divested products increase second half year manufacturing total consumer healthcare sales rationalisation delivered efficiencies benefit exchange selling general administration otc medicines selling general administration sga increased line sales growth vitamins naturals dermatologicals sales growth higher selling costs particularly support product offset declines categories notably smoking control launches avandia seretideand paxil offset savings gastrointestinal sales affected lower sales tumsin administration costs competitive us market analgesics affected voluntary recall panadolin australia following tampering threat research development research development rd expenditure increased less smoking control sales declined eight per cent reflecting competition increase sales pharmaceuticals rd million us market following introduction private label nicotine consumer healthcare rd million replacement therapynrt gum patch introduction two new glaxosmithkline smoking control products us trading profit market clear nicodermpatchand nicorette orange gum trading profit increased per cent increase sales prevented inroads private label brands excluding reflecting management sga line sales growth lower usa smoking control sales grew per cent rates increase cost sales rd oral care healthcare services sales aquafreshtoothpastes toothbrushes increased healthcare services businesses divested contributed percent notably usa rest world markets trading profit date divestment offset declines oral care brands profit taxation business performance nutritional healthcare strong sales growth achieved across nutritional healthcare analysis discussion profit taxation relates range sales lucozadebenefited strong growth lucozade business performance sportin uk operating incomeexpense divested products royalties income divested products products sold operating expense part regulatory approval merger income equity investments trading profit business performance illustrate glaxosmithkline business performance analysis trading profit subsequent discussion net operating income lower due fewer excludes merger items restructuring costs costs arising disposals older products income equity investments includes disposal healthcare services businesses disposals affymetrix shares second half year management believes exclusion nonrecurring items reducing groups holding per cent provides better comparison business performance periods presented accordingly information provided disposal associates supplement contained consolidated statement group reduced investment affymetrix inc first half profit loss pages prepared accordance uk realising gain million accounted gaap analysis discussion focus retained businesses disposal interest associate subsequently group pharmaceuticals consumer healthcare performance ceased significant influence affymetrix time healthcare services dealt separately ceased equity account investment disposals shares affymetrix made second half growth included investment disposals operating income cer sales profitslosses associates joint ventures cost sales share profits associates arises principally smithkline selling general beechams holding inquest diagnostics incorporated administration held august research development trading profit glaxosmithkline operating financial review prospects net interest payable manufacturing restructuring costs million incurred glaxo wellcome interest payable million smithkline beecham implementation investment income previously announced plans restructuring manufacturing activities share interest payable associate associate costs represent groups share restructuring costs net interest payable includes groups share net interest incurred associate quest diagnostics inc associate quest diagnostics inc whole august apart quest diagnostics inc divested businesses interest interest payable less investment income broadly stable impact disposal healthcare services businesses compared reflecting consistent average level august million million net credit net debt proceeds disposal restructuring costs incurred healthcare services divested products received late december million minor benefit net interest payablein taxation profit taxation operating incomeexpense together disposal business performance interest anassociate added million profit merger restructuring disposal taxation compared million taking subsidiaries account contribution associates comprising share total taxation profit less share interest less thegroups net interest payable profit tax million compared charge taxation business performance profit amounting million increase per cent million represents effective tax rate per cent consistent rate per cent expected glaxo merger items restructuring costs divested businesses wellcome rate per cent expected merger smithkline beecham costs effecting merger referred transaction costs amounted million costs comprise expenses earnings fees preparing implementing scheme arrangement earnings merger including obtaining approvals shareholders earnings per ordinary share p p regulatory authorities securing admission earnings per adr glaxosmithkline shares official list uk listing authority adjusted earnings costs incurred planning arising integration adjusted earnings per ordinary share p p glaxo wellcome smithkline beecham businesses adjusted earnings per adr unified glaxosmithkline business referred integration costs weighted average number shares millions amounted million costs include consultancy fees support integration planning severance costs adjusted earnings adjusted earnings per sharearepresented recognised arising initial stages integration order illustrate business performance appointment process initial asset writeoffs costs glaxosmithkline million recognised smithkline beecham respect adjusted earnings increased per cent cer adjusted earnings accelerated vesting share options share incentive awards per share increased per cent cer reflecting lower result merger costs recognised glaxo wellcome weighted average number shares weighted average number arising lapse performance conditions attaching shares purposes earnings per share decreased due share incentive awards result merger purchases shares employee share ownership trust order obtain regulatory approval merger glaxo satisfy future exercises share options wellcome smithkline beecham agreed number product divestments significant divestments famvir kytril sold december famvirwas sold novartis kytrilwas sold roche part sale kytril roche glaxosmithkline purchased exclusive rights coreg usa canadaoperating financial review prospectsglaxosmithkline selected financial data ukus gaap profit loss account amounts accordance uk gaap business performance retained businesses sales operating profit profit taxation earningsnet income business performance primary performance measure used management presented excluding merger items restructuring costs disposal subsidiaries earlier years exclude divested healthcare services business management believes exclusion nonrecurring items provides better comparison business performance periods presented accordingly information provided supplement contained consolidated statement profit loss pages prepared accordance ukgaap total results include nonrecurring items total results sales operating profit profit taxation earningsnet income earnings per share p p p p p weighted average number shares million dividends per glaxosmithkline share p glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividends per glaxosmithkline ads glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividends expressed terms glaxosmithkline shareads amounts accordance us gaap total results sales incomeloss operations profitloss tax net lossincome balance sheet amounts accordance uk gaap total assets net assets equity shareholders funds amounts accordance us gaap total assets net assets shareholders equity exchange rates guide holders adrs following tables set periods indicated information exchange rate us dollars sterling reported federal reserve bank new york noon buying rate average average rate year calculated average noon buying rates last day month year feb jan dec nov oct sept high low noon buying rate th march us glaxosmithkline operating financial review prospects results us accounting principles review discusses results glaxosmithkline plc changes shareholders equity years shareholders equity st beginning year december prepared us accounting principles net lossincome combination glaxo wellcome smithkline beecham shares issued acquisition accounted merger ukgaap financial share purchased cancelled statements glaxosmithkline presented two share issues share options companies combined periods presented treasury stock usgaap glaxo wellcome determined accounting dividends acquirer smithkline beecham purchase acquisition dated th december financial statements end year glaxosmithkline prior merger therefore glaxo wellcome net assets smithkline beecham book values glaxosmithkline glaxo wellcome incorporated smithkline beecham net assets ukgaap basis adjusted normal ukusgaap differences principal adjustments results inclusion unamortised goodwill intangible assets glaxos acquisition wellcome glaxo wellcomes acquisition summary results smithkline beecham dividends declared rather proposed sales basis treatment shares held employee share trading profit ownership trusts treasury stock rather investments operating profitloss profitloss tax prospects net loss glaxosmithkline published expectations future growth basic loss per share pence earnings per share ukgaapbasis excluding merger results glaxosmithkline glaxo wellcome restructuring items refer outlook sales increased primarily due acquisition smithkline glaxosmithkline expects incur costs deliver expense beecham th december block drug january savings synergies integration glaxo wellcome smithkline beecham operations beyond trading profit increased primarily result ukgaap costs expensed usgaap certain acquisition smithkline beecham december block costs expensed others represented drug january trading profit lower usgaapbasis adjustment value acquired goodwill uk gaapbasis resulting primarily charge sfas stockbased compensation amortisation adoption sfas recent fasb pronouncements product rights purchased received company adopted sfas accounting derivative regulatory approval instruments hedging activities st january sfas operating profitloss also includes significant difference requires derivatives carried balance sheet fair annual charge amortisation goodwill intangible assets value company recorded transition adjustment arising glaxos acquisition wellcome glaxo movements within derivative instruments adjustment wellcomes acquisition smithkline beecham sfas business combinations requires business intangible assets recognised balance sheet amortised combinations st july accounted using profit loss statement usgaap uk purchase method gaap additionally onetime charge million made write inprocess research development sfas goodwill intangible assets required acquired acquisition smithkline beecham effect implemented effect st january standard charges produce profit tax result reclassification certain intangible assets goodwill million tax minority interest net loss addition goodwill intangibles indefinite useful lives year million compared loss tax longer amortised subject annual impairment million tax minority interest net loss test amortisation expense goodwill intangibles million considered indefinite life billion sfas accounting obligations associated shareholders equity st december retirement longlived assets issued august shareholders equity st december ukgaap required implemented effect st january respect glaxosmithkline million standard requires fair value obligation associated retirement tangible longlived assets acquisition smithkline beecham th december capitalised asset cost financed issuance common stock premium par increased shareholders equity billion considerationis october fasb issued sfas accounting represented billion assets book value us impairment disposal longlived assets required gaap basis billion ukgaapbasis billion fair value implemented effect st january standard adjustments principally respect intangible assets goodwill develops one accounting model longlived assets including value billion ascribed inprocess research discontinued operations disposed sale company development written income statement currently assessing impact sfas glaxosmithkline financial statements section comprises directors statements independent auditors report financial statements financial statements consisting principal financial statements supporting notes additional financial data directors statements responsibility independent auditors report financial statements consolidated statement profit loss consolidated statement total recognised gains losses consolidated statement cash flow consolidated balance sheet reconciliation movements equity shareholders funds company balance sheet notes financial statements presentation financial statements accounting policies new accounting policies requirements exchange rates merger glaxo wellcome smithkline beecham segment information merger items restructuring costs divested businesses operating incomeexpense operating profit joint ventures associated undertakings net interest payable taxation earnings per share dividends goodwill intangible assets tangible fixed assets fixed asset investments equity investments stocks debtors creditors provisions liabilities charges contingent liabilities net debt commitments share capital share premium account nonequity minority interest reserves legal proceedings acquisitions disposals financial instruments related disclosures employee share schemes directors remuneration employee costs reconciliation us accounting principles principal group companies principal financial statements us financial record quarterly trend five year record glaxosmithkline directors statements responsibility directors statement responsibility relation internal control tothefinancial statements board audit committee reviewed directors assessment risks internal control framework operates glaxosmithkline plc considered responsible ensuring maintenance proper accounting effectiveness system internal control operation records disclose reasonable accuracy financial inthegroup year covered report position group time financial date approval board directors statements beprepared comply companies act combined code required law prepare financial statements financial period give true fair view state board considers glaxosmithkline plc applies principles affairs company group end combined code asdescribed corporate governance financial period ofthe profit loss period pages complied provisions responsible also ensuring operation systems combined codewiththeexception provisions relating internalcontrol taking reasonable steps safeguard appointment senior independent director assets group preventing detecting fraud companys position described board executive irregularities executive directors service contracts pensionable bonuses financial statements year ended st december terminationcommitments companys position comprising principal statements supporting notes set described remuneration report infinancial statements pages report chairman remuneration nominations committee unable attend annual general meeting directors confirm suitable accounting policies owing business commitments consistently applied preparation financial statements supported reasonable prudent judgements estimates required listing rules financial services authority asnecessary applicable accounting standards followed auditors haveconsidered directors statement compliance financial statements prepared going relation points combined code concern basis specified theirreview responsibilities auditors relation financial annual report statements set independent auditors report opposite annual report year ended st december comprising report directors financial statements financial statements year ended st december additional information investors approved included annual report published board directors signed behalf company hardcopy printed form companys web site internet directors responsible maintenance sir richard sykes chairman integrity annual report web site accordance th march uk legislation governing preparation dissemination financial statements access web site available outside uk comparable legislation may different directors remuneration remuneration report pages report describes boards policy directors remuneration applies glaxosmithkline plc sets details remuneration earned directors convenience remuneration report includes disclosable information relating directors officers interests statutory disclosures respect remuneration attributable todirectors glaxosmithkline plc set note financial statements remuneration report complies section b combined code going concern basis making enquiries directors reasonable expectationthat group company adequate resources continue operational existence foreseeable future forthis reason continue adopt going concern basis inpreparing accountsglaxosmithkline independent auditors report members glaxosmithkline plc audited consolidated financial statements basis audit opinion comprise consolidated statement profit loss conducted audit accordance auditing standards consolidated statement total recognised gains losses issued united kingdom auditing practices board consolidated statement cash flow consolidated balance sheet withauditing standards generally accepted united states related notes prepared anaudit includes examination test basis evidence relevant historical cost convention accounting policies set amounts disclosures financial statements also statement accounting policies also examined includes assessment significant estimates judgements amounts disclosed relating emoluments share options made directors preparation financial longterm incentives directors form part statements whether accounting policies appropriate remuneration report companys circumstances consistently applied adequately disclosed respective responsibilities directors auditors planned performed audit obtain directors responsibilities preparing annual report information explanations considered necessary consolidated financial statements accordance applicable order provide us sufficient evidence give reasonable united kingdom law accounting standards set assurance consolidated financial statements free statement directors responsibilities material misstatement whether caused fraud responsibility audit consolidated financial statements irregularity error forming opinion also evaluated accordance relevant legal regulatory requirements united overall adequacy presentation information kingdom auditing standards issued auditing practices board consolidated financial statements listing rules financial services authority united kingdom opinion report opinion whether financial statements give true fair view properly prepared opinion financial statements give true fair view inaccordance united kingdom companies act state affairs company group st december wealso report opinion report directors profit cash flows group year consistent consolidated financial statements ended properly prepared accordance company hasnot kept proper accounting records united kingdom companies act received information explanations require audit information specified law listing rules united states opinion regarding directors remuneration transactions disclosed opinion financial statements present fairly material read information contained annual report respects consolidated financial position group consider implications report become aware stdecember results consolidated anyapparent misstatements material inconsistencies operations andits consolidated cash flows three consolidated financial statements information comprises years period ended st december conformity report directors joint statement accounting principles generally accepted united kingdom chairman chief executive officer operating accounting principles generally accepted united kingdom financial review corporate governance statement vary certain significant respects accounting principles review whether corporate governance statement reflects generally accepted united states application latter companys compliance seven provisions would affected determination consolidated net income combined code specified review listing rules expressed insterling three years period ended report required consider whether stdecember determination consolidated boards statements internal control cover risks shareholders equity also expressed sterling st december controls form opinion effectiveness extent summarised note companys groups corporate governance procedures financial statements risk control procedures pricewaterhousecoopers chartered accountants registered auditors southwark towers london england th march glaxosmithkline consolidated statement profit loss merger restructuring business disposal performance subsidiaries total notes turnover including million relating acquisitions cost sales gross profit selling general administrative expenditure research development expenditure trading profit operating incomeexpense operating profit including million relating acquisitions share profitslosses joint ventures associated undertakings profit disposal interest associate product divestments merger transaction costs disposal businesses loss disposal utilisation provision profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation minority interests preference share dividends earnings profit attributable shareholders earnings per share p adjusted earnings per share p diluted earnings per share p profit attributable shareholders dividends retained profit items dealt arriving business performance operating profit relate continuing activities difference profit ordinary activities taxation retained profit stated historical cost equivalents consolidated statement total recognised gains losses profit attributable shareholders exchange movements overseas net assets uk tax exchange movements total recognised gains losses consolidated statement profit lossglaxosmithkline merger business performance restructuring restructuring business disposal retained divested disposal performance subsidiaries total businesses business total subsidiaries total p p p p p p glaxosmithkline consolidated statement cash flow reconciliation operating profit operating cash flows notes operating profit depreciation impairment intangible assets written amortisation goodwill intangible fixed assets loss sale tangible fixed assets profit sale equity investments decreaseincrease stocks increase trade debtors increase trade creditors increase pension provisions merger transaction costs paid net cash inflow operating activities cash flow statement net cash inflow operating activities dividends joint ventures associated undertakings returns investment servicing finance taxation paid capital expenditure financial investment acquisitions disposals equity dividends paid net cash outflowinflow management liquid resources financing management liquid resources financing decreaseincrease cash year reconciliation net cash flow movement net debt net debt beginning year decreaseincrease cash year cash outflowinflow management liquid resources net increase longterm loans net repayment shortterm loans net repayment ofincrease obligations finance leases net noncash funds subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year consolidated statement cash flowglaxosmithkline analysis cash flows returns investment servicing finance interest received interest paid dividends paid minority shareholders dividends paid preference shares taxation paid capital expenditure financial investment purchase tangible fixed assets sale tangible fixed assets purchase intangible assets sale intangible assets product divestments purchase shares employee share options awards proceeds shares employee share options purchase equity investments sale equity investments acquisitions disposalsnote purchase businesses cash acquired subsidiary disposal businesses investment joint ventures associated undertakings disposal interests associates financing issue ordinary share capital redemption preference shares issued subsidiary ordinary share capital purchased cancellation financing cash flows increase longterm loans repayment longterm loans net repayment shortterm loans net repayment ofincrease obligations finance leases analysis changes net debt cash flow acquisitions exchange cash repayable demand overdrafts debt due within one year commercial paper debt due one year euro bonds mediumterm notes management liquid resources cash balances repayable demand liquid investments net debt glaxosmithkline consolidated balance sheet notes goodwill intangible assets tangible assets investments fixed assets equity investments stocks debtors liquid investments cash bank current assets loans overdrafts creditors creditors amounts due within one year net current assets total assets less current liabilities loans creditors creditors amounts due one year provisions liabilities charges net assets called share capital share premium account reserves profit loss account equity shareholders funds nonequity minority interest equity minority interests capital employed approved board sir richard sykeschairman th march reconciliation movements equity shareholders funds notes equity shareholders funds beginning year total recognised gains losses year dividends ordinary shares issued ordinary shares purchased cancelled exchange movements goodwill written reserves goodwill written back equity shareholders funds end year glaxosmithkline company balance sheet notes shares subsidiary companies cost fixed assets amounts owed group undertakings cash bank current assets taxation dividends proposed creditors amounts due within one year net assets called share capital share premium account reserves profit loss account equity shareholders funds approved board sir richard sykeschairman th march glaxosmithkline notes financial statements presentation financial statements additional information accordance requirements usgenerally accepted accounting principles us gaap included description business notes financial statements note statement glaxosmithkline major global healthcare group differences reconciliation net income shareholders engaged creation discovery development manufacture equity uk us gaap provided principal marketing pharmaceutical products including vaccines financial statements presented accordance us gaap overthecounter otc medicines healthrelated consumer andin usgaap format products glaxosmithklines principal pharmaceutical products include medicines following therapeutic areas central merger glaxowellcome plc smithkline beecham plc nervous system disorders respiratory antibacterials antivirals glaxosmithkline plc acquired glaxo wellcome plc smithkline metabolic gastrointestinal vaccines oncology emesis beecham plc way scheme arrangement merger cardiovascular arthritis two companies became effective th december financial period ukgaap financial statements glaxosmithkline plc accounts cover financial year st january prepared merger glaxowellcome plc smithkline stdecember comparative figures financial beecham plc comparative figures years years st january st december st january st december st december therefore include tost december results glaxo wellcome plc smithkline beecham plc us gaap financial statements glaxosmithkline plc composition group prepared acquisition smithkline beecham plc list subsidiary associated undertakings glaxo wellcome plc th december accordingly opinion directors principally affected amount results smithkline beecham periods prior date profit net assets group given principal group consolidated companies note presentation statement profit loss composition financial statements columnar presentation adopted statement consolidated financial statements drawn accordance profit loss order illustrate underlying business performance uk generally accepted accounting principles ukgaap primary measure used management uk accounting presentation purpose certain items identified separately excluded financial statements comprise business performance comprise merger integration items including product divestments costs relating previously consolidated statement profit loss announced manufacturing restructuring theeffect consolidated statement total recognised gains losses disposals subsidiaries consolidated statement cash flow consolidated balance sheet trading profit reflects sales less cost sales comprising costs reconciliation movements equity shareholders funds ofmanufacture external royalties selling general company balance sheet administrative expenditure comprising costs selling notes financial statements distribution medical support currently marketed products costs administration costs research permitted section companies act development create future products sale profitand loss account company presented consolidated statement total recognised gains losses accounting convention comprises financial statements prepared using historical cost convention realised profit attributable shareholders reflected theconsolidated profit loss account accounting standards unrealised gain loss value groups overseas financial statements comply applicable uk accounting net assets less related foreign currency borrowings attributable standards currency movements period reconciliation movements equity shareholders funds accounting principles policies comprises items contributing increase decrease preparation financial statements conformity generally period shareholders funds items include accepted accounting principles requires management make estimates assumptions affect reported amounts total recognised gains losses period assets liabilities disclosure contingent assets dividends paid proposed liabilities date accounts reported amounts proceeds shares issued period revenues expenses reporting period actual results cost shares purchased cancellation could differ estimates share buyback programme changes goodwill arising acquisitions prior financial statements prepared accordance st january set directly reserves companys accounting policies approved board described note company implemented two new financial reporting standards described innote notes financial statements glaxosmithkline accounting policies foreign currency transactions foreign currency transactions group companies booked consolidation inlocal currency exchange rate ruling date consolidated accounts include transaction forward rate hedged forward assets liabilities results cash flow exchangecontract foreign currency assets liabilities company subsidiary undertakings including employee translated local currency rates exchange ruling share ownership trusts esots balance sheet date forward rate exchange differences groups share net assets results joint ventures areincluded trading profit associated undertakings revenue accounts undertakings consolidated made revenue recognised profit loss account goods st december services supplied external customers orders undertakings group material interest received turnover represents net invoice value accounted subsidiaries group exercises dominant deduction discounts given point sale products influence joint ventures group exercises joint control despatched available collection customers less associates group exercise significant accruals estimated future rebates returns value added influence esots accounted subsidiaries grounds tax sales taxes excluded revenue group de facto control expenditure interests acquired undertakings consolidated expenditure recognised respect goods services effective date acquisition interests sold consolidated received supplied accordance contractual terms upto date disposal provision made obligation exists future liability transactions balances subsidiary undertakings respect past event amount eliminated profit taken sales subsidiary obligation reliably estimated restructuring costs undertakings sales joint ventures associated undertakings recognised respect direct expenditures business products sold customers outside group reorganisation plans sufficiently detailed well advanced appropriate communication goodwill arising acquisition interestsin subsidiary affected undertaken balance sheet date undertakings joint ventures associated undertakings representing excess purchase consideration research development groups share separable net assets acquired capitalised research development expenditure charged profit asa separate item case subsidiary undertakings loss account period incurred tangible part cost investment case joint ventures fixed assets used research development depreciated associated undertakings goodwill denominated currency accordance groups policy inwhich acquisition made financed case acquisitions prior goodwill written environmental expenditure reserves subsequent disposal assets acquisitions environmental expenditure related existing conditions resulting related goodwill removed consolidated reserves past current operations current charged consolidated profit lossaccount future benefit discernible charged profit loss groups interests joint ventures accounted using account group determines liability sitebysite basis thegross equity method groups interests associated records liability time probable undertakings accounted using equity method reasonably estimated liability includes groups portion costs also portion potentially deferred taxation relief unrealised intragroup profit responsible parties costs probable accounted extent related taxation effect able satisfy respective share cleanup obligation isexpected reverse recoveries reimbursements virtually certain assets liabilities overseas subsidiary associated recorded assets undertakings joint ventures including related goodwill translated sterling rates exchange ruling balance legal disputes sheet date results cash flows overseas subsidiary provision made anticipated settlement costs legal associated undertakings joint ventures translated expenses associated legal disputes sterling using average rates exchange exchange adjustments group reasonable estimate made arising opening net assets profits theyear likely outcome dispute obligation exists retained overseas subsidiary associated undertakings dispute possible make reasonable joint ventures translated sterling less exchange differences estimate provision made costs associated claims arising related foreign currency borrowings taken directly made group third parties charged reserves reported statement total recognised gains profit loss account incurred andlosses translating sterling assets liabilities results cash flows overseas subsidiary associated undertakings joint ventures reported currencies hyperinflationary economies adjustments aremade reflect current price levels loss net monetary assetsis charged consolidated profit loss account glaxosmithkline notes financial statements accounting policiescontinued tangible fixed assets tangible fixed assets stated cost less provision pensions postretirement benefits depreciation costs acquiring developing computer cost providing pensions employee postretirement software internal use internet sites external use benefits charged consolidated profit loss account capitalised tangible fixed asset software site systematic rational basis based actuarial assumptions supports significant business system expenditure leads period benefit derived employees services creation durable asset difference charge contributions paid included asset liability consolidated balance sheet depreciationis calculated write cost tangible fixed assets excluding freehold land equal annual instalments employee share plans expected useful lives normal expected useful lives incentives form shares provided employees major categories tangible fixed assets share option share award schemes respect award schemes certain share option grants company provides freehold buildings years finance employee share ownership trusts purchase company leasehold land shorter lease term shares open market meet companys obligation buildings years provide shares employees exercise option award plant machinery years theexcess purchase price shares exercise fixtures equipment years price options awards charged profit loss erp systems software years account periods service respect options computer software years awards granted respect share option grants erp systems software generally involves significant customisation share options exercised accounted share issues prior implementation regarded useful exercise price additional employer costs respect options economic life seven years rather maximum five years awards charged profit loss account periods computer software service ondisposal tangible fixed asset cost related costs running employee share ownership trusts charged accumulated depreciation removed accounts profit loss account net amount less proceeds taken consolidated profit shares held employee share ownership trusts accounted loss account fixed asset investments cost less accrual costs charged leases goodwill leasing agreements transfer group substantially goodwill stated cost less provision amortisation benefits risks ownership asset treated amortisation calculated write cost equal annual finance leases asset purchased outright instalments expected useful life useful life assets included intangible fixed assets capital element normally expected exceed years leasing commitments shown obligations finance leases assets held finance leases depreciated intangible fixed assets shorter ofthe lease terms useful lives assets intangible assets stated cost less provision amortisation interest element lease rental charged profit leases operating leases annual rentals acquired licences patents knowhow marketing rights charged profit straightline basis lease term amortised estimated useful lives equal instalments longer years limit reduced impairment fixed assets year maximum allowed prior periods management believes carrying values fixed assets reviewed impairment better reflects useful economic lives assets items indication assets might impaired capitalised restricted related specific compounds firstyear impairment reviews conducted acquired goodwill products developed commercial applications intangible assets certain intangibles considered estimated useful lives determining amortisation charge anindefinite life therefore amortised intangibles reviewed annually andtake account estimated time subject annual impairment tests impairment determined takes bring compounds products market marketable byreference higher net realisable value value use products anydevelopment costs incurred group measured reference discounted future cash flows areassociated acquired licence patent knowhow provision impairment charged profit marketing rights written profit loss account yearconcerned whenincurred brands valued independently part fair value investments joint ventures associates businesses acquired third parties brand value investments joint ventures associated undertakings substantial longterm brands carried consolidated balance sheet groups share sold separately rest businesses acquired brands oftheir net assets date acquisition post areamortised estimated useful lives longer acquisition retained profits losses together goodwill years except end useful economic life arising acquisition net amortisation brand forseen stocks prior acquired minor brands similar intangibles stocksare included accounts lower cost including eliminated group balance sheet reserves year manufacturing overheads appropriate net realisable acquisition value cost generally determined first first basisnotes financial statementsglaxosmithkline accounting policiescontinued new accounting policies requirements taxation company implemented financial reporting standard deferred taxation calculated using liability method accounting policies transitional disclosure requirements accounted group company taxation deferred financial reporting standard retirement benefits frs accelerated reason timing differences deferred taxation relief updates existing standard provides new guidance accounted full onlongterm timing differences respect significant effect measurement results ofprovisions unfunded retirement benefits taxation deferred assets liabilities company frs adopts market value oraccelerated reason shortterm timing differences approach measurement retirement benefits requires accounted extent probable liability expanded disclosures disclosure requirements asset crystallise implemented company standard require implementation change measurement approach current asset investments current asset investments stated lower cost net frs deferred tax falls implemented company realisable value frs requires deferred tax accounted full case securities acquired significant premium provision basis rather partial provision basis present discount maturity value intended held redemption st december effect full provision basis would cost adjusted amortise premium discount life reduce deferred tax asset approximately million tomaturity security floating rate bonds stated cost interest income taken consolidated profit loss account exchange rates receivable basis group uses average exchange rates prevailing equity investments included current assets regarded period translate results cash flows overseas group asavailable sale subsidiary joint venture associated undertakings sterling period end rates translate net assets debt instruments undertakings thecurrencies influence debt instruments stated amount net proceeds translations relevant exchange rates adjustedto amortise finance cost debt evenly term debt average rates derivative financial instruments us group hold issue derivative financial instruments euro trading purposes yen period end rates derivative financial instruments used manage exposure us market risks treasury operations principal derivative euro instruments currency swaps forward exchange contracts yen interest rate swaps derivative contracts treated inception economic hedge underlying financial merger glaxo wellcome smithkline beecham instrument matching accounting treatment cash flows combination glaxo wellcome plc smithkline beecham plc derivative contracts high correlation specific treated merger th december uk gaap financial instrument hedged inception reflecting intentions respective sizes merging throughout hedge period derivative instruments longer parties designated hedges restated market value future changes value taken directly profit loss account merger accounting shares issued glaxosmithkline plc acquire glaxo wellcome smithkline beecham accounted currency swaps forward exchange contracts used fix par share premium arose shares acquired value related asset liability contract currency glaxosmithkline glaxo wellcome smithkline beecham contract rate accrued profit loss account similarly accounted nominal value shares issued life contract gains losses foreign exchange contracts inthe consolidated accounts glaxosmithkline results designated hedges forecast foreign exchange transactions netassets glaxo wellcome smithkline beecham deferred included measurement related foreign combined book amounts subject alignment adjustments currency transactions period occur gains losses balance sheet hedges accrued taken directly reserves inview proximity merger date financial yearend except forward premiumdiscounts recognised interest date relative insignificance business activity life contracts th december st december accounting date merger practical purposes taken stdecember interest differentials interest swap agreements recognised whole profit financial year consolidated profit loss account adjustment ofinterest glaxo wellcome plc smithkline beecham plc wasdeemed expense life agreement relate period prior merger date glaxosmithkline notes financial statements segment information analysis turnover profit taxation total assets net assets tangible fixed assets geographical business segment areset belowthe business segments consist pharmaceuticals prescription pharmaceuticals vaccines consumer healthcare oralcare otc medicines nutritional healthcare healthcare services clinical laboratory testing pharmacy benefit management thegeographical segments reflect groups significant regional markets consistent groups regional market management reportingstructure adjustments analysis profit tax geographic segment made ensure consistency treatment following sale diversified pharmaceutical services clinical laboratories healthcare services segment longer forms part ongoing business group business segment data includes allocation corporate costs segments intrasegment sales groups activities organised global basis geographical segmental figures therefore influenced location groups operating resources particular manufacture research variations time intragroup trading funding arrangements turnover business sector pharmaceuticals consumer healthcare healthcare services external turnover turnover location customer usa europe rest world external turnover profit tax business sector pharmaceuticals consumer healthcare healthcare services operating profit share profitslosses joint ventures associated undertakings profit disposals associates divestments merger transaction costs net interest payable profit taxation profit taxation taxation minority interests preference share dividends earnings total assets business sector pharmaceuticals consumer healthcare total assets net assets business sector pharmaceuticals consumer healthcare net assets block drug business integrated consumer healthcare segment year effect groups turnover estimated effect operating profit together analysis net assets acquired given note notes financial statementsglaxosmithkline segment informationcontinued turnover location subsidiary undertaking usa europe rest world gross turnover usa europe rest world intersegment turnover usa europe rest world external turnover profit tax location subsidiary undertaking usa europe rest world operating profit share profitslosses joint ventures associated undertakings profit disposals associates divestments merger transaction costs net interest payable profit taxation profit taxation taxation minority interests preference share dividends earnings total assets location subsidiary undertaking usa europe rest world total operating assets cash bank liquid investments total assets net assets location subsidiary undertaking usa europe rest world net operating assets net debt net assets glaxosmithkline notes financial statements segment informationcontinued plant land equipment computer assets buildings vehicles software construction total tangible fixed assets location subsidiary undertaking usa europe rest world total uk segment information given separately respect uk although included groups europe market region considered groups home segment purposes segmental reporting turnover location customer gross turnover intersegment turnover turnover location subsidiary operating profit total assets net operating assets merger items restructuring costs divested businesses manufacturing restructuring costs incurred glaxosmithkline implementation previously announced plans restructuring manufacturing activities costs also incurred glaxo wellcome smithkline beecham merger integration costs incurred relating integration glaxo wellcomeand smithkline beecham unified glaxosmithkline business costs include consultancy fees respect integration planning severance costs asset writeoffs costs related early vesting lapse performance conditions share options share incentive awards costs programme encourage staff convert glaxo wellcome smithkline beecham share options glaxosmithkline share options integration costs incurred relating integration block drug businesses costs include professional fees severance costs asset writeoffs product divestment income arises disposal famvir kytrilandother products required order obtain regulatory approval merger merger transaction costs incurred order effect merger costs comprise fees expenses incurred preparing implementing scheme arrangement merger disposal businesses primarily arose sale affymax includes million write goodwill previously eliminated group reserves disposal businesses relates disposal healthcare services restructuring costs incurred healthcare services disposal share associate relates restructuring costs incurred quest diagnostics restruc disposal merger turing block drug subsidiaries total manufacturing restructuring merger integration costs block drug integration costs effect operating profit disposal businesses effect profit tax effect taxation operating items effect taxation nonoperating items effect taxation effect earnings notes financial statementsglaxosmithkline merger items restructuring costs divested businesses continued restruc disposal merger turing associate subsidiaries total manufacturing restructuring merger integration costs effect operating profit share associate product divestments merger transaction costs disposal businesses loss disposal effect profit tax effect taxation operating items effect taxation nonoperating items effect taxation effect earnings restruc disposal turing associate subsidiaries total manufacturing restructuring healthcare services restructuring effect operating profit share associate disposal businesses loss disposal utilisation provision effect profit tax effect taxation operating items effect taxation nonoperating items effect taxation effect earnings operating incomeexpense royalties income operating expense income equity investments disposals royalties income principally core recurring income form royalties outlicensing intellectual property operating expense comprises nonrecurring costs related product liability claims product withdrawals income equity investments disposals arises equity investment sales equity investment writedowns due adverse market conditions product property disposals analyses operating incomeexpense amended follow classifications glaxosmithkline notes financial statements operating profit following items charged operating profit employee costs note advertising distribution costs depreciation tangible fixed assets owned assets leased assets amortisation goodwill amortisation intangible fixed assets exchange lossesgains foreign currency depositsloans operating lease rentals plant machinery land buildings audit fees fees auditors work auditors ukfirm auditors overseas firms included within audit fees fee relating company audit glaxosmithkline plc included within fees auditors work million million relating merger glaxo wellcome smithkline beecham fees relate many integration projects undertaken around group particularly human resources information technology global manufacture supply fees persons consultancy services amounted million joint ventures associated undertakings share profitslosses joint ventures associated undertakings share profits quest diagnostics inc share lossesprofits associated undertakings goodwill written share turnover joint ventures sales joint ventures associated undertakings net interest payable interest payable bank loans overdrafts loans respect finance leases share interest payable associate investment income interest income provision market value adjustments notes financial statements glaxosmithkline taxation taxation charge based profits period uk corporation tax uk statutory rate less double taxation relief overseas taxation deferred taxation share taxation charge associates reconciliation taxation rate ukstatutory rate taxation deferred taxation provided fixed assets effect special taxation status manufacturing locations net cost different rates taxation overseas undertakings share option deductions usa tax losses rd credits previously recognised differences taxation rate business performance merger restructuring costs taxation rate total group results profits arising manufacturing operations singapore puerto rico ireland taxed reduced rates effect reduction taxation charge increased earnings per share p p p integrated nature groups worldwide operations involving significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax disagreements revenue authorities price goods transferred group companies different tax jurisdictions produce conflicting claims revenue authorities profits fall taxed individual territories resolution issues continuing factoflife glaxosmithkline usa number years glaxosmithkline significant open issues relating transfer pricing issues affect years present concern number products although significant relates success zantac respect claims us internal revenue service irs substantially exceed groups estimation taxation liabilities irs claims continue subject discussions us uk tax authorities competent authority provisions double tax convention two countries within discussions wide variation views us uk tax authorities exceptionally may unable reach agreement settle dispute event uk us tax authorities reaching agreement matter may resolved litigation glaxosmithkline uses best advice determining transfer pricing methodology seeking manage transfer pricing issues satisfactory conclusion basis external professional advice continues believe made adequate provision liabilities likely arise open assessments save shown accounts provision made taxation would arise distribution profits retained overseas subsidiary associated undertakings grounds remittance profit retained st december required way incremental tax arise glaxosmithkline notes financial statements taxation continued tax creditor deferred tax tax balances st january exchange adjustments acquisition subsidiary chargecredit profit loss account cash paid movements st december full potential provided deferred taxation assetliability accelerated capital allowances stock valuation adjustment intragroup profit product business disposals pensions postretirement benefits manufacturing restructuring tax losses timing differences categories provided deferred taxation stock valuation adjustments intragroup profit timing differences arecurrent earnings per share p p p basic earnings per share adjustment merger items restructuring costs disposal subsidiaries merger integration transaction costs product divestments restructuring costs block drug integration costs disposal subsidiaries associates adjusted earnings per share diluted earnings per share earnings per share calculated dividing profit attributable shareholders weighted average number ofshares issue period numbers used calculating basic diluted earnings per share reconciledbelow illustrate business performance primary performance measure used management adjusted earnings adjusted earnings per share presented excluding merger items integration restructuring costs disposals subsidiaries management believes exclusion nonrecurring items provides better comparison business performance periods presented accordingly information provided supplement contained consolidated statement profit loss pages prepared accordance ukgaap basic diluted earnings per share include nonrecurring items net profit period attributable shareholders earnings basic diluted adjustments merger items restructuring costs disposal subsidiaries adjusted earnings weighted average number shares issue millions millions millions basic adjusted dilution share options diluted shares held employee share ownership trusts excludednotes financial statements glaxosmithkline dividends glaxosmithkline plc first interim second interim third interim fourth interim glaxo wellcome plc interim second interim final smithkline beecham plc first interim second interim third interim fourth interim dividends stated deducting dividends receivable trustees employee share ownership plans trusts whereapplicable dividends per share p glaxosmithkline plc first interim second interim third interim fourth interim glaxo wellcome plc per glaxo wellcome share p p interim second interim final equivalent dividend per glaxosmithkline share dividend per glaxo wellcome share smithkline beecham plc per smithkline beecham share first interim second interim third interim fourth interim smithkline beecham plc equivalent dividend per glaxosmithkline share first interim second interim third interim fourth interim glaxosmithkline notes financial statements goodwill total cost st january exchange adjustments additions cost st december amortisation st january exchange adjustments provision year amortisation st december net book value st january net book value st december licences intangible assets patents etc brands total cost st january exchange adjustments additions acquisition subsidiary disposals assets written cost st december amortisation st january exchange adjustments provision year assets written amortisation st december impairment st january exchange adjustments impairment loss impairment st december net book value st january net book value st december brands largely comprise portfolio sterling products panadol solpadeineand hedex newly acquired block drug products sensodyne polidentand poligrip considered indefinite life given strength durability brand level marketing support accordingly amortised thevaluation sterling brand reviewed annually using year cash flow forecast basis original independent assessment acquired impairment loss calculated using discount rate ten per cent valuation block drug brand also reviewed annually using year cash flow forecast discount rate per centnotes financial statementsglaxosmithkline plant land equipment computer assets tangible fixed assets buildings vehicles software construction total cost st january exchange adjustments additions acquisition subsidiary disposals reclassifications cost st december depreciation st january exchange adjustments provision year disposals depreciation st december impairment st january impairment loss disposals impairment st december net book value st january net book value st december net book value st december groups land buildings comprises freehold properties million st january million properties leases years million st january million properties leases less years million stjanuary million included plant equipment vehicles st december leased assets cost million st january million accumulated depreciation million st january million net book value million st january million impairment loss principally relates reductions forecast cash flows resulting decisions close manufacturing facilities andhasbeen measured reference value use using discount rate per cent joint associated equity fixed asset investments ventures undertakings investments shares total st january exchange adjustments additions charge year impairment transfer current assets reclassification disposals retained profit year goodwill amortisation st december investments joint ventures comprise million share gross assets million million share gross liabilities nil principal associated undertaking quest diagnostics inc us clinical laboratory business listed new york stock exchange book value st december million million market value million million group owns percent quest per cent book value includes goodwill amortised years amortisation charge million goodwill st december amounts million million goodwill million relates continuing group interest clinical laboratories assets attributed quest remains eliminated group reserves equity investments comprise listed investments million unlisted investments million market value listed investments million investments shares consist shares held employee share ownership trusts details given note glaxosmithkline notes financial statements equity investments st january exchange adjustments additions transfer fixed asset investments impairment disposals st december equity investments comprise listed investments million million themarket value listed investments million million stocks raw materials consumables work progress finished goods debtors amounts due within one year trade debtors debtors prepaid pension contributions prepayments accrued income amounts due one year debtors prepayments accrued income deferred taxation note debtors include trading balances million nilmillion due joint ventures associated undertakings creditors amounts due within one year trade creditors taxation note social security creditors accruals deferred income dividends proposed amounts due one year taxation note creditors accruals deferred income creditors include trading balances nil million due joint ventures associated undertakings accruals include accruals wages salaries million millionnotes financial statements glaxosmithkline provisions pensions indemnified legal postretirement manufacturing merger disposal liabilities charges benefits restructuring integration liabilities disputes provisions total st january exchange adjustments charge year applied acquisition subsidiary movements st december group recognised costs respect plans manufacturing restructuring initiated following merger glaxo wellcome smithkline beecham acquisition block drug plans implemented period costs recognised provision principally respect identified severances sites announced manufacturing activities cease expected incurred mainly costs asset writedowns recognised impairment fixed assets group recognised costs respect plans integration glaxo wellcome smithkline beecham businesses additional costs incurred implementation integration following merger continues costs recognised provision principally respect programme encourage staff convert glaxo wellcome smithkline beecham share options glaxosmithkline share options respect identified severances expected incurred provision indemnified disposal liabilities relates indemnities granted third parties respect operations disposed prior years including provisions indemnities purchase price adjustments respect exit healthcare services businesses provisions legal disputes matters include amounts relating us antitrust product liability contract terminations selfinsurance environmental cleanup property rental amounts provided include directors best estimates obligations arising quantified unquantified claims based current knowledge taking appropriate legal advice outcome legal claims matters glaxosmithkline involved assured final judgement given settlement reached however directors taken appropriate legal advice expect glaxosmithklines liability matters taking account provisions tax benefits insurance material adverse effect financial condition results operations cash flows glaxosmithkline involved number legal disputes including notification possible claims early stage matter reliable estimate outcome made accordingly provision recorded matters nature groups business number matters may subject negotiation litigation several years largest individual amounts provided expected settled within one two years discussion litigation issues refer legal proceedings note contingent liabilities contingent liabilities comprising warranties discounted bills performance guarantees items arising normal course business amounted st december million million glaxosmithkline notes financial statements net debt liquid investments cash bank loans overdrafts due within one year bank loans overdrafts commercial paper eurobonds mediumterm notes obligations finance leases loans loans due one year bank loans eurobonds mediumterm notes loan stock obligations finance leases loans net debt balance sheet date groups liquid investments aggregate market value million million loans overdrafts due within one year commercial paper comprises us billion programme million issue st december st december million backed committed facilities days duration million renewable annually liquid investments million weighted average interest rate commercial paper borrowings st december per cent weighted average interest rate loans overdrafts due within one year st december per cent loans due one year december billion fixed rate per cent year bond issued new billion european medium term programme loans due one year repayable various periods follows one two years two three years three four years four five years five years loans repayable five years carry interest effective rates per cent per cent repayment dates range notes financial statements glaxosmithkline net debt continued secured loans loans amounting million million secured charges fixed current assets finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations financial instruments information given note commitments capital commitments contracted provided accounts intangible fixed assets tangible fixed assets acquisition block drug number commitments made licensing agreements principally shionogi neurocrine tanabe bayer roche payments become due future milestones achieved agreements relate compounds early stages development milestone payments continue number years compounds move successfully development process generally closer product marketing approval greater possibility success commitments operating leases pay rentals next year operating leases land buildings expire one year less one five years five years operating leases plant equipment vehicles expire one year less one five years commitments operating leases pay rentals future years thereafter glaxosmithkline notes financial statements share share capital share premium account redeemable preference shares ordinary shares p p ccm oi uu nm number number share capital authorised st december st december share capital issued fully paid share capital issued prior scheme arrangement share capital issued scheme arrangement share capital issued share option schemes st december share capital redeemed par share capital issued share option schemes share capital purchased cancelled st december number number shares issuable outstanding options note st december st december number unissued shares option st december st december redeemable preference shares redeemed company st august nominal amount redeemable preference shares converted ordinary shares pence resulting authorised share capital st december billion ordinary shares pence rd october glaxosmithkline announced plans invest billion buying shares market programme covers purchases companys employee trusts relating share option grants share based incentives also covers purchases company shares cancellation total billion spent exact amount timing future purchases determined company dependent market conditions factors th march shares purchased cancelled cost million details substantial shareholdings refer substantial shareholdings nonequity minority interest sb holdings corporation sbh corp subsidiary incorporated delaware usa issue million flexible auction market preferred stock flex amps comprising shares issued six series dividend half shares fixed issuance seven year period dividend half fixed five year period ended varies predominately prevailing interest rates set every seven weeks auction shares also traded sbh corp also issue million auction rate preference stock arps comprising shares issued five series dividend also varies conditions similar flex amps described february march smithkline beecham corporation sb corp subsidiary incorporated pennsylvania usa repaid million arps comprising shares issued eight series together arps flex amps constitute preference shares represent nonequity minority interest smithkline beecham plc certain circumstances guarantees payment dividends declared preference shares smithkline beecham plc also agreed sbh corp certain circumstances provide support sbh corp relation principal however guarantee support limited circumstances could holder preference shares favourable position holder preference share smithkline beecham plc preference shares represent longterm nonequity minority interest group balance sheet accordance frs capital instrumentsnotes financial statements glaxosmithkline profit reserves reserves loss account total st december goodwill written back exchange movements uk tax exchange movements shares issued profit attributable shareholders dividends revaluation goodwill due exchange st december goodwill written back exchange movements uk tax exchange movements shares issued profit attributable shareholders dividends revaluation goodwill due exchange st december goodwill written back exchange movements shares purchased cancellation profit attributable shareholders dividends revaluation goodwill due exchange st december goodwill arising acquisitions st january written reserves amounts million including goodwill million previously held goodwill reserve offset reserves goodwill written back relates primarily disposals affymax part groups holding quest diagnostics inc goodwill denominated local currencies subject revaluation amounted million st december goodwill acquisitions st january capitalised accordance accounting policy set note exchange movements taken reserves include losses million losses million gains million foreign currency loans less deposits losses million gains million losses million retranslation net assets losses million losses million gains million goodwill eliminated reserves exchange adjustments debited reserves amount cumulatively million reserves include merger reserve created merger glaxo wellcome smithkline beecham amounting million st december million million reserves also include capital redemption reserve created result share buyback programme amounting million st december nil total reserves amounted million st december million million million nil nil relates company million million million relates subsidiary undertakings million million million relates joint ventures associated undertakings profit glaxosmithkline plc year million th december st december nil dividends million th december st december nil gave retained profit million th december st december nil cost shares purchased cancellation million th december st december nil profit loss account reserve st december stood million nil glaxosmithkline notes financial statements legal proceedings marketing authorisations also issued eight european countries products containing paroxetine hydrochloride group involved various legal administrative anhydrate another variant groups product generic products proceedings considered normal business principally containing anhydrate market germany intellectual property cases product liability governmental austria denmark glaxosmithkline believes marketing investigations significant described either paroxetine hydrochloride anhydrate product paroxetine mesylate product third parties european countries infringes intellectual property patents vigorously litigating position actions many usa number distributors generic drugs filed european countries applications us food drug administration fda market generic versions paxilseroxat paroxetine hydrochloride may geneva pharmaceuticals commenced action prior expiration groups patent paroxetine theus district court eastern district virginia four hydrochloride hemihydrate response group filed patents recently issued glaxosmithkline covering clavulanic acid actions distributors infringement various key ingredient augmentinand timentin geneva asked groups patents court declare new patents expire invalid august geneva extended complaint cover three july glaxosmithkline filed action apotex additional patents expire hearing genevas us district court northern district illinois infringement summary judgement motions challenging validity concluded one groups patents paroxetine hydrochloride apotex october trial judge yet issued decision filed abbreviated new drug application anda geneva alleges suit holder pending anda fda seeking approval introduce generic form paxil trial filed february another novartis subsidiary discovery date set case continuing june group filed action geneva september teva pharmaceuticals filed similar action pharmaceuticals subsidiary novartis pharmaceuticals challenging four recently issued patents patent expiring us district court eastern district pennsylvania december cover augmentin teva action infringement groups patents paroxetine hydrochloride consolidated geneva case court set may following notice genevas anda filing case trial date consolidated action december hearing consolidated similar infringement actions generic tevas motion summary judgement trial judge ruled companies subsequently filed andas additional infringement bench holding patent expiring december actions brought based patents issued subsequent invalid groups patent expiring invalid original filing cases consolidated group teva since filed second motion summary judgement also filed action apotex relating certain new invalidity groups patents covering augmentinwith expiry patents eastern district pennsylvania parties dates group continues believe patents consolidated action seeking agreement discovery schedule expiring valid intends appeal march glaxosmithkline filed action pentech ruling contrary us district court northern district illinois five distributors generic pharmaceutical products filed infringement groups patents paroxetine hydrochloride andas sustained release bupropion hydrochloride tablets pentech filed anda capsule version paxil asserting wellbutrin srand zyban usa accompanied case compound presentation infringe groups patents certification invalidity groups patents group patents invalid even us fda approve brought suit filing parties grounds pentech anda glaxosmithkline believes pentech patent infringement group filed suit andrx capsule would substitutable paxiltablets discovery pharmaceuticals first file anda us district court continuing case southern district florida february district october glaxosmithkline filed action synthon court judge granted andrxs summary judgement motion us district court middle district north carolina ruled product infringe groups patents infringement groups patents paroxetine hydrochloride group appealing decision actions also filed paroxetine mesylate synthon filed b application watson pharmaceuticals us district court paper nda us fda using paroxetine mesylate southern district ohio eon labs manufacturing us different salt form paroxetine used marketed district court eastern district new york impax form paxil even us fda approves synthon application laboratories us district court northern district glaxosmithkline believes synthon compound would california excel us district court new jersey substitutable paxil trial date set district watson case settled remaining cases still intheir early stages following expiration data exclusivity period europe marketing authorisation issued synthon regulatory group filed action infringement patents authorities denmark paroxetine mesylate different salt cefuroxime axetil active ingredient groups ceftinanti form paroxetine hydrochloride used marketed infective product ranbaxy pharmaceuticals us form seroxatpaxil authorisations granted six district court new jersey preliminary injunction granted european countries mutual recognition process favour glaxosmithkline august us court assessment others group initiated appeals vacated injunction remanded case litigation challenging approval danish medicines agency district court full trial merits january grounds authorisation granted ranbaxy announced us fda approved ranbaxys abridged procedure paroxetine mesylate application generic version essentially similar seroxatnotes financial statementsglaxosmithkline legal proceedings continued since ppa product withdrawal group received numerous personal injury class action lawsuits filed state federal group filed similar action apotex second courts alleging personal injury increased risk injury use distributor generic pharmaceutical products us district products containing ppa unfair deceptive business practices court northern district illinois case still plaintiffs seek remedies including compensatory punitive earlystages damages medical monitoring refunds federal cases august group commenced action us district consolidated multidistrict litigation proceeding us court new jersey reddycheminor dr reddys district court district washington lawsuits laboratories alleging infringement three patents early stages determination whether ondansetron active ingredient zofrantablets lawsuits permitted proceed class actions defendants filed anda us food drug august bayer ag withdrew baycolcerivastatin sodium administration fda approval anda stayed worldwide light reports adverse events including deaths earlier january resolution patent infringement involving rhadomyolysis glaxosmithkline participated litigation case still early stages marketing baycolin usa pursuant copromotion agreement bayer licence holder product liability manufacturer product following withdrawal bayer us food drug administration became aware glaxosmithkline received numerous lawsuits filed state reports cardiac valvular problems individuals federal courts usa behalf individual putative fenfluramine dexfenfluramine alone combination classes former baycolusers number suits allege phentermine prescribed part regimen weight plaintiffs suffered personal injuries including rhadomyolysis reduction requested voluntary withdrawal fenfluramine use baycol others claim persons took baycol dexfenfluramine market reports cardiac although injured may risk future injury may valvular problems subsequent withdrawal products suffered economic damages purchasing using baycol market spawned numerous product liability lawsuits filed plaintiffs seek remedies including compensatory punitive manufacturers distributors fenfluramine statutory damages creation funds medical monitoring dexfenfluramine phentermine one number federal cases consolidated multidistrict litigation manufacturers phentermine group defendant proceeding us district court district minnesota numerous lawsuits various state federal district courts lawsuits early stages usa many filed class actions determination whether lawsuits permitted lawsuits seek relief including combination compensatory proceed class actions punitive damages medical monitoring refunds purchases drugs judicial panel multidistrict following voluntary withdrawal lotronexin usa litigation issued order consolidating transferring federal november number lawsuits filed actions district court eastern district pennsylvania group state federal district courts including individual court approved global settlement proposed defendant personal injury actions purported class actions asserting product wyeth sold fenfluramine dexfenfluramine liability consumer fraud claims plaintiffs seek remedies settlement subsequently confirmed third circuit court including compensatory punitive statutory damages appeals include phentermine defendants actions early stages although tentative trial dates including group individual plaintiffs may elect opt cases set class settlement pursue claims individually wyeth glaxosmithkline along number pharmaceutical continues settle individual state court cases trial companies named defendant number group continues dismissed lawsuits settled purported class action individual personal injury lawsuits wyeth state federal district courts usa alleging thimerosal glaxosmithkline received purported class action preservative used vaccines causes neurodevelopmental lawsuits filed state federal courts usa alleging disorders injuries plaintiffs seek remedies including paroxetine active ingredient paxil addictive causes compensatory punitive statutory damages cost dependency withdrawal reactions plaintiffs seek remedies fund medical monitoring research lawsuits including compensatory punitive damages cost early stages determination fund medical monitoring lawsuits early stages whether purported class actions permitted determination whether proceed class actions lawsuits permitted proceed class actions government investigations last decade litigation glaxosmithkline received subpoenas us attorneys manufacturers prozac ssri products homicidal office boston massachusetts requesting production suicidal behaviour exhibited users products group documents period present relating received claims lawsuits respect paxil repackaging relabelling private label arrangements none purport class actions glaxosmithkline discussed thirdparty customers following report yale haemorrhagic stroke project period issue civil criminal investigation suggested association first use phenylpropanolamine whether prices charged third parties glaxosmithkline ppa decongestant haemorrhagic stroke group products must counted medicaid best price purposes manufacturers voluntarily withdrew consumer healthcare group providing documents response subpoenas products ppa active ingredient glaxosmithkline notes financial statements legal proceedings continued following district court decision antitrust claims alleging glaxosmithkline also received letters centers competitive injury overcharges filed teva medicare medicaid services cms stating cmss position pharmaceuticals generic manufacturer nabumetone certain prices included medicaid purported classes direct purchasers payers respectively best price requesting glaxosmithkline retroactively resulting alleged fraudulent procurement patent adjust best price reports quarters prior july wrongful listing patent fda orange book include prices prosecution sham patent infringement litigation cases filed us district courts district massachusetts glaxosmithkline responding subpoenas office eastern district pennsylvania december inspector general us department health human january early stages services us department justice states texas california connection allegations pharmaceutical commercial matters companies including glaxosmithkline violated federal fraud otsuka pharmaceutical co ltd initiated arbitration proceedings abuse laws federal false claims act december concerning groups unilateral withdrawal respect texas california comparable state laws result grepafloxacin raxarvaxar october safety reasons ofthe way certain drugs priced way medicare otsuka alleges product withdrawal simultaneous public medicaid programmes reimburse drugs first announcement constituted material breaches licence quarter nevada montana state attorneys general supply agreements group believes underlying product filed civil lawsuit state court glaxosmithkline withdrawal consistent terms agreements several drug companies action claims behalf valid defences exist claims answer served state payer behalf instate patients consumers first quarter damages restitution based defendants pricing undefined set pharmaceutical products addition private sbcl indemnities payer class action lawsuits filed glaxosmithkline connection sale smithkline beecham clinical several federal district courts actions laboratories sbcl quest diagnostics inc group early stages agreed indemnify quest diagnostics aftertax basis november us federal trade commission staff advised respect certain liabilities arising conduct sbcl group staff conducting nonpublic investigation business prior closing including governmental private claims determine whether group violating section arising us governments investigation sbcls billing federal trade commission act monopolizing attempting marketing practices monopolize market paroxetine hydrochloride preventing generic competition paxiland requested group submit environmental matters certain information connection investigation glaxosmithkline notified potential responsibility group cooperated staffs investigation relating past operations past waste disposal practices certain sites primarily usa matters following public reference ftc investigation four purported subject litigation including proceedings initiated us consumer class actions filed alleging group federal state governments waste disposal site remediation monopolised market paxil treble damages sought costs tort actions brought private parties glaxosmithkline alleged overcharges flowing conduct cases advised may responsible party early stage determination whether approximately sites appear national priority permitted proceed class actions list created comprehensive environmental response compensation liability act superfund antitrust us pharmaceutical businesses smithkline proceedings seek require operators hazardous waste beecham glaxo wellcome group party number facilities transporters waste sites generators antitrust suits certain certified class actions hazardous waste disposed sites clean sites instituted nations retail pharmacies consumers reimburse government cleanup costs instances several states alleging conspiracies restraint trade glaxosmithkline involved alleged generator hazardous challenging pricing practices group significant waste although sites glaxosmithkline number pharmaceutical companies wholesalers involved current former operator facility although also sued similar litigation actions superfund provides defendants jointly severally except several actions pending state courts consolidated liable cleanup costs proceedings frequently resolved pretrial purposes us district court northern basis nature quantity waste disposed district illinois federal class action component site generator glaxosmithklines proportionate liability includes pharmacies representing approximately twothirds total cleanup costs substantially determined us retail sales volume settled glaxo wellcome sites referred smithkline beecham since time group glaxosmithklines potential liability varies greatly site site entered settlements satisfactory terms group cost investigation study remediation sites engaged conspiracy admission wrongdoing could time substantial glaxosmithkline routinely accrues made included final agreements amounts related share liability matters august us district court district massachusetts ruled groups patent nabumetone relafen tax matters invalid anticipatory art inequitable conduct group filed pending tax matters described note appeal decision november notes financial statementsglaxosmithkline acquisitions disposals details acquisition disposal subsidiary associated undertakings joint ventures given book fair value net assets goodwill cost values adjustments acquired capitalised acquisition acquisitions block drug shionogi joint venture block drug company inc january group acquired block drug cash consideration million net assets block drug incorporated accounts fair value follows book fair value net assets value adjustments acquired intangible fixed assets goodwill tangible fixed assets net current assets provisions fair value adjustment intangible fixed assets million reflects capitalisation brands block drug business integrated group possible separately identify postacquisition cash flows turnover cost sales block drug products together estimated sga rd expenditure follows turnover cost sales gross profit selling general administrative expenditure research development expenditure operating profit shionogi joint venture group established joint venture shionogi develop commercialise number compounds contributed parties group acquired per cent equity share capital cash consideration million committed make contributions certain development milestones achieved disposals quest diagnostics inc may group disposed million shares investment quest diagnostics inc cash proceeds million reducing groups holding st december per cent recognising charge goodwill previously written reserves million profit million recognised affymax group completed sale affymax business affymax inc new holding company million nonvoting preference shares affymax inc representing value million million recognising charge goodwill previously written reserves million loss million made disposal costs million incurred completing sale tagamet february group sold tagamet japan sumitomo pharmaceutical co ltd cash consideration million recognising charge goodwill previously written reserves million loss million recognised quest diagnostics affymax tagamet block drug shionogi total cash flows cash consideration paid cash acquired net cash payment acquisitions net cash proceeds disposals glaxosmithkline notes financial statements acquisitions disposals continued book fair value net assets goodwill cost values adjustments acquired capitalised acquisition acquisitions glaxo wellcome sa acquisition minority interests glaxo wellcome sa group acquired per cent glaxo wellcome sa formerly polfa poznan sa poland cash consideration million goodwill million capitalised amortised line initial acquisition disposals affymetrix inc may group sold two million shares affymetrix inc cash proceeds million realising profit million sb clinical laboratories final cash settlement us million million paid october complete sale sb clinical laboratories sb clinical glaxo laboratories affymetrix wellcome sa total cash flows cash consideration paid cash acquired net cash payment acquisitions net cash proceeds disposals book fair value net assets cost values adjustments acquired goodwill acquisition acquisitions amoun pharmaceuticals industries co sae glaxo wellcome kk quest diagnostics incorporated amoun pharmaceuticals industries co sae apic glaxo wellcome egypt acquired per cent apic million cash goodwill million capitalised glaxo wellcome kk group completed merger nippon glaxo limited nippon wellcome kk nw form glaxo wellcome kk quest diagnostics inc group acquired per cent equity interest quest part consideration disposal sb clinical laboratories million goodwill arising million remained eliminated reserves million capitalised disposals diversified pharmaceutical services dps group sold dps million realising loss million provision million made sb clinical laboratories group sold sb clinical laboratories quest million cash equity interest quest valued million costs million goodwill written back reserves million profit loss made transaction affymetrix inc group sold one million shares affymetrix inc cash proceeds million realising profit million sb clinical laboratories dps affymetrix apic total cash flows cash consideration paid cash acquired net cash payment acquisitions net cash proceeds disposals notes financial statementsglaxosmithkline financial instruments related disclosures fair value financial assets liabilities table presents carrying amounts uk policies gaap fair values groups financial assets discussion groups objectives policies liabilities st december st december debtors management offinancial instruments associated risks creditors due within one year excluded included treasury policies financial review fair values financial assets liabilities included investments atthe amount instrument could exchanged group holds number equity investments frequently current transaction willing parties forced entities group entered research collaborations liquidationsale following methods assumptions group seeks realise value investments used estimate thefair values inpart research collaboration helps create therefore equity investments market value based quoted market certain investments regarded available sale prices case listed investments market value accounted foras current asset investments purposes reference quoted prices case material unlisted ofusgaap investments classified available sale investments group liquid investments representing funds surplus cash bank approximates carrying amount immediate operating requirements accounted liquid investments based quoted market prices case current asset investments purposes usgaap marketable securities approximates carrying amount investments classified available sale inthe case time deposits short maturity shortterm loans overdrafts approximates carrying proceeds sale investments classified available amount short maturity instruments saleunder us gaap year ended stdecember mediumterm loans market value based quoted market weremillion proceeds include rollover liquid prices case eurobonds fixed rate funds shortterm deposit gross gains losses reflected borrowings approximates carrying amount case consolidated profit loss account respect investments offloating rate bank loans loans classified available sale us gaap million forward exchange contracts based market prices millionrespectively exchange rates balance sheet date currency swaps based market valuations balance foreign exchange risk management sheetdate group entered forward foreign exchange contracts interest rate instruments based market valuations inorder swap liquid assets borrowings currencies balance sheet date required group purposes st december debtors creditors approximates carrying amount group outstanding contracts sell purchase foreign provisions approximates carrying amount currency total notional principal amount million stdecember million majority fair value investments shares contracts periods months less group st december investments shares end year group number currency swaps million million fair value inplace respect mediumterm debt instruments million million difference carrying amount fair value represents gross unrealised gains borrowings denominated swapped foreign currencies million investments excluded financial match investments overseas group assets treated instrument disclosure fair value market value based ahedge relevant net assets exchange gains quoted market price losses recorded reserves shares represent purchases employee share ownership trusts interest rate risk management satisfy future exercises options awards employee manage fixedfloating interest rate profile debt group incentive schemes purchases matched options several interest rate swaps outstanding commercial banks predetermined exercise prices gain loss recognised st december measured exercise price rather market value concentrations credit risk credit exposures financialinstruments group believe exposed major concentrations credit risk group exposed creditrelated losses event nonperformance counterparties financial instruments expect counterparties fail meet obligations group applies boardapproved limits amount credit exposure one counterparty employs strict minimum credit worthiness criteria choice counterparty glaxosmithkline notes financial statements financial instruments related disclosures continued classification fair values financial assets liabilities following table sets classification financial assets liabilities provides reconciliation group net debt note shortterm debtors creditors excluded financial assets liabilities provisions included contractual obligation settle cash carrying fair carrying fair amount value amount value net debt liquid investments cash bank current asset financial instruments sterling notes bonds us dollar notes bonds notes bonds swapped us dollars currency swaps notes bonds swapped yen currency swaps mediumterm borrowings shortterm loans overdrafts total borrowings interest rate swaps forward exchange contracts purchase forward exchange contracts sell total derivative instruments management net debt total net debt fixed asset equity investments current asset equity investments debtors due year creditors due year provisions foreign exchange derivatives auction rate preference shares subsidiary money market preference shares subsidiary flexible auction rate preference shares subsidiary total nonequity minority interest total financial assets liabilities total financial assets total financial liabilities currency swaps presented alongside underlying principal instrument carrying amounts instruments adjusted effect currency swaps acting hedges difference carrying amount fair value equity fixed current assets liquid investments represents gross unrealised gains million million respectivelynotes financial statementsglaxosmithkline financial instruments related disclosures continued currency interest rate risk profile financial liabilities financial liabilities taking account currency interest rate swaps analysed total financial liabilities comprise total borrowings million million creditors due one year million million provisions million million nonequity minority interest preference shares ofmillion million exclude foreign exchange derivatives million nil creditors due within one year excluded benchmark rate determining interest payments floating rate financial liabilities tables libor fixed rate noninterest bearing average average st december interest years floating average rate rate rate years total currency fixed maturity us dollars sterling euro japanese yen currencies fixed rate noninterest bearing average average st december interest years floating average rate rate rate years total currency fixed maturity us dollars sterling euro japanese yen currencies currency interest rate risk profile financial assets total financial assets comprise fixed asset equity investments million million current asset equity investments million million liquid investments million million cash bank million million debtors due one year million million exclude foreign exchange derivatives nil million debtors due within one year excluded st december fixed floating noninterest rate rate bearing total currency us dollars sterling euro japanese yen currencies st december fixed floating noninterest rate rate bearing total currency us dollars sterling euro japanese yen currencies glaxosmithkline notes financial statements financial instruments related disclosures continued currency exposure net monetary assetsliabilities groups currency exposures give rise net currency gains losses recognised profit loss account arise principally companies sterling functional currency monetary assets liabilities denominated overseas functional currency andborrowings designated hedge overseas net assets excluded table stdecember functional currency group operation net monetary assetsliabilities sterling us euro yen total held nonfunctional currency sterling us dollars euro japanese yen stdecember functional currency group operation net monetary assetsliabilities sterling us euro yen total held nonfunctional currency sterling us dollars euro japanese yen nonequity finance minority total total debt leases interests maturity financial liabilities within one year demand one two years two five years five years gains losses net hedges unrecognised gains losses beginning year gains losses arising previous years recognised year gains losses arising beginning year still unrecognised end year unrecognised gains losses arising year total unrecognised gains losses end year expected recognised within one year expected recognised one year total unrecognised gains losses end year committed facilities group committed facilities back commercial paper programme million million days duration renewable annuallynotes financial statementsglaxosmithkline employee share schemes group operates share option schemes whereby options granted employees acquire shares adss glaxosmithkline plc grant price share award schemes whereby awards granted employees acquire shares adss glaxosmithkline plc cost subject tothe achievement performance targets details given relate schemes operated glaxosmithkline separately glaxo wellcome smithkline beecham date merger became schemes glaxosmithkline merger glaxo wellcome option outstanding date merger converted one glaxosmithkline option smithkline beecham share option wasconverted glaxosmithkline share option smithkline beecham ads option converted glaxosmithkline ads options corresponding adjustments grant price glaxosmithkline share option schemes group operates share option schemes savingsrelated share option schemes grants share options schemes normally exercisable three ten years date grant grants savingsrelated share option schemes normally exercisable three years saving options share option schemes normally granted market price ruling date grant accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant options outstanding share option share option savingsrelated schemes shares schemes adss share option schemes st december weighted weighted weighted number exercise number exercise number exercise price price price th december converted gw options converted sb options options exercised options cancelled st december options granted options exercised options cancelled st december range exercise prices order encourage employees convert options held glaxo wellcome smithkline beecham shares adss glaxosmithkline shares adss programme established give additional cash benefit ten per cent exercise price original option provided employee voluntarily leave group two years date merger exercise option earlier six months expiry date original option two years date merger options outstanding share option share option savingsrelated schemes shares schemes adss share option schemes st december weighted latest weighted latest weighted latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options exercisable except options shares granted options shares adss granted savingsrelated share options granted change effective exercise price outstanding options year options granted st december th march glaxosmithkline notes financial statements employee share schemes continued options exercisable share option share option savingsrelated schemes shares schemes adss share option schemes weighted weighted weighted number exercise number exercise number exercise price price price st december gw sb st december gsk st december gsk glaxosmithkline share award schemes group operates performance share plan whereby awards granted directors senior staff cost percentage award vests based upon performance glaxosmithkline three year measurement period performance conditions consist two parts applies per cent award first part condition compares glaxosmithklines total shareholder return tsr period tsr companies ukftse index period second part performance condition compares glaxosmithklines earnings per share growth increase ukretail price index three year performance period shares adss number shares adss issuable number number th december converted glaxo wellcome awards converted smithkline beecham awards awards exercised st december awards granted awards exercised awards cancelled st december awards relating shares relating adss exercisable st december employee share ownership trusts group sponsors employee share ownership trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees employee share ownership trusts purchase shares onthe open market finance provided group way loan contributions expected cost obligations deliver shares schemes normally spread periods service respect awards options granted accelerated charge made respect outstanding cost providing shares awards options became exercisable solely result merger shares held share award schemes number shares nominal value cost less amortisation market value shares held share option schemes number shares nominal value cost less amortisation market value trustees waived rights dividends shares held employee share ownership trustsnotes financial statementsglaxosmithkline employee share schemescontinued glaxo wellcome share option schemes date merger glaxo wellcome options except share options granted savingsrelated share options granted became exercisable performance conditions applicable lapsed savingsrelated share option schemes share option schemes total weighted weighted weighted exercise exercise exercise number shares issuable outstanding options number price number price number price st december options granted options exercised options cancelled st december options granted options exercised options cancelled converted glaxosmithkline options st december glaxo wellcome share award schemes glaxo wellcome operated long term incentive plan annual incentive plan long term incentive plan granted awards shares directors senior staff nominal cost percentage award vested based performance glaxo wellcome threeyear period annual incentive plan performance bonus consisting basic award ofshares matching award threeyear retention period result merger awards long term incentive plan became payable full retention period annual incentive plan lapsed number shares issuable share award schemes number st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled converted glaxosmithkline awards st december glaxosmithkline notes financial statements employee share schemescontinued smithkline beecham share option schemes date merger smithkline beecham share options became exercisable shares adss weighted weighted exercise exercise number shares adss issuable outstanding options number price number price st december options granted options exercised options cancelled st december options granted options exercised options cancelled converted glaxosmithkline options st december smithkline beecham midterm incentive plan smithkline beecham adopted midterm incentive plan mtip participations mtip granted annually senior staff smithkline beecham designating target number shares participant based job grade following threeyear measurement period rn committee reviewed smithkline beechams total shareholder return relative companies comprising ftse index made final award proportion target number shares per cent depending performance first two measurement periods ended st december per cent per cent respectively target number shares awarded receipt award could deferred case shares remained mtip result merger outstanding awards became payable per cent target number shares end threeyear cycle shares adss number shares issuable midterm incentive plan number number st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled converted glaxosmithkline awards st december option pricing purposes valuing options arrive stockbased compensation adjustment reconciliation us accounting principles note blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives options granted share option schemes years years savings related share option schemes years yearsnotes financial statementsglaxosmithkline directors remuneration glaxosmithklines policy directors remuneration together details remuneration received directors given inthe remuneration report directors appointed board company rd may received remuneration glaxosmithkline plc continued remunerated glaxo wellcome plc smithkline beecham plc services companies themergerbetween glaxo wellcome smithkline beecham completed th december point glaxo wellcome smithkline beecham became subsidiaries glaxosmithkline plc statutory disclosures respect directors remuneration attributable directors glaxosmithkline plc relation servicesto company subsidiaries th st december set directors compensation salary fees benefits emoluments bonus total compensation date appointment st december benefits salary fees emoluments bonus total emoluments individual director executive directors dr j p garnier mr j coombe nonexecutive directors sir richard sykes sir roger hurn sir peter walters mr p allaire dr barzach mr c bonham sir christopher hogg sir peter job mr j h mcarthur mr f mchenry sir ian prosser dr r schmitz dr l shapiro mr j young total compensation glaxosmithkline notes financial statements employee costs wages salaries social security costs pension postretirement costs cost sharebased incentive plans severance costs arising integration restructuring activities pension postretirement costs arising integration group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff consequence time took complete merger glaxosmithkline replaced needed leavers contractors year end level contractors disproportionately high movement compared reflects conversion contract employees permanent employees redundancies due merger integration additional employees acquisition block drug numbers group employees end financial year given financial record pension postretirement costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid schemes unfunded defined benefit schemes defined contribution schemes unfunded postretirement healthcare schemes postemployment costs pension postretirement costs arising integration pensions group undertakings operate pension arrangements cover groups material obligations provide pensions retired employees thesearrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length ofservice defined benefit schemes also include defined contribution sections aredescribed hybrid schemes table majority cases contributions defined benefit schemes determined accordance advice independent professionally qualified actuaries formal independent actuarial valuations groups main plans undertaken regularly normally least every three years theassets funded schemes generally held separately administered trusts insured pension costs accounting purposes assessed accordance independent actuarial advice generally using projected unit method spreading surpluses deficits average expected remaining service lives respective memberships certain countries pension benefits provided unfunded basis scheme administered trustee company whereassets held specific purpose matching liabilities unfunded schemes provision included within provisions pensions postretirement benefits charge profits respect benefits aggregate ofthe increase year intheassessed liabilities members still service net movement provisions set pensions inpayment liabilities generally assessed annually accordance advice independent actuariesnotes financial statementsglaxosmithkline employee costs continued throughout pension arrangements majority former glaxo wellcome companies former smithkline beecham companies continued operated separately however instances including usa pension arrangements merged accordingly following information deals set arrangements separately market value assets groups funded defined benefit pension funds date latest actuarial valuations billion sufficient cover per cent benefits accrued members allowing future salary pension increases uk defined benefit pension schemes account approximately per cent groups plans asset valuation projected benefit terms us defined benefit pension schemes account approximately per cent groups plans asset valuation projected benefit terms uk uk pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants new uk employees entitled join new defined contribution scheme relevant assumptions used calculating pension costs uk defined benefit schemes accounting purposes follows glaxo wellcome smithkline beecham pa pa pa pa rate increase future earnings discount rate expected longterm rate return investments expected pension increases uk equity dividend growth regular cost glaxo wellcome pension arrangements million became million credit accounts allowance made spreading surplus disclosed level percentage salary expected future working lifetime existing members years recent triennial actuarial valuations glaxo wellcome schemes funding purposes carried stmarch date assets schemes represented per cent actuarial value benefits accrued members allowing future salary pension increases trustees uk pension schemes agreed companys request grant various benefit improvements included five per cent enhancement entitlement beneficiaries allowance made improvements funding level fallen per cent following valuations company contributions schemes remain suspended least next formal valuation expected remain suspended beyond thetotal market value assets held schemes st march million regular cost smithkline beecham schemes million increased accounting cost million allowance made spreading deficit expected future working lifetime current employees scheme years latest valuation carried st december date actuarial value scheme assets represented per cent actuarial value accrued service liabilities based assumptions total market value assets held scheme st december million usa usa former glaxo wellcome smithkline beecham defined benefit hybrid schemes merged year relevant assumptions used calculating pension costs accounting purposes follows glaxo glaxo smithkline smithkline wellcome beecham pa pa pa rate increase future earnings discount rate expected longterm rate return investments us equity dividend growth na regular cost us scheme million increased accounting cost million allowance made spreading deficit expected future working lifetime current employees scheme latest valuation carried st january date actuarial value scheme assets represented per cent actuarial value theaccrued service liabilities total market value assets held scheme st january million glaxosmithkline notes financial statements employee costs continued frs disclosures group continues account pension arrangements accordance ssap accounting pension costs transitional provisions frs retirement benefits certain disclosures required basis valuation methodology adopted frs defined benefit schemes fair values pension scheme assets st december compared future pension liabilities calculated projected unit method relevant assumptions used frs calculations follows rest uk usa world pa pa pa rate increase future earnings discount rate expected pension increases na cash balance creditconversion rate na na inflation rate expected rates return assets fair values assets liabilities uk us defined benefit schemes together aggregated data defined benefit schemes group st december follows uk usa rest world group average expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value scheme liabilities net value schemes surplus deferred tax liability net value schemes deficit deferred tax asset group total uk defined benefit schemes also defined contribution sections account balances totalling million st december uk schemes closed new members projected unit method valuing pension scheme liabilities current service cost increase members schemes approach retirement deficits frs reflect different bases valuing assets liabilities compared ssap including immediate impact fair values assets st december result poor stock market performance fair values assets held uk us pension schemes fallen approximately per cent seven per cent respectively year group also operates number unfunded postretirement healthcare schemes principal one usa liability frs us scheme assessed using assumptions us pension scheme together assumption future medical inflation seven per cent reducing per cent per year five per cent basis liability usscheme assessed million reduced million taking account deferred tax valuation basis applied accounts instead ssap valuation basis effect profit loss account reserve st december taking account deferred tax would follows profit loss account reserve per balance sheet pension liability frs pension liability ssap per balance sheet postretirement healthcare schemes frs postretirement healthcare schemes provision per balance sheet profit loss account reserve including pension postretirement healthcare liability notes financial statements glaxosmithkline reconciliation usaccounting principles summary material differences uk us gaap financial statements analyses reconciliations presented capitalised interest note represent financial information would uk gaap group capitalise interest usgaap required us generally accepted accounting principles gaap requires interest incurred part cost constructing fixed applied instead ukgaap assets capitalised amortised life asset significant difference us uk gaap computer software ukgaap combination glaxo wellcome plc uk gaap company capitalises costs incurred smithkline beecham plc accounted merger acquiring developing computer software internal use pooling interest usgaap transaction software supports significant business system accounted purchase business combination glaxo expenditure leads creation durable asset us gaap wellcome acquiring smithkline beecham company applies sop accounting costs computer software developed obtained internal use glaxosmithkline plc formed give effect scheme restricts categories costs capitalised arrangement merger glaxo wellcome plc smithkline beecham plc effective thdecember glaxosmithkline plc goodwill intangible fixed assets acquired whole issued share capital glaxo wellcome plc beginning company changed accounting policy smithkline beecham plc exchange shares forgoodwill intangible assets ukgaap respect glaxosmithkline plcupon completion merger former acquisitions material difference exist shareholders glaxo wellcome held approximately per cent uk usgaap difference continues exist former shareholders smithkline beecham held respect prior years goodwill intangible assets fully approximately per cent issued share capital amortised usgaap goodwill arising acquisitions glaxosmithkline plc st january set shareholders funds uk gaap us gaap goodwill capitalised amortised combination glaxo wellcome smithkline beecham expected useful economic life charged income accounted merger ukgaap financial intangible assets recognised st january us statements glaxosmithkline ukgaap represent purchase accounting requirements amortised combined financial statements glaxo wellcome smithkline estimated revenue earning life taken patent beecham historical basis periods presented lifeplusfive years us gaap business combination qualify uk gaap costs incurred integrating pooling interests accounting glaxo wellcome restructuring wellcome smithkline beecham block drug determined accounting acquirer purchase acquisition businesses following acquisitions dated thdecember us gaap financial respectively charged profit loss account post statements glaxosmithkline prior merger therefore acquisition us gaap certain ofsuch costs considered glaxo wellcome allocation purchase consideration thereby affecting view proximity merger date financial year end goodwill arising acquisition date relative insignificance business activity ukgaap certain intangible assets related specific th december st december accounting compounds products purchased third party date acquisition practical purposes taken developed commercial applications capitalised stdecember usgaap payments made compounds products reconciliation consolidated income statements still development yet received regulatory consolidated statements comprehensive income changes approval charged directly profit loss time shareholder equity three years ended st december receive regulatory approval correspondingly reflect purchase method merger transaction costs accounting theacquisition smithkline beecham glaxo glaxo wellcome incurred total mergerrelated transaction costs wellcome income statement presented us gaap million excluding integration restructuring costs format therefore certain exceptional items ukgaap uk gaap merger transaction costs expensed product divestments merger integration costs addition incurred usgaap direct acquisition costs writeoff inprocess research development acquiring company included portion purchase classified within operating profit consideration consolidated balance sheet consolidated statement cash restructuring costs flows usgaap usgaapformat also presented prior adoption frs provisions contingent liabilities balance sheet st december includes fair value andcontingent assets requirements recording provision acquired assets liabilities smithkline beecham plc restructuring costs prescriptive usgaap prepared usgaap ukgaap accordingly adjustments made financial statements reflect purchase method eliminate ukgaapprovision restructuring costs accounting combination glaxo wellcome smithkline notmeet usgaaprequirements beecham also material adjustments would required usgaap applied instead ukgaap theperiods presented summary purchase accounting adjustments usgaap adjustments provided reconciliations profit attributable shareholders equity shareholders funds uk usgaap glaxosmithkline notes financial statements reconciliation us accounting principles continued foreign currency hedging group enters forward exchange contracts marketable securities financial instruments ukgaap treated hedges marketable securities consist primarily equity securities future income matching principle used match gain certain liquid investments ukgaap securities loss hedging contracts foreign currency stated lower cost net realisable value us transaction profits relate us gaap gaap securities available sale statement instruments qualify hedge accounting unrealised financial accounting standard sfas accounting gain loss hedges future profits transactions must certain investments debt equity securities carried valued year end market rates recognised net fair value unrealised gains losses net tax reported income current year separate component shareholders equity derivative instruments pensions postretirement benefits statement financial accounting standard accounting key differences uk ssap usgaap relation derivative instruments hedging activities sfas defined benefit pension plans amended sfas sfas interpreted ukgaap effect variations cost derivatives implementation group adopted group accumulated successive valuations amortised effective st january sfas establishes accounting aggregate basis us gaap amortisation reporting standards derivative instruments including certain transition asset costs past service benefit derivative instruments embedded contracts collectively improvements separately tracked experience gainslosses referred derivatives hedging activities sfas dealt aggregate basis amortised outside requires entity recognise derivatives either assets per cent corridor liabilities consolidated balance sheet measure instruments fair value sfas prescribes requirements uk gaap allows measurements plan assets liabilities designation documentation hedging relationships based result latest actuarial valuation usgaap ongoing assessments effectiveness order qualify hedge requires measurement plan assets liabilities made accounting date financial statements three months prior date group also evaluates contracts embedded derivatives considers whether embedded derivatives bifurcated disclosures required sfas included note separated host contracts accordance sfas stockbased compensation requirements embedded derivatives exist clearly uk gaap share options accounted equity closely related host contract accounted exercised valued issuance price usgaap group separately host contract derivatives changes applies sfas accounting stockbased compensation fair value recorded current earnings related accounting interpretations accounting option plans group designate derivatives qualifying require options fair valued grant date hedge instruments sfas accordingly recorded included profit loss vesting period options cumulative effect adopting sfas st january result merger certain groups options vested representing initial revaluation derivatives items immediately requiring acceleration compensation expense described tax charge million amount stockbased compensation expense related comprehensive income cumulative effect net accelerated vesting million disclosures income gains losses related fair value adjustments required sfas included note additionally derivative instruments classified consolidated statement group entitled receive tax deduction amount treated income cashflows accordance nature compensation us tax rules employee stock options derivative exercised usemployees year ukgaap treated reduction tax expense fair value book value derivative instruments respect whereas usgaap amount credited equity financial assets liabilities st december disclosed classification fair value financial assets liabilities employee share ownership trust esot table note uk gaap shares groups stock held esot arerecorded cost less provision representing difference valuation derivative instruments cost option exercise price accounted fair value derivative instruments sensitive movements fixed asset investments projected losses exercise underlying market rates variables group monitors options covered shares recorded profit fair value derivative instruments periodic basis cross loss account life theoptions us gaap shares currency swaps valued using standard valuation models groups stock purchased esot accounted within counterparty valuations thirdparty valuations standard shareholders equity cost gainsorlosses arising subsequent valuation models used group consider relevant discount issuance shares employees satisfy share options rates market yield curve valuation date forward recorded adjustments toshareholders equity currency exchange rates counterparty risk significant rates variables obtained market sources valuations based remaining term maturity instrument foreign currency forwards valued using forward rates observed quoted prices relevant markets possible group assumes parties longterm contracts economically viable immediately exercise early termination rights economically beneficial rights exist contractnotes financial statements glaxosmithkline reconciliation us accounting principles continued sfas requires goodwill longer amortised estimated useful life company must instead identify value dividends reporting units purpose assessing least annually uk gaap dividends proposed provided year potential impairment goodwill allocated reporting unit respect recommended board ofdirectors additionally company need reassess useful lives approval shareholders usgaap suchdividends existing recognised intangible assets intangible assets deemed provided declared board ofdirectors indefinite lives longer amortised instead tested deferred taxation annually potential impairment separate intangible assets uk gaap deferred taxation accounted finite lives continue amortised useful lives extent probable taxation liabilities benefits group adopt sfas st january since become payable crystallise within foreseeable future extensive effort needed adopt sfas practical us gaap sfas accounting income taxes requires deferred fully estimate impact adopting sfas groups taxation provided full liability basis valuation financial statements st december group allowance established respect deferred tax assets unamortised goodwill approximately billion total goodwill likelythan portion amortisation amortisation indefinitelived intangible assets realised approximately billion million respectively year ended st december incurred exceptional items usgaap items classified exceptional uk gaap meet definition extraordinary us gaap therefore june fasb approved sfas accounting classified operating expense obligations associated retirement longlived assets required implemented group effect consolidated statement cash flows st january standard requires fair value usgaap cash flow statement reports changes cash liability asset retirement obligation recognised cash equivalents includes shortterm highly liquid period incurred reasonable estimate fair value investments original maturities three months less made associated asset retirement costs capitalised onlythree categories cash flows reported operating part carrying amount asset depreciated activities including tax interest investing activities including useful life october fasb issued sfas accounting capital expenditures acquisitions disposals together impairment disposal longlived assets cashflows available sale current asset investments required implemented group effect st andfinancing activities including dividends paid statement january standard develops one accounting model ofcash flows presented longlived assets including discontinued operations disposed cash cash equivalents sale group currently assessing impact uk gaap cash balance includes cash bank standards cash balances usgaap cash cash equivalents include cash bank certain liquid investments original maturities three months less comprehensive income statement requirement sfas reporting comprehensive income provide comprehensive income statement met ukgaap statement total recognised gains losses pages statement comprehensive income usgaap three years period ending st december presented pages usgaap statement includes net impact gains losses equity liquid investments translation adjustments recent fasb pronouncements july financial accounting standards board fasb issued statement business combinations sfas statement goodwill intangible assets sfas sfas prohibits poolingofinterests method accounting business combinations requires purchase method accounting business combinations initiated th june prescribes initial recognition measurement goodwill intangible assets accounting negative goodwill required disclosures respect business combinations glaxosmithkline notes financial statements reconciliation us accounting principles continued glaxo glaxo smithkline us gaap smithkline uk gaap adjustments us gaap reconciliation consolidated income statement revenues cost sales gross profit selling general administrative expenditure research development expenditure trading profit operating incomeexpense amortisation goodwill intangible assets writeoff inprocess rd acquired product divestments merger transaction costs operating profit share profitslosses joint ventures associated undertakings lossprofit disposal interest associate profit dissolution joint venture disposal businesses provision loss disposal loss disposal subsidiary utilisation provision profit interest net interest expense profit ordinary activities taxation taxation profit ordinary activities taxation minority interests preference share dividends earnings profit attributable shareholdersnet lossincome basic lossearnings per share us gaap pence p diluted lossearnings per share us gaap pence p basic lossearnings per ads usgaap diluted lossearnings per ads us gaap consolidated statement comprehensive income changes shareholders equity usgaap shareholders equity beginning year net lossincome exchange movements overseas net assets unrealised lossgain equity investments net tax unrealised lossgain liquid investments net tax cumulative effect change accounting principle comprehensive lossincome dividends shares purchased cancelled shares issued employee share ownership plan shares issued purchase smithkline beecham shareholders equity end year notes financial statementsglaxosmithkline less smithkline less smithkline glaxo beecham glaxo glaxo beecham glaxo smithkline preacquisition us gaap smithkline smithkline preacquisition us gaap smithkline uk gaap uk gaap adjustments us gaap uk gaap uk gaap adjustments us gaap p p p p glaxosmithkline notes financial statements reconciliation us accounting principles continued consolidated balance sheet underus gaap assets current assets cash cash equivalents marketable securities accounts notes receivable inventories prepaid expenses deferred income taxes total current assets goodwill intangible assets property plant equipment investments affiliates assets deferred income taxes total assets liabilities shareholders equity current liabilities cash overdrafts accounts payable shortterm borrowings capital lease obligations income taxes dividends payable deferred income taxes accrued liabilities total current liabilities longterm borrowings capital lease obligations liabilities deferred income taxes total liabilities minority interest contingencies commitments notes shareholders equity common stock per share par value shares authorised shares issued redeemable preference shares per share par value shares authorised nil shares outstanding additional paidin capital retained deficit cumulative comprehensive loss treasury stock total shareholders equity total liabilities shareholders equity certain balance sheet items st december reclassified comparative purposesnotes financial statementsglaxosmithkline reconciliation us accounting principles continued consolidated statement cash flows usgaap cash flows operating activities net lossincome adjustments reconcile net income net cash provided operating activities depreciation amortisation goodwill intangibles writeoff inprocess rd acquired impairment lossgain sale fixed assets productive assets deferred taxes tax benefit exercise stock options income associate loss sale associate investment changes operating assets liabilities net acquisitions decreaseincrease inventory increase trade debtors increase trade creditors increase pension provisions derivatives net cash provided operating activities cash flows investing activities acquisition fixed assets acquisition intangible assets acquisition smithkline beecham cash received acquisition acquisition new businesses net cash acquired proceeds disposition fixed assets businesses proceeds sale intangible fixed assets decreaseincrease liquid investments decreaseincrease equity investments net cash used inby provided investing activities cash flows financing activities proceeds additional borrowings reduction debt purchase treasury stock dividends paid net repayment ofincrease shortterm loans net increase inrepayment cash overdrafts redemption preference shares issued subsidiary ordinary shares purchased cancellation issue share capital net cash used financing activities net decreaseincrease cash cash equivalents exchange rate movements cash cash equivalents beginning year cash cash equivalents end year supplemental cash flow information cash paid year interest income taxes noncash investing financing activities purchase acquisition dated th december group acquired outstanding shares smithkline beecham exchange shares ofglaxosmithkline conjunction acquisition liabilities assumed follows fair value assets acquired fair value shares issued fair value liabilities assumed glaxosmithkline notes financial statements reconciliation us accounting principles continued cthe market value investments included book value smithkline beechams net assets us gaap acquisition smithkline beecham increase investments relates increases fair market us gaap financial statements glaxosmithkline prior tothe value nonmarketable securities st december merger glaxo wellcome us gaap accounting acquirer included inthis amount increases equity investments acquisition smithkline beecham accounted equity investments measured fair value purchase method date merger thdecember excess fair value underlying tangible assets liabilities recognised goodwill within investments purchase accounting adjustments goodwill amortised years order determine proper allocation purchase price related acquired assets smithkline beecham us gaap dthe fair value attributed pension obligations reflects purchase accounting cost acquisition calculated using recognition previously unrecognised actuarial gainslosses market value shares issued fair value vested options prior service costs transition amounts amounts recognised exchanged direct external acquisition costs allocated based actuarial assessments acquisitiondate fair value net assets acquired result fair value ethe fair value attributed intangible assets relates exercise increases values smithkline beechams inventory primarily managements estimate value product tangible fixed assets investments pension obligations rights inclusive respective patents trademarks recognised fair market values attributed intangible onexisting products assembled workforce thefair assets mainly product rights inclusive patents trademarks value product rights determined based assembled workforce inprocess research development discounted net future cash flow analysis current approved together appropriate deferred taxation effects difference product portfolio includes existing approved products cost acquisition fair value assets within pharmaceutical therapeutic areas consumer liabilities smithkline beecham recorded asgoodwill healthcare product portfolios supplemental products amount allocated inprocess research development development process build upon existing chemical entities required us gaap expensed immediately thefirst within existing areas andwhich subject separate reporting period business combination us food drug administration approval also included glaxosmithkline period ended stdecember fair management based estimates weighted average value adjustments recorded amount inventory useful life product rights future period expensed additional amortisation depreciation substantial majority estimated net future cash flow berecorded respect fair value adjustments tangible value expected realised approximately years intangible assets resulting goodwill periods pharmaceuticals years consumer healthcare brands respective economic useful lives fair value assembled workforce amortised adjustments assets liabilities smithkline beecham year period based smithkline beechams historical reflect fair values allocation excess purchase turnover rate considered goodwill sfas consideration fair value net assets acquired based f amount total consideration allocated smithkline onmanagement best estimates fair value summarised beechams inprocess research development projects iprd thetable opposite discussed estimated using current estimates status athe total assumed purchase consideration calculated prospects rd portfolio iprd includes bymultiplying number glaxosmithkline shares issued identified projects advanced stage development tosmithkline beechams shareholders outstanding management believes reasonable estimates projected smithkline beecham shares average fair value glaxo cash flows prepared include basic discovery wellcome securities average fair value glaxo wellcome portfolio gene patents reported iprd value securities calculated period four days prior intended reflect present value development subsequent theannouncement merger activities currentlyunderway value allocated iprd th january total assumed purchase consideration determined utilising risk adjusted income approach also included fair value smithkline beecham vested included earnings discounted appropriate cost capital options exchanged vested options glaxosmithkline investment estimates future cash flows related total number smithkline beecham vested options individual iprd projects based existing estimates multiplied bythe respective fair value ordinary revenues contribution margin project shares adr plans determined thjanuary gadditional liabilities relate restructuring costs directly linked bthe increase fair value inventory fixed assets plans place date acquisition determined based difference carrying value liabilities reflect costs close certain smithkline beecham market value assets increase inventory manufacturing sites redundancy costs liabilities expensed inventory sold increase relate additional deferred tax liabilities previously infixed assets allocated respective category recognised depreciated remaining useful lives assets hdeferred taxes computed excess fair value book value goodwill inprocess research development using applicable weighted average statutory tax rates goodwill represents remainder unallocated purchase consideration goodwill amortised expected economic life years notes financial statementsglaxosmithkline reconciliation us accounting principles continued purchase accounting adjustments total assumed purchase consideration outstanding shares costs fees transaction less book value smithkline beecham net assets us gaap less goodwill excess fair value inventory b excess fair value tangible fixed assets b excess fair value investments c excess fair value pension asset fair value attributed intangible assets e fair value attributed workforce e fair value attributed inprocess rd projects f additional liabilities assumed g deferred tax liabilities related purchase price adjustments h goodwill acquisition smithkline beecham plc block drug company inc pro forma results unaudited following table reflects results operations us gaap pro forma basis january acquisition block drug completed st january december acquisition smithkline beecham completed st january pro forma results operations include amortisation acquired goodwill intangibles butdonot include writeoff inprocess rd orinventory adjustments net sales earnings interest income taxes minority interest net income pence pence earnings per share diluted earnings per share earnings per ads diluted earnings per ads pro forma financial information necessarily indicative theoperating results would occurred acquisition consummated dates indicated necessarily indicative future operating results glaxosmithkline notes financial statements reconciliation us accounting principles continued following summary material adjustments profit shareholders funds would required us gaap applied instead uk gaap adjustments reflected balance sheet income statements presented accordance usgaap profit profit attributable shareholders uk gaap less smithkline beechams preacquisition profit attributable shareholders uk gaap merger alignment adjustments usgaap adjustments writeoff smithkline beecham inprocess rd acquired capitalised interest computer software purchased intangibles amortisation goodwill amortisation intangible assets recognition cost sales fair value stepup inventory disposal purchased investment loss disposal subsidiary pensions stockbased compensation provision esot shares derivative instruments restructuring tax benefits exercise us stock options merger transaction costs deferred taxation impairment equity investments net lossincome us gaap equity shareholders funds equity shareholders funds uk gaap usgaapadjustments inventory tangible fixed assets investments workforce product rights capitalised interest computer software goodwill intangible assets unrealised gains marketable securities pensions postretirement benefits employee share ownership trust restructuring costs derivative instruments dividends deferred taxation shareholders equity us gaap certain items year ended st december reclassified comparative purposesnotes financial statements glaxosmithkline reconciliation us accounting principles continued earnings per share us gaap weighted average number shares issue millions millions millions basic adjustments share options diluted adsshares held employee share ownership trusts excluded shares issue taxation total tax expense uk gaap current tax expense deferred tax expense total tax expense us gaap current tax expense deferred tax expense total tax expense deferred taxation usgaap classification glaxosmithklines deferred taxation liabilities assets us gaap follows liabilities stock valuation adjustment current deferred taxation liabilities accelerated capital allowances unremitted foreign investment income product rights timing differences total deferred taxation liabilities assets intragroup profit timing differences current deferred taxation assets asset disposal pensions postretirement benefits manufacturing restructuring tax losses timing differences total deferred taxation assets net deferred taxation us gaap difference uk effective taxation rate us effective taxation rate primarily related fair value adjustments goodwill intangibles related acquisition wellcome smithkline beecham glaxosmithkline notes financial statements reconciliation us accounting principles continued segment information usgaap uk gaap segment information presented note includes results operations information historical combined glaxo wellcome smithkline beecham basis us gaap segment information results operations reflects merged operations glaxosmithkline relates glaxo wellcome periods practical purposes regarded prior acquisition smithkline beecham glaxo wellcome operated one segment pharmaceuticals segment information respect assets relates glaxo wellcome smithkline beecham consolidated basis st december acquisition smithkline beecham glaxo wellcome occurred th december turnover location customer usa europe rest world external turnover turnover business sector pharmaceuticals consumer healthcare external turnover operating profitloss business sector pharmaceuticals consumer healthcare operating profitloss turnover location subsidiary undertaking usa europe rest world gross turnover usa europe rest world intersegment turnover usa europe rest world external turnover profit tax location subsidiary undertaking usa europe rest world operating profitloss share profits joint ventures associated undertakings lossprofit disposal subsidiary associate net interest payable profitloss taxation profitloss taxation taxation minority interests preference share dividends earningsnet incomeloss notes financial statementsglaxosmithkline reconciliation us accounting principles continued total assets business sector pharmaceuticals consumer healthcare total assets total assets location subsidiary undertaking usa europe rest world total operating assets cash cash equivalents marketable securities total assets plant land equipment computer assets total total buildings vehicles software construction tangible fixed assets location subsidiary undertaking usa europe rest world total uk segment information given separately respect uk although included groups europe market region considered groups home segment purposes segmental reporting turnover location customer gross turnover intersegment turnover turnover location subsidiary operating profit total assets glaxosmithkline notes financial statements reconciliation us accounting principles continued pensions usgaap sfas disclosures year ended st december provided relation employees glaxosmithkline income statement disclosures provided relation employees glaxo wellcome balance sheet disclosures provided consolidated basis relation employees glaxo wellcome smithkline beecham disclosures provided relation employees glaxo wellcome average number persons employed group including directors year number number number manufacturing selling general administration research development pension postretirement costs uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid schemes unfunded defined benefit schemes defined contribution schemes unfunded postretirement healthcare schemes postemployment costs disclosures include additional information required sfas pension costs uk us major overseas defined benefit pension plans restated following tables accordance us gaap pension costs million million million respect minor retirement plans recalculated accordance requirements sfas excluded net periodic pension costincome major retirement plans comprised service cost interest cost expected return plan assets amortisation prior service cost amortisation transition obligation recognised net actuarial gain net periodic pension costincome us gaap termination benefits curtailment costs major assumptions used computing pension incomecost pa pa pa rates future pay increases discount rate expected longterm rates return plan assets aggregate average international plan assumptions vary significantly us assumptionsnotes financial statementsglaxosmithkline reconciliation us accounting principles continued change benefit obligation benefit obligation beginning year amendments service cost interest cost plan participants contributions actuarial loss benefits paid acquisition termination benefits curtailment costs exchange benefit obligation end year benefit obligation end year pension plans accumulated benefit obligations excess plan assets change plan assets fair value plan assets beginning year actual return plan assets employer contribution plan participants contributions benefits paid acquisition exchange fair value plan assets end year fair value plan assets end year pension plans accumulated benefit obligations excess plan assets plan assets consist primarily investments uk overseas equities fixed interest securities securities linked uk index retail price inflation property st december uk equities included million glaxosmithkline shares million glaxowellcome shares market value million million funded status funded status unrecognised net actuarial gainloss unrecognised prior service cost unrecognised transition obligation net amount recognised amounts recognised statement financial position consist prepaid benefit cost accrued pension liability additional required liability intangible asset accumulated comprehensive income net amount recognised glaxosmithkline notes financial statements reconciliation us accounting principles continued postretirement healthcare usgaap disclosures provided relation employees glaxosmithkline income statement disclosures provided relation employees glaxo wellcome balance sheet disclosures provided consolidated basis relation employees glaxo wellcome smithkline beecham disclosures provided relation employees glaxo wellcome net healthcare cost service cost interest cost amortisation prior service cost net healthcare cost major assumptions used calculating net healthcare cost pa pa pa rate future healthcare inflation discount rate rate future healthcare inflation rate reflects fact benefits certain groups participants capped change benefit obligation benefit obligation beginning year amendments service cost interest cost plan participants contributions actuarial loss benefits paid acquisition curtailments exchange benefit obligation end year change plan assets fair value plan assets beginning year employer plan participants contributions benefits paid fair value plan assets end year funded status funded status unrecognised net actuarial loss unrecognised prior service cost accrued postretirement healthcare cost decrease increase impact per cent variation rate future healthcare inflation would effect total service interest cost effect provision postretirement benefits notes financial statements glaxosmithkline principal group companies following represent principal subsidiary associated undertakings glaxosmithkline group stdecember details given country incorporation principal country operation location headquarters business segment business activities share capital undertakings comprising ordinary shares wholly owned group except interest shown otherwise europe location subsidiary undertaking segment activity england greenford glaxosmithkline services plc formerly glaxo wellcome plc ph h brentford smithkline beecham plc phch h r p e greenford glaxo group ltd ph h brentford smithkline beecham research ltd ph brentford smithkline beecham investments ltd phch f brentford glaxosmithkline research development ltd ph r formerly glaxo wellcome research development ltd brentford glaxosmithkline export ltd formerly glaxo wellcome export ltd ph e greenford wellcome foundation ltd ph h r p greenford wellcome limited phch h brentford smithkline beecham swg ltd ch e stockley park glaxo operations uk ltd ph p stockley park glaxo wellcome uk ltd ph h p brentford staffordmiller ltd ch p austria vienna glaxosmithkline pharma gmbh formerly glaxo wellcome pharma gmbh ph belgium genval glaxosmithkline belgium sa formerly glaxo wellcome belgium sa ph rixensart glaxosmithkline biologicals sa formerly smithkline beecham biologicals sa ph p e wavre glaxosmithkline biologicals manufacturing sa ph p e formerly smithkline beecham biologicals manufacturing sa channel st peter port sb insurance ltd phch islands denmark ballerup smithkline beecham ch brndby glaxosmithkline pharma formerly glaxo wellcome ph finland espoo glaxosmithkline oy formerly glaxo wellcome oy ph france paris glaxosmithkline sante grand publique formerly smithkline beecham ch sant et hygiene sas paris groupe glaxo wellcome ph r p germany buehl glaxosmithkline consumer healthcare gmbh co kg formerly smithkline ch beecham gmbh co kg munich smithkline beecham gmbh ph greece athens glaxo wellcome aebe ph h p athens smithkline beecham cisa phch hungary budapest glaxosmithkline kft formerly smithkline beecham kft phch ireland carrigaline smithkline beecham cork ltd note ph p carrigaline smithkline beecham manufacturingltd note ph p dublin glaxo wellcome international note phch h dublin smithkline beecham ireland ltd note phch dublin sterling health ltd note ch dublin smithkline beecham consumer brands ltd note ch dublin beecham products ireland ltd note ch dublin smithkline beecham pharmaceuticals ltd note ph italy verona glaxosmithkline spa formerly glaxo wellcome spa ph milan glaxosmithkline consumer healthcare spa formerly maggioni spa ch h luxembourg glaxosmithkline international luxembourg sa phch h glaxosmithkline luxembourg sa phch h glaxosmithkline notes financial statements principal group companies continued europe location subsidiary undertaking segment activity netherlands rijswijk glaxosmithkline bv formerly smithkline beecham farma bv ph zeist glaxosmithkline consumer brands bv formerly smithkline beecham ch consumer brands bv zeist glaxo wellcome international bv phch h zeist glaxo wellcome investments bv phch h norway oslo glaxosmithkline formerly glaxo wellcome ph poland poznan glaxosmithkline pharmaceuticals sa formerly glaxo wellcome sa ph p warsaw glaxosmithkline consumer healthcare sp zoo formerly smithkline ch beecham polska sp zoo portugal lisbon instituto lusofarmaco lda ph spain madrid glaxo wellcome sa ph r p madrid smithkline beecham sa ph sweden mlndal glaxosmithkline ab formerly smithkline beecham ab ph switzerland thoerihaus glaxosmithkline investments switzerland gmbh phch h thoerihaus glaxosmithkline international switzerland gmbh phch h berne glaxo wellcome ag ph zug adechsa gmbh ph e turkey istanbul glaxo wellcome isas ph p usa usa philadelphia smithkline beecham corporation phch h r p e pittsburgh glaxosmithkline consumer healthcare lp formerly smithkline ch p beecham consumer healthcare lp note ii jersey city block drug company inc ch h p wilmington glaxosmithkline financial inc formerly glaxo wellcome financial inc phch f wilmington smithkline beecham holdings corporation phch h wilmington glaxosmithkline holdings americas inc phch h formerly smithkline beecham holdings americas inc americas bermuda hamilton glaxosmithkline insurance ltd phch formerly glaxo wellcome insurance bermuda ltd canada mississauga glaxosmithkline inc phch r p asia pacific australia boronia glaxo wellcome australia ltd ph p dandenong smithkline beecham australia pty ltd phch china hong kong glaxo wellcome china ltd ph tianjin sinoamerican tianjin smith kline french laboratories ltd ph india mumbai glaxosmithkline pharmaceuticals ltd formerly glaxo india ltd note ii ph p nabha smithkline beecham consumer healthcare ltd note ii ch p malaysia selangor glaxosmithkline pharmaceutical sdn bhd ph darul ehsan formerly glaxo wellcome malaysia sdn bhd new zealand auckland glaxo wellcome new zealand ltd ph p pakistan karachi glaxo wellcome pakistan ltd ph p karachi beecham pakistan private ltd phch philippines manila glaxo wellcome philippines inc ph singapore singapore glaxo wellcome manufacturing pte ltd ph p south korea seoul glaxosmithkline korea formerly glaxo wellcome korea ph p taiwan taipei glaxo wellcome taiwan ltd ph p mnotes financial statementsglaxosmithkline principal group companies continued japan location subsidiary undertaking segment activity japan tokyo glaxosmithkline kk formerly glaxo wellcome kk ph r p kobe block drug japan inc ch latin america argentina buenos aires glaxosmithkline argentina sa formerly smithkline beecham argentina sa phch p brazil rio de janeiro glaxo wellcome sa ph p rio de janeiro smithkline beecham brasil ltda phch colombia bogota glaxosmithkline colombia sa formerly smithkline beecham colombia sa phch mexico mexico city glaxo wellcome mexico sa de cv ph p cuernavaca smithkline beecham mexico sa de cv phch p puerto rico san juan glaxo wellcome puerto rico inc ph hato rey sb pharmco puerto rico inc ph p venezuela caracas glaxo wellcome ca ph p middle east africa egypt cairo glaxo wellcome egypt sae ph p south africa midrand glaxo wellcome south africa pty ltd ph p johannesburg smithkline beecham consumer healthcare pty ltd ch p usa location associated undertaking usa teterboro quest diagnostics inc new jersey notes exempt provisions section companies amendmentact ireland ii consolidated subsidiary undertaking accordance section companies act grounds significant influence business segment phpharmaceuticals chconsumer healthcare business activity ddevelopment eexporting ffinance hholding company iinsurance mmarketing pproduction rresearch full details group subsidiary associated undertakings attached companys annual return filed registrar ofcompanies glaxosmithkline principal financial statements us following information provided convenience us shareholders accordance requirements new york stockexchange principal financial statements prepared ukgaap sterling translated us consolidated profit loss account consolidated statement recognised gains losses consolidated cash flow statement average exchange rates consolidated balance sheet period end exchange rates exchange rates used given note tothe financial statements consolidated profit loss account business total business total business total turnover cost sales gross profit selling general administrative expenditure research development expenditure trading profit operating incomeexpense operating profit share profitslosses joint ventures associates profit disposal interest associate product divestments merger transaction costs disposal businesses loss disposal utilisation provision profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation minority interests preference share dividends earnings profit attributable shareholders us us us earnings per ads adjusted earnings per ads columnar presentation profit loss account adopted order illustrate underlying business performance primary measure used management forthispurpose certain items excluded business performance business column presented column items comprise merger items including product divestments costs relating previously announced manufacturing restructurings effect business disposals prior years consolidated statement total recognised gains losses profit attributable shareholders exchange movements overseas net assets uk tax exchange movements total recognised gains losses principal financial statements usglaxosmithkline consolidated cash flow statement net cash inflow operating activities earnings joint ventures associated undertakings returns investment servicing finance taxation paid capital expenditure financial investment acquisitions disposals equity dividends paid net cash outflowinflow management liquid resources financing management liquid resources financing decreaseincrease cash year consolidated balance sheet goodwill intangible assets tangible assets investments fixed assets equity investments stocks debtors liquid investments cash bank current assets loans overdrafts creditors creditors amounts due within one year net current assets total assets less current liabilities loans creditors creditors amounts due one year provisions liabilities charges net assets called share capital share premium account reserves profit loss account equity shareholders funds nonequity minority interest equity minority interests capital employed glaxosmithkline financial record quarterly trend analysis provided quarter group results sterling financial year analysis business performance results total results pharmaceutical sales therapeutic area profit loss account business performance months q cer cer sales pharmaceuticals consumer healthcare total sales cost sales selling general administrative expenditure research development expenditure operating costs trading profit pharmaceuticals consumer healthcare total trading profit operating incomeexpense operating profit share profitslosses joint ventures associated undertakings profit disposal interest associate profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation minority interests preference share dividends earnings profit attributable shareholders earnings per share p p profit loss account total sales pharmaceuticals consumer healthcare total sales cost sales selling general administrative expenditure research development expenditure operating costs trading profit pharmaceuticals consumer healthcare total trading profit operating incomeexpense operating profit share profitslosses joint ventures associated undertakings profit disposal interest associate disposal businesses product divestments merger transaction costs profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation minority interests preference share dividends earnings profit attributable shareholders earnings per share p pfinancial record glaxosmithkline months q months q q cer cer cer cer cer p p p p p p p p p p glaxosmithkline financial record pharmaceutical sales total group q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair flixotideflovent serevent seretideadvair flixonaseflonase ventolin becotide antibacterials augmentin zinnatceftin fortum amoxil antivirals hiv trizivir combivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix metabolic gastrointestinal avandia zantac vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sales financial recordglaxosmithkline pharmaceutical sales usa q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair flixotideflovent serevent seretideadvair flixonaseflonase ventolin becotide antibacterials augmentin zinnatceftin fortum amoxil antivirals hiv trizivir combivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix metabolic gastrointestinal avandia zantac vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sales glaxosmithkline financial record pharmaceutical sales europe q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair flixotideflovent serevent seretideadvair flixonaseflonase ventolin becotide antibacterials augmentin zinnatceftin fortum amoxil antivirals hiv trizivir combivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix metabolic gastrointestinal avandia zantac vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sales financial recordglaxosmithkline pharmaceutical sales rest world q q q q cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory flixotideflovent serevent seretideadvair flixotideflovent serevent seretideadvair flixonaseflonase ventolin becotide antibacterials augmentin zinnatceftin fortum amoxil antivirals hiv trizivir combivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix metabolic gastrointestinal avandia zantac vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovascular coreg arthritis relafen total pharmaceutical sales glaxosmithkline financial record five year record record financial performance provided analysed accordance current reporting practice sales business segment pharmaceuticals consumer healthcare retained businesses healthcare services pharmaceutical sales therapeutic area central nervous system disorders respiratory antibacterials antivirals metabolic gastrointestinal vaccines oncology emesis cardiovascular arthritis others continuing business divested products pharmaceutical sales geographic area usa europe rest world asia pacific japan latin america middle east africa canada total rest world consumer healthcare sales otc medicines oral care nutritional healthcare continuing business divested products financial recordglaxosmithkline business performance results retained businesses sales rd expenditure per cent sales trading profit per cent sales net interest payable profit taxation earnings profit attributable shareholders business performance primary performance measure used management presented excluding merger items integration restructuring costs disposal subsidiaries management believes exclusion nonrecurring items provides better comparison business performance periods presented accordingly information provided supplement included consolidated statement profit loss pages prepared accordance ukgaap total results include nonrecurring items merger restructuring disposal subsidiaries manufacturing restructuring merger costs product divestments items lossprofit taxation lossprofit attributable shareholders total results sales profit taxation earnings profit attributable shareholders dividends retained profit return capital employed per cent return capital employed calculated total profit taxation percentage average capital employed year share statistics earnings per share p dividends per glaxosmithkline share p glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividends per glaxosmithkline ads glaxosmithkline shareholder glaxo wellcome shareholder smithkline beecham shareholder dividends expressed terms glaxosmithkline shareads merger glaxo wellcome smithkline beecham thdecember shareholders adr holders received shares glaxosmithkline following ratios glaxo wellcome share glaxosmithkline share smithkline beecham share glaxosmithkline shares glaxo wellcome ads glaxosmithkline ads smithkline beecham ads glaxosmithkline adss glaxosmithkline ads represents glaxosmithkline shares glaxosmithkline financial record net assets fixed assets assets liabilities net operating assets net debt capital employed share capital share premium goodwill reserve reserves equity shareholders funds minority interests capital expenditure tangible fixed assets number employees usa europe rest world asia pacific japan latin america middle east africa canada total rest world manufacturing selling administration research development number employees number permanent employed staff end financial period excludes employees employed managed glaxosmithkline contract basis consequence time took complete merger glaxosmithkline replaced needed leavers contractors year end level contractors disproportionately high movement compared reflects conversion contract employees permanent employees redundancies due merger integration additional employees acquisition block drugglaxosmithkline investor information section discusses shareholder return return shareholders form dividends share price movements provides information shareholders shareholder return taxation information shareholders shareholder information share capital glaxosmithkline shareholder return merger glaxo wellcome smithkline beecham dividends glaxosmithkline pays dividends quarterly present expected boards glaxo wellcome smithkline beecham level dividend first three quarters announced th january agreed terms higher dividend fourth quarter quarters dividend proposed merger equals two companies subject announced time quarterly results announcement shareholder approval regulatory clearance based relative stock market valuations glaxo wellcome smithkline glaxosmithklines dividend payout policy set beecham months preceding announcement documents glaxo wellcomesmithkline beecham merger merger shareholders glaxo wellcome would hold issued shareholders assuming earnings continue approximately per cent shareholders smithkline grow glaxosmithkline least maintain annual dividend beecham approximately per cent combined group pence per share line glaxo wellcomes dividend pence per glaxo wellcome share whilstbuilding towards higher following shareholder approvals clearance regulatory dividend cover ratio distributable profitsand dividends authorities merger became effective th december board declared dividends follows merger implemented way scheme arrangement new holding company glaxosmithkline plc acquired glaxo wellcome smithkline beecham accordance gw sb agreed merger terms shareholders glaxo wellcome dividends per share pence pence pence smithkline beecham received exchange existing first interim shares shares glaxosmithkline follows second interim third interim glaxo wellcome ordinary share glaxosmithkline fourth interim ordinary share total smithkline beecham ordinary share glaxosmithkline ordinary shares dividends paid represent dividends paid glaxo case shares held american depositary shares adss wellcome smithkline beecham shareholders expressed evidenced american depositary receipts adrs glaxo dividends per glaxosmithkline share wellcome ads represented two glaxo wellcome ordinary shares smithkline beecham ads represented five smithkline dividends beecham ordinary shares glaxosmithkline ads represents respect financial year ended st december two glaxosmithkline ordinary shares accordingly holders glaxo wellcome adrs holders smithkline beecham adrs glaxo wellcome paid interim dividend p per ordinary share received second interim dividend p per ordinary share total dividend per glaxo wellcome share year p total glaxo wellcome ads glaxosmithkline ads equivalent dividend per glaxosmithkline ordinary share p smithkline beecham ads glaxosmithkline adss smithkline beecham paid first second third interim dividend glaxosmithkline shares commenced trading london stock p per ordinary share fourth interim dividend p per exchange glaxosmithkline adss commenced trading ordinary share total dividend per share year p new york stock exchange th december total equivalent dividend per glaxosmithkline ordinary share p taxation general information concerning uk us tax effects share ownership set 'taxation information shareholders ' shareholders doubt taxation position consult professional advisers general guide shareholders glaxosmithkline received advice merger direct effect tax position uk resident shareholders us resident shareholders information contained scheme document issued shareholders th july shareholder return glaxosmithkline dividends adss share price guide holders adrs tables set dividends paid per ads us dollars last five years dividends share price gsk gsk gw sb adjusted uk tax credit less withholding tax applicable st january translated us dollars applicable exchange rates high year since th april claims refunds tax credits dividends low year uk tax authorities negligible benefit us th december shareholders st december increasedecrease year year gsk gw sb table sets middle market quotations shares london stock exchange derived daily official list companys share price declined nine per cent price st january st december decline compares decrease ftse index dividends paid glaxo wellcome smithkline beecham adr per cent year relative outperformance holders expressed dividends per glaxosmithkline ads glaxosmithkline due investor preference defensive growth characteristics pharmaceutical sector dividend calendar uncertain economic period together glaxosmithklines first quarter strong business performance year results announcement th april market capitalisation exdividend date st may market capitalisation glaxosmithkline st december record date rd may billion date glaxosmithkline third largest payable th july company market capitalisation ftse index second quarter smithkline beecham plc floating rate unsecured loan stock results announcement th july exdividend date st july record date nd august loan stock listed exchange holders may payable rd october require smithkline beecham plc redeem loan stock par ie every loan stock held first business day third quarter march june september december holders wishing redeem results announcement rd october part loan stock complete notice exdividend date th october back loan stock certificate return registrar record date st november arrive least days relevant redemption date payable rd january glaxosmithkline taxation information shareholders information shareholders stamp duty uk stamp duty case may stamp duty reserve tax summary principal tax consequences holders sdrt subject certain exemptions payable shares adrs citizens residents united kingdom purchase shares rate per cent purchase price united states set complete analysis minimum charge stamp duty liability arises possible tax consequences purchase ownership securities holders securities advised consult us shareholders tax advisers respect tax consequences purchase ownership shares adrs including taxation dividends specifically consequences state local tax laws gross amount dividends received including amounts united states respect associated tax credit uk withholding tax treated foreign source dividend income us tax purposes new ukus income tax convention signed eligible dividend received deduction allowed us however date set ratification statements corporations dividends adrs payable us dollars regarding united kingdom united states tax laws dividends shares payable pounds sterling dividends practices set based laws paid pounds sterling included income us practices force date report dollar amount calculated reference exchange rate us holders adrs generally treated owners day dividends received holder uk taxes underlying shares purposes current united withheld dividend distributions eligible credit statesunited kingdom double taxation conventions relating holder 's us federal income tax liability subject generally income gains income tax convention estate gift taxes applicable limitations holder 's tax position estate gift tax convention purposes us determine whether effective use made credits uk internal revenue code amended code withholding taxes us tax liability th april rate tax credits reduced one following analysis deals dividends paid th april ninth act abolished consequently claims refunds advance corporation tax act abolished tax credits dividends paid date dividends paid date negligible benefit us shareholders uk shareholders taxation capital gains taxation dividends generally us holders subject uk capital gains tax th april rate tax credits reduced one subject us tax capital gains realised sale ninth result compensating reductions rate tax disposal shares adrs dividend income increase tax borne uk resident individual shareholders tax credits however estate gift taxes longer repayable shareholders tax liability less estate gift tax convention us shareholder associated tax credit generally subject uk inheritance tax taxation capital gains stamp duty uk shareholders may liable uk tax gains uk stamp duty case may sdrt subject disposal shares adrs may also entitled certain exemptions payable issue transfer shares indexation relief taper relief sales indexation relief adr custodian depository rate per cent calculated market value shares st march price issued amount consideration provided cost subsequent purchases date transferred sale value transferred purchase indexation relief individual shareholders ceased consideration th april taper relief available individual shareholders sdrt would payable transfer adr uk hold deemed hold shares least three years stamp duty payable transfer adr provided sold instrument transfer executed remains times outside uk stamp duty transfer adr inheritance tax would payable rate per cent consideration individual shareholders may liable inheritance tax transfer sale underlying shares would result transfer shares adrs tax may charged liability uk stamp duty case may sdrt rate amount value shareholder 's estate reduced per cent result transfer way gift disposal less full market value exceptionally gift disposal minimum charge stamp duty liability subject uk inheritance tax us estate gift tax arises estate gift tax convention would generally provide tax paid united states credited tax payable united kingdomglaxosmithkline shareholder information ordinary shares investors holding shares company nominee service arrange nominee service appointed proxy company 's shares listed london stock exchange respect shareholding order attend vote meeting registrar company 's share register administered lloyds tsb adr holders wishing attend meeting must obtain proxy registrars also provide following services bank new york enable attend meeting vote business transacted adr holders glaxosmithkline investment plan may instruct bank new york shares plan enables shareholders reinvest quarterly dividends represented adrs voted completing andor make monthly investments company 's ordinary returning voting card provided bank new york shares using special dealing arrangement accordance instructions given glaxosmithkline individual savings account glaxosmithkline individual savings account isa financial reporting taxefficient way invest company 's ordinary shares financial reporting calendar glaxosmithkline corporate sponsored nominee announcement st quarter results th april corporate sponsored nominee provides facility announcement nd quarter results th july shareholders hold shares without need share publication halfyear reportreview august certificates shareholders ' details held main share register remain confidential announcement rd quarter results rd october preliminary announcement annual results february shareview service publication annual reportreview march shareview portfolio service provides shareholders information investment company shareholders may register service wwwshareviewcouk results announcements results announcements issued london stock share dealing facility exchange lse made available lse news service natwest stockbrokers limited offers sharedealing service time shortly afterwards issued media behalf company shareholders wishing buy sell made available company 's web site filed company 's shares usa securities exchange commission sec new york stock exchange share price information share price information available company 's web site financial reports wwwgskcom information also available ceefax teletext company publishes annual report investor ft cityline calling needing full detail report annual review interim calls charged p minute times report review published halfyear financial reports sent shareholders date american depositary shares publication available date company 's company 's shares listed new york stock exchange web site shareholders provided review may elect form american depositary shares adss receive also report evidenced american depositary receipts adrs one copies previous financial reports available company 's represents two ordinary shares web site printed copies obtained company 's registrar uk company 's customer response adr programme administrator center usa adr programme administered bank new york also provide following services publications global buydirect first time glaxosmithkline producing social global buydirect direct ads purchasesale dividend environmental review entitled performance integrity reinvestment plan adr holders incorporate information pressing issues core business generated significant interest annual general meeting external shareholders include medicines developing world community involvement environmental health queen elizabeth ii conference centre th may safety performance integrity available broad sanctuary westminster secretariat companys head office company london swp ee web site wwwgskcom may annual general meeting company 's principal forum communication private shareholders addition formal resolutions put meeting presentation chief executive officer performance business future development opportunity questions board chairmen board 's committees take questions matters relating committees glaxosmithkline share capital nature trading market glaxo wellcome pence per share ordinary shares company listed london fiscal periods th december high low stock exchange th december shares also quarter ended st december listed new york stock exchange inthe form american quarter ended th september depositary shares adss date quarter ended th june quarter ended st march following table sets periods indicated high low middle market quotations pence shares london stock exchange derived daily official list high low last reported sales prices us dollars adss new york stock exchange derived new us dollars per ads york stock exchange composite tape fiscal periods th december high low information relating share ads prices glaxo quarter ended st december wellcome smithkline beecham prior date merger quarter ended th september also given quarter ended th june quarter ended st march glaxosmithkline pence per share fiscal periods th december high low quarter ended st march february january december smithkline beecham pence per share november fiscal periods th december high low october quarter ended st december september quarter ended th september quarter ended st december quarter ended th june quarter ended th september quarter ended st march quarter ended th june quarter ended st march th st december us dollars per ads us dollars per ads fiscal periods th december high low fiscal periods th december high low quarter ended st march quarter ended st december february quarter ended th september january quarter ended th june december quarter ended st march november october september quarter ended st december quarter ended th september quarter ended th june th december quarter ended st march th st december th march share capital glaxosmithkline analysis shareholdings number total number analysis shareholdings st december accounts accounts total shares holding shares totals held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited totals bank new yorks holding held bny nominees limited represents companys adr programme whereby ads represents two ordinary shares p nominal value th march number holders record shares usa holdings shares thenumberof registered holders adrs holdings adrs certain shares adrs held brokers nominees number holders record registered holders usa representative number beneficial holders orofthe residence beneficial holders control company far known company directly indirectly owned controlled one corporations government thecompany know arrangements operation might result change control company substantial shareholdings th march company received notification following interest three per cent shares bnynominees limited holds shares representing per cent shares held behalf holders american depositary receipts far known company person owner three per cent shares company directors officers interests directors officers company defined thecompanies act share options company given remuneration report pages exchange controls limitations affecting securityholders currently uk laws decrees regulations restricting import export capital affecting remittance dividends orother payments holders companys shares nonresidents uk limitations relating non residents uk english law companys memorandum articles association right tobe holder vote respect companys shares glaxosmithkline cross reference form f table provided cross reference information included annual report requirements form f item item identity directors senior management advisers na financial information consolidated statements financial information offer statistics expected timetable na financial statements see item key information legal proceedings selected financial data b significant changes na risk factors offer listing information company share price history history development company c markets b business overview products additional information competition b memorandum articles association note regulation c material contracts marketing distribution exchange controls manufacture supply e taxation research development h documents display intellectual property quantitative qualitative disclosures market risk information technology treasury policies environment health safety note financial instruments related disclosures global community partnerships description securities equity securities na access medicines developing world defaults dividend arrearages delinquencies na c organisational structure property plant equipment material modifications rights security holders environmental responsibility use proceeds na note segment information reserved note tangible fixed assets reserved operating financial review prospects financial statements na operating results financial statements directors statements responsibility independent auditors report us accounting principles consolidated statement profit loss b liquidity capital resources consolidated statement total recognised gains losses c research development patents licenses etc consolidated statement cash flow trend information consolidated balance sheet directors senior management employees reconciliation movements equity shareholders funds directors senior management company balance sheet b compensation notes financial statements remuneration report exhibits c board practices corporate governance employees note glaxosmithkline people information responsive item incorporated reference note employee costs memorandum articles association glaxosmithkline financial record pages groups annual report form f e share ownership year ended st december glaxosmithkline people note employee share schemes share options incentive plans directors interests major shareholders related party transactions major shareholders b related party transactions cross reference form f glaxosmithkline cautionary factors may affect future results related party transactions groups reports filed us securities exchange glaxosmithkline per cent interest quest diagnostics commission commission including annual report inc activities quest part companys core form f year ended st december business interest held investment form f contain written information released oral statements made public future behalf material contracts group may contain forwardlooking statements forward boards glaxo wellcome plc smithkline beecham plc looking statements give thegroups current expectations announced th january terms agreement forecasts future events aninvestor identify forthe proposed merger two companies merger statements fact donot relate strictly historical wasimplemented way scheme arrangement current facts use words anticipate estimate thdecember date glaxosmithkline plc expect intend project plan believe acquired thewhole issued share capital glaxo words terms similar meaning connection wellcome plc andsmithkline beecham plc discussion future operating financial performance particular include statements relating future actions january glaxosmithkline completed acquisition prospective products product approvals future performance block drug company inc manufacturer toothpaste results current anticipated products sales efforts oral healthcare consumer products us million expenses outcome contingencies legal million proceedings financial results group undertakes obligation update forwardlooking statements whether documents display result new information future events otherwise documents referred annual report available forwardlooking statements involve inherent risks inspection registered office company uncertainties group cautions investors number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pages annual report glaxosmithkline glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax us equivalent tax depreciation advance corporation tax act advance payment uk tax made dividends paid direct us equivalent american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary shares american depositary shares adss ordinary shares registered new york stock exchange calledup share capital ordinary shares issued fully paid cer growth growth constant exchange rates combined code guidelines required listing rules financial services authority address principal aspects corporate governance company glaxosmithkline plc creditors accounts payable currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates debtors accounts receivable defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share dividend cover profit attributable shareholdersnet income divided dividends payable shareholders earnings per share basic income per share employee share ownership trusts trusts established group satisfy share based employee incentive plans equity shareholders funds aggregation shares reserves owned shareholders us equivalent shareholders equity finance lease capital lease free cash flow cash resources available payment dividends shareholders acquisitions freehold ownership absolute rights perpetuity gearing ratio net debt percentage shareholders funds net debt minority interests group glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements bymaking offsetting commitments intangible fixed assets assets without physical substance brands licences patents knowhow marketing rights purchased outside parties interest cover number times profit interest exceeds net interest payable interest payable interest expense interest receivable interest income nonequity minority interest preference shares issued subsidiary outside parties preference shares shares issued varying dividend rates treated outside interests profit income profit loss account reserve retained earnings profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue shares outstanding statement total recognised gains losses statement comprehensive income stocks inventories subsidiary undertaking affiliate glaxosmithkline holds majority shareholding andor exercises control tangible fixed assets property plant equipment turnover revenueglaxosmithkline index contact details inside back cover financial statements access medicines contaminated land financial summary accountability audit contingent liabilities financial trends ratios accounting policies control company fixed asset investments accounting standards corporate executive team foreign exchange risk management acquisitions disposals corporate governance forwardlooking statements corporate social responsibility committee adr programme administrator critical accounting policies g inside back cover cross reference form f gearing ratio american depositary shares global community partnerships animals research global supply initiative annual general meeting derivative financial instruments glossary terms antitrust going concern basis antibacterials dermatologicals goodwill description business antivirals dialogue shareholders directtoconsumer advertising governmental investigations associated companies directors senior management group companies directors h interests healthcare services audit committee interests contracts hedging auditors independent remuneration history development company b report hiv aids balance sheet responsibility service contracts share options impairment assets block drug share ownership guidelines diversity independent auditors board executive divested businesses information technology board committees divested products inlicensing business community dividends intangible assets business performance e intellectual property early drug discovery business segments earningsearnings per share interest cover c interest rate risk management capital employed internal control capital expenditure employees investments cardiovascular costs diversity cash flow involvement investor information numbers j cautionary factors may affect performance reward joint ventures future results share schemes associates centralnervoussystemcnsdisorders training development employee share ownership trusts centres excellence drug discovery l chairman chief executive leases officers statement environment health safety legal proceedings charitable donations liquid investments chlorofluorocarbons cfcs equity risk management combined code european monetary union loans overdrafts commitments exchange controls communications exchange rates lymphatic filariasis community investment competition external suppliers consumer healthcare malaria f business sectorsegment manufacture supply fair values finance committee competition manufacturing restructuring financial assets liabilities manufacturing supply financial highlights marketing distribution market capitalisation financial instruments new products marketing distribution financial period sales maturity counterparty risk financial position research development memorandum articles financial record regulation association year record trade marks merger accounting adjustments quarterly trend constant exchange rate cer metabolic gastrointestinal financial reporting calendar glaxosmithkline index n r u net debt reconciliation equity uk segment shareholders funds us gaap reconciliation us accounting net interest payable principles registrar consolidated balance sheet regulation consolidated income statement new products remuneration nominations comprehensive income nonexecutive directors committee changes shareholders equity noon buying rate remuneration report consolidated statement cash flows nutritional healthcare report directors earnings per shareads research collaborations material differences research development uk us gaap accounting policy postretirement benefits oncology emesis animals research purchase accounting consumer healthcare results usaccounting principles operating financial review diseases developing world segment information prospects expenditure selected financial data oral care taxation operating incomeexpense pharmaceuticals us convenience translation principal pipeline financial statements outlook respiratory overthecounter otc medicines v p return capital employed vaccines patents revenue accounting policy payment policies risk factors w pension postretirement risk oversight compliance council rocc world economy benefits world market sales performace integrity consumer healthcare pharmaceuticals approvals submissions pharmaceuticals business sector competition sb clinical laboratories manufacturing supply segment information marketing distribution selected financial data products senior management compensation sales interests share buyback research development share capital regulation share premium patents trade marks share price pipeline share purchases presentation financial statements share statistics price controls shareholder information principal financial statements us shareholder return shareholders funds profit loss account shareholdings analysis statement total recognised gains losses property plant equipment strategic master plan provisions liabilities charges taxation taxation information shareholders tax rate trade marks treasury operations treasury policies tuberculosis contact details internet information investors company available glaxosmithklines corporate web site wwwgskcom head office registered office glaxosmithkline plc great west road brentford middlesex tw gs tel united kingdom united states america investor relations europe investor relations great west road one franklin plaza brentford po box middlesex tw gs philadelphia tel tel fax fax registrar adr programme administrator lloyds tsb registrars bank new york causeway shareholder relations worthing po box west sussex bn da church street station new york ny general enquiries annual report orderline tel toll free corporate nominee service tel outside usa tel inside uk tel outside uk customer response center tel toll free shareholder investment plans dividend reinvestment queries tel inside uk tel outside uk monthly savings plan queries tel inside uk tel outside uk isa enquiries tel inside uk tel outside uk glaxo wellcome smithkline beecham corporate peps share centre limited oxford house oxford road aylesbury bucks hp sz tel corporate share dealing facility natwest stockbrokers corporate employee service mansell street london e tel inside uk tel outside uk paper used production document made pulp harvested sustainable forests also using sawmill residues forest thinnings elemental chlorinefree printed hyway uk using waterless print process solvent free inkswwwgskcom